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ABSTRACT 
 
Atopic eczema has a profound negative impact on patients and their families 
and improved therapeutic options are required.  Although, the pathogenesis is 
still not fully understood, evidence of a primary barrier defect predisposing to 
increased stimulation of the innate and adaptive immune system increases.   
 
Cyclosporine A (CsA) is an effective therapy for inflammatory skin disease.  
CsA binds to cyclophilin B (CypB) with high affinity, mediating T-cell 
immunosuppression.  CsA also exerts T-cell independent effects in skin. The 
Reynolds lab has previously shown that CypB is expressed and secreted by 
normal human epidermal keratinocytes (NHEK).  In this work we aimed to 
investigate the functional role of CypB in the epidermis.  
 
Confocal analysis of normal human skin revealed CypB expression within the 
granular cell layer.  Transduction of NHEK with retroviral vectors containing 
CypBWT-GFP, CypBW128A-GFP (a mutant reducing CsA binding by 97%) 
positively regulated keratinocyte differentiation (transglutaminase promoter 
luciferase and enzyme activity).  In addition, transduction of NHEK with CypBWT 
and CypBW128A significantly increased colony formation and keratinocyte 
proliferation compared to empty vector.  Furthermore, conditioned medium from 
NHEKs transduced with CypBWT or CypBW128A increased proliferation of naïve 
NHEK. Conversely, knockdown of CypBWT reduced NHEK proliferation.  
Moreover, NHEK transduced with CypBWT formed thicker epidermal equivalents 
compared with empty vector controls. 
 
Analysis of eczematous skin treated with CsA, showed changes in expression 
of CypB before and following 2 weeks of CsA treatment.  An increase in 
filaggrin expression in eczematous skin during these early phases of treatment 
with CsA, suggests that CsA may act by positively repairing impaired barrier 
function.  These studies provide an increased understanding of the 
physiological and pathological role of CypB in keratinocytes, further insight into 
the mechanism of action of CsA and may identify CypB as a novel drug target 
for atopic eczema.    
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INTRODUCTION 
 
Atopic eczema and atopic disease asthma, hayfever and allergy, are increasing 
in frequency, affecting approximately 22-25% of children worldwide (Odhiambo 
et al., 2009). The reported lifetime prevalence of atopic eczema in adults is 8-
17% before the age of 60 and this cohort represents a more severe and 
persistent group of patients (Hoare et al., 2000; Montnemery et al., 2003).   The 
development of atopic eczema is often seen prior to the development of asthma 
and allergic rhinitis, with half of atopic eczema patients developing asthma and 
two thirds developing allergic rhinitis, a sequence known as the atopic march 
(Spergel and Paller, 2003). 
 
Atopic eczema has a profound negative impact on quality of life, not only for 
patients but also for the whole family (Baron et al., 2006).  30% of consultations 
in primary care are concerned with skin disease and 10-20% of referrals to a 
dermatologist are for atopic eczema (Charman et al., 2003).  
 
The precise pathogenesis of atopic eczema remains incompletely understood 
with complex genetic and environmental components contributing to its 
pathogenesis.  Although atopic eczema was for many years primarily 
considered to be an immunological disease, there is a increasing evidence of a 
primary epithelial barrier defect (S. J. Brown et al., 2008).  A complex and 
carefully orchestrated program of proliferation and differentiation occurs in order 
for the epidermis to achieve its primary role in barrier function which begins 
when the basal cells switch from cell division to a program of terminal 
differentiation to form corneocytes (Eckert et al., 1997).   Studies have shown 
genetic linkage between the epidermal differentiation complex (EDC) on 
Chromosome 1q2 and atopic eczema suggesting a role for barrier function and 
repair in this disorder (Sugiura et al., 2005).  More recently, mutations in the 
filaggrin (FLG) gene have been shown to predispose to childhood eczema 
(Palmer et al., 2006; Sandilands et al., 2007) and are strongly associated with a 
more severe course persisting into adult life (Barker et al., 2007).    
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Moderate to severe atopic eczema can be difficult to manage and often requires 
UVB phototherapy or second-line systemic treatments (S. Brown and Reynolds, 
2006).  
Ciclosporin (CsA), an immunosuppressant agent, revolutionised organ 
transplant surgery due to its ability to block the activation of T-lymphocytes and 
prevent graft rejection (M. Schreiber et al., 1997). Its mechanism of action on T-
cells has been well established: CsA binds specifically to cyclophilins, the 
intracellular receptors for CsA, of which Cyclophilin B (CypB) has the highest 
affinity. This interaction subsequently prevents T-cell activation via the 
calcineurin/NFAT pathway (Rao et al., 1997).   
 
CsA is extremely effective in the treatment of atopic eczema (Sowden et al., 
1991).  It works quickly and significantly improves quality of life but its use is 
limited due to long term side effects (Salek et al., 1993).  There is good 
evidence indicating that CsA exerts effects in the skin that are independent of 
its action on T-cells (Fisher et al., 1988; Taylor et al., 1993; Prens et al., 1995; 
Reynolds et al., 1998). 
 
The cyclophilins belong to a group of enzymes known as immunophilins that 
possess a highly conserved ligand binding domain and peptidyl-prolyl cis-trans 
isomerase (PPIase) activity, important for protein folding, assembly and 
trafficking (Michael T G Ivery, 2000b; Al-Daraji et al., 2002).  The cyclophilins 
are the specific internal receptors for CsA.  Cyclophilin B (CypB) has a high 
affinity for CsA and is able to mediate the immunosuppressive effects of CsA 
(Allain et al., 1996).   
 
CypB binds to CsA with 10 times higher affinity than CypA.  The W128 residue 
which is found in the very conserved 310 helix of CypB, and all eukaryotic 
cyclophilins is essential for CsA binding. Substituting alanine for tryptophan at 
residue 128 in the CsA-binding region reduces CsA binding by 97%, but does 
not have a significant effect on its PPIase activity (Carpentier et al., 1999).  The 
CypB-CsA complex binds to calcineurin and has a higher inhibitory effect on 
calcineurin activity compared to the CypA-CsA complex due to particular 
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residues (G77, D155 and D158) found on CypB which are not found in CypA 
(Carpentier et al., 2000). 
CypB has also been shown to interact with two types of receptors known as 
Type I (CD147) and Type II (glycosaminoglycans) binding sites which are 
involved in signalling events and biological activity, respectively.  The Type I 
binding site is situated within the CsA binding pocket of the molecule of CypB 
and the Type II site is found within its N-terminal and are thus positioned on 
opposite sides of the molecule.  Interaction via the Type II site increases the 
local concentration near the Type I receptor (Carpentier et al., 2002). 
We have found that CypB is expressed in the granular layer of normal human 
epidermis, suggesting that it may play a role in epidermal differentiation.  The 
Reynolds’ lab has shown that components of the cyclophilin pathway are 
expressed and functional in human epidermis and keratinocytes (Al-Daraji et al., 
2002) and that CypB is expressed and secreted by normal human epidermal 
keratinocytes (Fearon et al., 2011).  
 
The role of CypB in the epidermis requires further investigation and by studying 
the mechanism of action of therapeutic agents such as CsA we aim to gain 
further understanding of the pathogenesis of atopic eczema and potentially 
develop new therapeutic targets and safer and more effective treatment 
strategies. 
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Chapter 1: Normal Skin 
 
1.1 The Structure and Function of Normal Skin 
Human skin consists of an outer epidermis, an underlying dermis and a 
subcutis.  Adult skin weighs approximately 6% of our body weight and covers 
2m2 in area (Tobin, 2005).   
 
The epidermis is a stratified, non-vascularised epithelium measuring between 
75-150μm on the face and trunk and increasing to 600μm on the palms and 
soles. The epidermis consists of four distinct layers: the outer stratum corneum, 
followed by the stratum granulosum, stratum spinosum and stratum basale 
(Tobin, 2006) .   Beneath this is the dermis, an underlying connective tissue 
providing strength, elasticity and nutrition and measuring between less than 
2mm – 4mm.  The rete pegs of the epidermis interlock with the dermal papillae 
which increases the surface area in contact with each other.  Within the dermis, 
fibroblasts produce collagen, elastin and glycosaminoglycans (GAGs) as well as 
other components which make up the fibrous and elastic components of the 
extracellular matrix (ECM) (Tobin, 2006).  The dermis consists of an upper 
papillary layer with thin collagen fibres and a lower reticular part where the 
collagen fibres are thicker and more haphazardly arranged.  Within the dermis 
lie skin appendages derived from epithelial germ cells which form the hair 
follicles, sebaceous glands and apocrine and eccrine sweat glands.  Blood 
vessels, lymphatics and nerves are all found throughout the dermis (Fig 2). The 
nails are also an important skin appendage providing protection to the distal 
phalynx and improving fine touch and manipulation (Tobin, 2006).   
 
Between the epidermis and dermis lies the dermo-epidermal junction, a highly 
complex interface that has a key role in cell anchorage, adhesion, migration and 
differentiation, acting as a barrier and filter and involved in signalling between 
the ECM and the basal cells of the epidermis.  Below the dermis lies the sub-
cutis or hypodermis (Tobin, 2006).  
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Human skin provides the protective interface between the harsh external 
environment and the complexities of the human body.  It is a physical barrier 
protecting us against electrolyte and fluid imbalance, the entry of microorganisms, 
mechanical and chemical damage and ultraviolet radiation (Tobin, 2006).  It is a 
sensory organ detecting touch, vibration, pressure, temperature variations, pain and 
pruritus.  It has important autonomic functions  maintaining cutaneous homestasis by 
regulating vasomotor functions, sweat gland secretion and pilomotor activity.  In 
addition, it is important in secretory activity, for physiologic function, and excretory 
activity, for elimination of waste products of metabolism (Tobin, 2006).  It has an 
important immunological role - with keratinocytes playing a significant part as well as 
the resident immune Langerhans’ cells, circulating lymphocytes, neutrophils and 
other cells of the immune system which together with cutaneous blood vessels, 
lymphatics and lymph nodes collectively make up the skin immune system (Tobin, 
2006).  Finally, its role in sociosexual communication is extremely important. 
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1.1.1 The Epidermis  
The epidermis is a highly compartmentalised structure that provides us with a 
physical and permeable barrier.  It is continuously renewed throughout life, in 
order to replace cells lost through normal exposure to the environment, via a 
carefully orchestrated process of proliferation, differentiation and apoptosis 
(Eckert et al., 1997; Chaturvedi et al., 1999).  The keratinocyte is the major cell 
that makes up 95% of the epidermis.  These cells travel from their attachment to 
the basement membrane from the basal layer (stratum basale) through each 
layer to become anucleated corneocytes – dead but metabolically active 
flattened cells known as squames (Figure 1).   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  The four layers of the epidermis. 
 
Corneocytes have a tough insoluble cornified cell envelope (CE) that replaces 
the plasma membrane and are cross linked by intercellular lipid to make up the 
stratum corneum.  This process of terminally differentiating keratinocytes is 
known as cornification or keratinisation (Candi et al., 2005). 
 
Keratinocytes are linked via several types of intercellular junctions: 
desmosomes which allow cells to withstand trauma; gap junctions that connect 
the cytoplasm of adjacent keratinocytes and other cells; adherens junctions 
concerned with cell motility, changes in shape and cell interactions; and tight 
junctions which regulate permeability and cellular polarity (Green and Simpson, 
2007; Mese et al., 2007; Niessen, 2007).  The other important cells residing 
within the epidermis are melanocytes, Langerhans’ cells and Merkel cells. 
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1.1.2 Epidermal Proliferation and Differentiation 
The process of epidermal differentiation begins when basal stem cells switch 
from cell division to a program of terminal differentiation to form corneocytes (or 
squames), a process which takes approximately 60 days (Hunter et al., 1995).  
In normal epidermis, the rate of proliferation of the basal keratinocytes is 
precisely balanced by the desquamation of the corneocytes at the surface of the 
skin in order to form a functional barrier (Candi et al., 2005).   
 
Three populations of keratinocyte stem cells (KSC) have been identified – the 
interfollicular epidermal stem cells in the epidermal basal layer, the hair follicle 
stem cells of the bulge and the sebaceous gland stem cells located immediately 
above the hair bulge.  These three populations appear to function independently 
of each other, although may be able to replicate any skin structure if the 
epidermis is stressed (Eckert et al., 2012). 
 
Stratum Basale: The basal layer is protected in the epidermis from dehydration, 
chemical and mechanical damage and irradiation (Eckert et al., 1997). The cells 
of the basal layer include the undifferentiated, mitotic keratinocyte stem cells 
and are important in maintaining the interfollicular epidermis. 
 
Two types of proliferating basal keratinocytes exist: stem cells which have high 
proliferative potential and transit-ampliflying cells which are destined to undergo 
terminal differentiation.  Stem cells are responsible for epidermal maintenance 
and repair.  They give rise to daughter cells, which can either be stem cells 
themselves, or transit-amplifying cells.  The transit-amplifying cells undergo a 
few cell divisions and are then committed to differentiate terminally (Jones et al., 
1995).  These committed cells detach from the basement membrane and 
migrate to the surface, undergoing a series of morphological and biochemical 
changes which can be identified at each layer of the epidermis (Fuchs, 1990).    
 
Barandon and Green have identified three populations of cells in keratinocyte 
culture which have differences in proliferative potentiation:  the holo-, para- and 
metaclones.  The holocones have high proliferative potention and give rise to 
the largest colonies in clonal growth assays.  Holoclones are rich in markers of 
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the epidermal basal layer, including β1 integrin.  These cells correspond to the 
stem cell population.  The paraclones differentiate after only limited proliferation 
and the meroclones have an intermediate proliferative capacity and morphology 
(Barrandon and Green, 1987; Eckert et al., 2012).  The paraclones correspond 
to the transient amplifying cells (Eckert et al., 2012). 
 
The main structural proteins of the basal keratinocytes are keratins K5 and K14.  
They assemble into keratin intermediate filaments (KIF).  Together with 
microtubules (tubulin) and microfilaments (actin), KIF’s form the cytoskeleton of 
the keratinocyte.  KIF’s extend from the desmosomes towards the nuclear 
lamina bridging adjacent keratinocytes.  Desmosomes scaffold keratinocytes 
into a three dimensional structure.  They are composed of glycoproteins 
belonging to the cadherin family which are Ca2+ dependent cell-adhesion 
molecules. The cells of the basal layer are polarized with their basal surface 
attached to the basement membrane extracellular matrix components (including 
laminin and collagen IV secreted by keratinocytes).  KIFs attach to 
hemidesmosomes via α6β4 integrins that act as heterodimeric transmembrane 
receptors adhering the basal keratinocyte to the basement membrane.  The 
integrins are a family of cell surface receptors mediating cell-cell and cell-
extracellular matrix adhesion.  α6-integrin and β4-integrin are putative 
epidermal stem cell markers (Candi et al., 2005; Radoja et al., 2006; Eckert et 
al., 2012).  
 
Stratum spinosum: The keratinocytes in the suprabasal layers are post mitotic 
and produce a new set of structural keratins, K1 and K10, which form the 
cytoskeletal filaments that aggregate into tonofilaments(Fuchs, 1990; Candi et 
al., 2005).   Other keratins are expressed in specific locations, such as K9 in the 
palms and soles(Candi et al., 2005).  These suprabasal cells express involucrin 
(INV) and transglutaminase (TG) and also make envoplakin and 
periplakin(Steinert, 2000).  Concurrently, lamellar granules (or Odland bodies) 
that synthesize and store lipids are also produced (Candi et al., 2005). 
 
Stratum granulosum: As the spinous cells migrate to the granular layer further 
envelope proteins are expressed, namely loricrin and small proline-rich proteins 
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(SPRs) (Candi et al., 2005).  The granular cells acquire characteristic cellular 
inclusions called keratohyalin granules (KHG) in cornifying epithelia and thus 
are found in the granular cells of the skin, cornea and hard palate but not in 
non-cornified squamous epithelia (McGrath et al., 2004).  Human loricrin is 
deposited in the granular layer in KHGs and then intermixed with profilaggrin 
(Candi et al., 2005).  Profilaggrin is a highly phosphorylated, insoluble protein 
consisting of an N-terminus and multiple filaggrin repeats joined by linker 
peptides.  The filaggrin (FLG) repeats vary from 10-12 in humans (Pearton et 
al., 2002).   
 
Stratum corneum and the formation of the cornified cell envelope: The formation 
of the cornified cell envelope is initiated by a rise in intracellular calcium ([Ca2+]i) 
levels which activates transglutaminase 1 (TG1) and triggers the expression of 
INV, envoplakin and periplakin, the latter two forming heterodimers.  As [Ca2+]i
 
continues to rise TG1 crosslinks the plakins and INV by forming Nε-(γ-
glutamyl)lysine isopeptide bonds which form the scaffold of the cell envelope 
and provides it with its resistant and insoluble properties(Eckert et al., 2005).   
 
Transglutaminases (TG) comprise a family of Ca2+ dependent enzymes that 
catalyse the formation of very stable isopeptide bonds (Eckert et al., 2005). 
Four of the nine mammalian TG’s are expressed in the epidermis.  TG1, TG3 
and TG5 are expressed in the spinous and granular layers and are involved in 
CE assembly; TG2 is expressed under specific situations such as wound 
healing (Candi et al., 2005; Eckert et al., 2005). 
 
Lamellar bodies, lipid-protein complexes involved in storage and secretion of 
cellular lipids, accumulate in the granular layer.  At the interface of the granular 
and cornified layers, fusion of the lamellar body membranes’ with the apical 
plasma membrane delivers their contents into the extracellular space (Kalinin et 
al, 2001).  This enriches the plasma membrane with ω-hydroxy-ceramides.  
This coating of the CE contributes to epithelial elasticity and barrier function 
(Kalinin et al., 2001; Candi et al., 2005). 
 
10 
 
As cornification progresses the 400kD profilaggrin is dephosphorylated and 
proteolytically cleaved to release 10, 11 or 12 functional filaggrin subunits.  
Filaggrin (filament aggregating protein - FLG) binds to the cytoplasmic KIF to 
form tight macrofibril bundles (Pearton et al., 2002).  This causes the KIF 
cytoskeleton to collapse forming the flattened cornified cells in which KIFs are 
aligned parallel to the outer surface of the epidermis.  These events must occur 
rapidly because the half life of FLG is 6 hours and FLG is then degraded into 
free hygroscopic amino acids, ‘natural moisturing factors’, essential for water 
retention, osmolarity and also flexibility of the cornified layer (Candi et al., 2005; 
S. J. Brown et al., 2012). 
 
Loricrin constitutes about 80% of the cornified cell envelope. Loricrin is 
complexed with various amounts of SPRs by TG3 and these oligomers are 
translocated to the cell periphery and crosslinked onto the pre-existing scaffold 
by TG1 (Kalinin et al., 2001).  The ratio of SPRs to loricrin varies between 
different body sites. Both give mechanical strength to the CE but the varying 
amounts of SPRs may alter the physical properties of the skin at different 
anatomical sites (Candi et al., 2005). 
 
The final anuclear, cornified cell consists mostly of bundled intermediate 
filaments of keratins (mainly 1, 2e, 10) embedded in a FLG matrix, covalently 
attached to envo- and periplakins and crosslinked to INV, loricrin and SPRs 
following degradation of organelles, microtubules, microfilaments and most 
desmosomal components.  Several other proteins are also involved in 
epidermal differentiation such as S100 proteins, a family of Ca2+ binding 
proteins which are expressed in the basal and spinous layers, and later the late 
envelope proteins (LEPs).  Corneocytes are surrounded by insoluble lipids and 
tightly attached to each other by corneodesmosomes (modified desmosomes), 
which are proteolytically cleaved in the uppermost layers of the stratum 
corneum to allow desquamation (Candi et al., 2005)(Candi et al, 2005). 
 
Proteases: These are involved in three processes in epidermal differentiation:  
1) proteolytic processing of some cornified-envelope precursors are required 
before cornified envelope formation can occur, 2) the loss of nuclei and 
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mitochondria requires proteolytic processing and 3) desquamation requires 
proteolysis of the corneodesmosomes.  There are three classes of intracellular 
proteases: lysosomal proteases, calpains and caspases.  The cathepsin family 
includes some lysosomal proteases.  Cathepsin D is important in cell survival 
and in keratinocytes is involved in proteolytic processing of TG1 required for CE 
formation.  The calpains may also be involved in TG1 processing.  Caspases 
regulate apoptosis (human caspases -2, -3, -6, -7, -8, -9 and -10) and 
inflammation (human caspases -1, -4, -5).   Caspase 14 is a member of the 
caspase family that is expressed and processed in association with keratinocyte 
differentiation at the transition from the granular to the cornified layer (Lippens 
et al., 2000; Candi et al., 2005). 
 
 
1.1.3 The epidermal differentiation complex 
A high proportion of the genes encoding the proteins important for terminal 
differentiation of the human epidermis are found in the epidermal differentiation 
complex (EDC) which maps to a 2.05-Mb region on chromosome 1q21 
(Mischke et al., 1996).  There are three families, related structurally, functionally 
and evolutionarily (Marenholz et al., 1996): 
1.  Structural proteins, including INV, loricrin and three classes of SPRs: two 
SPRR1 genes, eight SPRR2 genes and the SPRR3 gene. 
2. The intermediate filament associated proteins profilaggrin and trichohyalin 
3. 14 genes of the calcium-binding proteins S100 family (Eckert et al., 2004). 
 
1.1.4 Epidermal gene regulation 
The morphological changes occurring in the epidermis are the result of genes 
being turned on and off at specific times during the differentiation process.  The 
most common mode of gene regulation is transcription regulation (i.e. rate of 
RNA synthesis).  Every gene includes sequences designed to control RNA 
synthesis.  These sequences can be divided into two classes.  Firstly, 
sequences that control the rate of basal transcription and are common to most 
genes.  They include the TATA box sequence and the INR (initiator) sequence.  
These sequences bind to ubiquitous proteins that are used by nearly all 
promoters to initiate and maintain RNA transcription and include the TATA 
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binding protein, RNA polymerase II (Pol II) and other transcription activation 
factors.  This region of DNA ensures that RNA synthesis is initiated at the 
appropriate position along the DNA sequence and, in the absence of other 
transcriptional regulators, drive transcription at a low but physiologically relevant 
rate.  The second class of sequences modulate basal transcription and mediate 
the response to specific stimuli (Eckert et al., 1997). 
 
In keratinocytes, the expression of most genes is regulated at the transcription 
level by a class of proteins called transcription factors.  Transcription factors are 
nuclear proteins that mediate the final part of the signal from the cell surface to 
the nucleus and the gene by binding to a specific DNA sequence that is usually 
located upstream and adjacent to the sequence that encodes the gene to 
control the rate of its transcription.  This sequence is known as a silencer or 
enhancer and is called cis-acting as it is linked, on the same DNA strand, to the 
gene that it regulates.  These sequences are often located 50-5000 bp 
upstream of the binding sites for the basal transcription proteins.  Binding of the 
transcription factor to this site can either activate or suppress the gene (Eckert 
et al., 1997). 
 
Transcription factors usually have several functional domains.  All contain a 
DNA binding domain and a domain that regulates transcription, but also 
frequently contain a domain that regulates their activity via a phosphorylation 
site of the ligand binding site.  Combinations of a transcription factor family can 
also assemble to regulate gene expression.  Transcription factors can also 
integrate signals from the cell surface via signal transduction pathways.  These 
pathways regulate keratinocyte proliferation and differentiation (Eckert et al., 
1997): 
 
 AP1 factors function as homo- and heterodimers of the jun (c-jun, junB, 
junD) and fos (Fra-1, Fra-2, c-fos, fosB) family members.  AP1 sites have 
been shown to be functionally important as an activator of gene 
expression and that activation has been shown to be important for the 
transcription of keratins K1, K5, profilaggrin, filaggrin, Loricrin and TG1 
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as well as others.  Different AP1 family members regulate expression of 
different genes (Eckert et al., 1997). 
 AP2 is a transcription factor that has been shown to activate transcription 
of INV.  In addition it has been shown to be important in activating 
transcription of K5,K14 and TG1 (Eckert et al., 1997). 
 Sp1 is a transcription factor that has been identified as a regulator of 
TG3, INV and K5 (Eckert et al., 1997). 
 NFB activation results in protection against apoptosis by upregulating 
anti-apoptotic genes such as members of the Bcl-2 family and cellular 
inhibitors of apoptosis.  In vitro and mouse data reveal that in epidermal 
differentiation the regulation of NFb appears to be significant as the 
expression of NFb dependent anti-apoptotic proteins is increased in 
differentiating keratinocytes.  This may protect keratinocytes against 
apoptosis when cells undergo cornification (Lippens et al., 2005). 
 NFAT is a family of transcription factors encompassing 5 proteins that 
are related to the Rel/ NFb family.  NFAT activates transcription of a 
large number of genes including the regulation of cell differentiation 
programs in a number of cell types (Hogan et al., 2003).  The Reynolds 
lab has shown that endogenous NFAT translocates to the nucleus in 
human keratinocytes in response to differentiation stimuli following 
activation of calcineurin suggesting that the calcineurin/NFAT pathway 
may play a role in regulating keratinocyte differentiation (Al-Daraji et al., 
2002).   This will be discussed in detail later (Chapter 3.1). 
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1.1.5 Molecular Controls of Epidermal Differentiation 
These extracellular regulators control the balance between growth and terminal 
differentiation.   
 
Growth stimulatory signals:  Epidermal Growth Factor (EGF) stimulates cell 
proliferation and differentiation. Transforming growth factor α (TGF-α) is 
synthesized by keratinocytes and stimulates proliferation in an autocrine 
fashion.  Retinoic acid (at concentrations of 10-7 – 10-10 M) promotes 
proliferation and these changes are mediated by nuclear retinoic acid receptors 
(RARs).  Keratinocyte growth factor (KGF) and IL-6 are also growth stimulatory 
signals(Fuchs, 1990). 
 
Growth inhibitory signals: Transforming growth factor β (TGF-β) inhibits DNA 
synthesis and cell division and inhibits growth of basal cells.  TGF-βs are found 
predominantly in the differentiating layers and may be important in inflammation 
and repair regulation(Fuchs, 1990).  TNF-α, IFN-α and IFN-γ have keratinocyte 
cytostatic effects. 
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1.1.6 Calcium 
Calcium signalling:  Calcium ions (Ca2+) are important messengers carrying 
signals essential for the development and function of a cell from the beginning 
to the end of life.   
 
Ca2+ signalling involves an intracellular increase in calcium ions.  These signals 
usually involve a combination of release of Ca2+ from intracellular stores and 
influx of Ca2+ across the plasma membrane.  Entry of extracellular Ca2+ maybe 
via voltage-operated channels (VOCs), receptor-operated channel (ROCs) or 
store operated channels (SOCs).  SOC is also known as capacitative calcium 
entry (Berridge, 1997b; Putney, 2005).  
 
The endoplasmic reticulum (ER), or a specialised component of it, provides an 
important store for Ca2+ providing a source for the intracellular release of Ca2+ to 
the cytoplasm in the course of Ca2+ - dependent signalling processes.  The 
release of Ca2+ from intracellular stores is either via the messenger inositol 
trisphosphate (IP3) and/or additionally via calcium-induced calcium release.  
The Ca2+ ATPase pump which transfers Ca2+ to the lumen of the ER or to the 
cytosol is known as SERCA.   In most cell types, depletion of intra cellular Ca2+ 
stores signals the activation of capacitative calcium entry (Berridge, 1997a; 
Putney, 2005).   
 
In order for Ca2+ to fulfil its role as a key second messenger depends largely on 
a number of heterogenous calcium binding proteins (CBP) such as calmodulin, 
S100 proteins and calcineurin.  These CBP contribute to the intracellular control 
of Ca2+ concentration as well as acting as Ca2+ transporters across the cell 
membranes or as Ca2+ modulated sensors thus contributing to calcium 
homeostasis and signalling pathways (Yanez et al., 2012). 
 
Calcium and Epidermal differentiation: Ca2+ is critical for controlling the balance 
of proliferation and differentiation.  Elevation of extracellular Ca2+ ([Ca2+]o) to 
>1.0mM triggers an acute and then sustained increase in intracellular Ca2+ ([Ca 
2+]i) and tightly controls epidermal differentiation and expression of EDC genes 
(Bikle et al., 1996). 
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In keratinocytes, [Ca2+]o activates the phospholipase C (PLC) pathway resulting 
in a rise in inositol trisphosphate (IP3) that coincides with the increase in [Ca 
2+]i.  
IP3
  may then mediate the rise in [Ca 
2+]i
 by the result of calcium-activated PLC 
activity or by releasing calcium from intracellular stores.  In addition, [Ca2+]o
 
stimulates transmembrane calcium flux by activating chloride channels, causing 
hyperpolarization of the membrane, and activating voltage independent non-
specific cation channels permeable to Ca2+ (Bikle et al., 1996). 
Specific functions of Ca2+ in keratinocyte differentiation are in transcription of 
EDC genes, activation of the TGs, desmosomal integrity, regulation of Ca2+-
dependent proteases and in protein deamination (Eckert et al., 1997). 
 
1.1.6 Keratinocytes and cutaneous inflammation 
Keratinocytes can themselves initiate inflammatory reactions.  Many cytokines 
are produced by keratinocytes and include the pro-inflammatory cytokines IL-1, 
IL-3, IL-6, IL-8, Granulocyte colony-stimulating factor (G-CSF), Macrophage 
colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and TNF-α.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Rapid cascade of cytokines in response to keratinocyte injury, adapted 
from McKenzie and Sauder (McKenzie and Sauder, 1990) 
 
 
In response to epidermal barrier disruption (Figure 2), keratinocytes can rapidly 
generate an inflammatory response via a cascade and network of cytokines.  
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The IL-1 family are essential proinflammatory cytokines.  IL-1α and IL-1β both 
act via IL-1 receptor type I (IL-1R).  IL-1α seems to exist at a constitutive level 
whereas IL-1β is only detectable upon stimulation (Contassot et al., 2012).  
Cytokines act in an autocrine fashion:  IL-1 release stimulates further release of 
IL-1 and also stimulates the production of IL-8, IL-6, TNF-α, and GM-CSF from 
neighbouring keratinocytes.  T-cells rapidly proliferate under the influence of IL-
1.  Activated T cells produce IL-2, IL-4 and IL-5 which stimulate B-cell 
proliferation and antibody production.  TNF-α release from IL-1 stimulated 
keratinocytes enhances the inflammatory responses initiated by IL-1 and 
enhances MHC expression and antigen presentation to lymphocytes.  IL-1 and 
TNF-α are not only chemotactic for leukocytes but also induce expression of 
intercellular adhesion molecules (ICAMS).  Circulating leukocytes adhere to 
ICAM expressing cells at the site of injury and become activated by local 
cytokines.  IL-1 stimulates keratinocyte chemotaxis, proliferation and 
differentiation (McKenzie and Sauder, 1990; Segre, 2006).  High levels of 
cytokines IL-6 and IL-8 are found in psoriasis.  Up-regulation of ICAM 
expression on keratinocytes is seen in atopic dermatitis and psoriasis 
(McKenzie and Sauder, 1990). 
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Chapter 2:  Inflammatory Skin Disease  
 
Atopic eczema and psoriasis are two of the most common inflammatory skin 
conditions.  Immunological mechanisms have been primarily studied as the 
aetiology for atopic eczema and psoriasis.  Histologically, both conditions are 
accompanied by a T-cell predominant inflammatory infiltrate of the dermis and 
epidermis.  However, both are characterised by abnormal epidermal 
differentiation and impaired barrier function.  There is increasing evidence to 
suggest that a primary epithelial barrier defect plays an important role in the 
pathogenesis of psoriasis and atopic eczema (Griffiths et al., 2006; Nickoloff, 
2006).  In both, the degree of epidermal barrier disruption correlates with the 
severity of the condition (Segre, 2006). 
 
Atopic eczema and atopic disease are increasing in frequency now affecting 
approximately 20% of the population in the developed world.  Acute eczema is 
characterised by spongiosis (intercellular oedema) and is regularly 
accompanied by infiltration of leukocytes, mostly lymphocytes, into the 
epidermis and upper dermis where a switch from a Th1 to a Th2 cytokine profile 
(IL-4, IL-5, IL-10, IL-13) in lesional skin of AD is well established.  As the 
disease becomes chronic, the infiltration of lymphocytes and spongiosis 
diminishes and acanthosis (thickening of the stratum spinosum), hyperkeratosis 
and parakeratosis, signifying abnormal keratinocyte differentiation, occur 
(Griffiths et al., 2006; Howell et al., 2007). 
 
Psoriasis affects approximately 2% of the population in western countries.  
Psoriatic plaques are characterized by increased keratinocyte proliferation 
leading to epidermal hyperplasia and hyperkeratosis, abnormal keratinocyte 
differentiation (parakeratosis), infiltration of the epidermis and dermis by 
activated lymphocytes and neutrophils and tortuous and dilated upper dermal 
blood vessels. A T helper type 1 (Th1) profile of cytokines predominates (i.e. 
IFN-γ, IL-2, and IL-12) (Griffiths et al., 2006). 
 
Both atopic eczema and psoriasis have complex genetic and environmental 
components contributing to their pathogenesis.  Genetic linkage of both atopic 
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eczema and psoriasis to the EDC on chromosome 1q21 strongly suggests a 
role for barrier function and repair in these disorders (Sugiura et al., 2005; 
Segre, 2006).   A large scale DNA microarray analysis of 23,000 genes in skin 
biopsies from 17 patients with atopic eczema revealed down-regulation of 
cornified envelope genes and up-regulation of the alternative keratinisation 
pathway – a mechanism in place which responds to conditions requiring rapid 
epidermal regeneration and protective gene expression which in atopic eczema 
may not be adequately regulated.  The genes with the greatest difference in 
expression were FLG and loricrin which were down regulated and S100A8 and 
S100A7 which were upregulated (Sugiura et al., 2005).  The S100 proteins are 
also markedly overexpressed in psoriasis (Eckert et al., 2004). 
 
In support of this, mutations in the FLG gene have been shown to be implicated 
in the pathogenesis for atopic eczema implying impaired skin barrier function in 
the development of atopic disease.  Reduced expression of FLG has been 
shown by immunofluorescence, in patients with atopic dermatitis (Palmer et al., 
2006). 
 
In psoriasis, an additional susceptibility locus has been mapped to PSORS4 on 
chromosome 1q21 within the EDC (Capon et al., 2001).   
  
2.1 Atopic Eczema and Filaggrin  
The world wide prevelance of atopic eczema has increased by approximately 
threefold since the 1960’s with social and environmental factors influencing the 
expression for atopic eczema.  Advances in understanding the pathogenesis of 
atopic eczema and atopic disease have been made possible following the 
identification that mutations in the FLG gene are associated with barrier defects 
(Eichenfield et al., 2012). 
 
FLG was first identified in the late 1970s by Dale and its role in keratin filament 
aggregation established (Dale, 1977; Dale et al., 1978).  Sybert and colleagues, 
in 1985, identified that FLG abnormalities contribute to ichthyosis vulgaris (IV) 
(Smith et al., 2006; Eichenfield et al., 2012; McLean and Irvine, 2012).  In 2006, 
Smith et al after overcoming the technical difficulty in sequencing FLG, showed 
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that null mutations in the FLG gene was the cause of IV which was inherited by 
a semi-dominant Mendelian inheritance (Smith, Irvine et al. 2006).  IV is a 
common disorder, occurring in 1 in 250 individuals, characterized clinically by 
xerosis, scaling, hyperkeratosis, keratosis pilaris, palmar and plantar 
hyperlinearity, as well as a strong association with atopic disorders.   
 
Loss-of-function mutations in the FLG gene are common with approximately 
10% of individuals in European populations carrying at least one FLG mutation, 
which are associated with a 50% reduction in FLG protein production.  The first 
two recurrent loss-of-function mutations identified were the R501X and 
2282del4 mutations, but several others have been since identified with 
population-specific patterns being identified worldwide (Figure 3) (Sandilands et 
al., 2007; Irvine et al., 2011).   
 
 
 
 
 
 
 
 
 
 
 
 
 
The association of the loss-of-function FLG gene mutation and the development 
of atopic eczema has been widely established and replicated.  In addition, 
patients with atopic eczema who have the FLG mutation have more severe and 
more persistant eczema and are more likely to develop asthma and multiple 
allergies including peanut allergies and are more at risk of acquiring herpes 
virus infections (S. J. Brown et al., 2011; McLean and Irvine, 2012).  
 
Figure 3.  Schematic of the human FLG gene.  The FLG gene is polymorphic with 
common allelic variants showing 10,11, or 12 almost identical tandem repeats in exon 3, 
demonstrating intragenic copy number variation.  Each repeat at the DNA level encodes a 
complete copy of the functional 324 amino-acid filaggrin polypeptide product of the gene.  
The location of 11 known mutations are shown.  Recurrent mutations can occur on the 
background of a 10-, 11- or 12- repeat allele; UTR – untranslated repeat (modified from 
O’Reagan et al and Brown et al (O'Regan et al., 2008), (S. J. Brown et al., 2012) 
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Interestingly, the intragenic copy number mutations are also important, as the 
total FLG repeat number (the FLG index) significantly predicts atopic eczema 
risk:  an increase in FLG copy number leads to a reduced risk of developing 
atopic eczema (S. J. Brown et al., 2012) .   Kesic et al have shown that FLG 
expression is downregulated in all cases of moderate-severe atopic eczema 
even in the absence of FLG-null alleles (Kezic et al., 2011; McLean and Irvine, 
2012).  
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2.2 Atopic eczema and antimicrobial peptides 
Antimicrobial peptides (AMP) are innate defence proteins expressed in the skin.  
Two main groups of AMPs are the β-defensins and the cathelicidins.   These 
innate defense proteins were first discovered for their antimicrobial actions but 
have since been found to play an important role in triggering the adaptive 
immune response.  They have different regulatory pathways but both β-
defensins and cathelicidins are released at high local concentrations when 
needed in response to infection or epidermal injury.  The cathelicidins have 
been shown to protect against skin infections but many additional peptides have 
also been described to have antimicrobial properties.  β-defensins are 
chemotactic for memory T cells and immature dendritic cells.  Once stimulated 
they release a variety of cytokines (Figure 4) (Schauber and Gallo, 2007). 
 
 
.   
 
 
 
 
 
 
Figure 4.  Schematic showing cytokine and chemokine realease from human 
kertinocytes following antibicrobial peptide stimulation, modified from Schauber 
and Gallo (Schauber and Gallo, 2007) 
 
Patients with atopic eczema have been shown to have a relative deficiency of 
AMP compared to patients with other inflammatory skin diseases.  This may be 
associated with staphylococcal colonization which is very common in atopic 
eczema, who are then at increased risk of developing infection (Eichenfield et 
al., 2012). 
 
If a barrier defect allows secondary immunological changes that mediate the 
development of atopic eczema then early intervention may prevent its 
development and even halt the progression of the atopic march. 
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Chapter 3. CYCLOSPORINE A 
 
3.1 Cyclosporine A, Calcineurin and NFAT 
Cyclosporine (CsA) is a cyclic 11 amino-acid peptide produced by the fungus 
Tolypocladium inflatum and is an immunosuppressant agent which, along with 
FK506, revolutionised transplant surgery due to their ability to block the 
activation of T-lymphocytes and prevent graft rejection in organ and bone 
marrow transplantation (S. L. Schreiber and Crabtree, 1992). 
 
CsA is known to act on the cells of the immune system with a preference for T 
cells.  CsA blocks the activation and proliferation of T cells through inhibition of 
T cell receptor-mediated IL-2 production by preventing NFAT translocation to 
the nucleus (Buurman et al., 1986).  CsA binds specifically to intracellular 
receptors called cyclophilin (CyP), a member of the immunophilin family.  
FK506 binds specifically to the immunophilin FKBP12 .  The CsA-CyP complex 
then binds to and inhibits calcineurin, a Ca2+ and calmodulin dependent 
serine/threonine phosphatase.  Inactivation of calcineurin prevents 
dephosphorylation of the nuclear localization sequence (NLS) of Nuclear Factor 
of Activated T cells (NFAT) (Buurman et al., 1986).   
 
The NFAT family are a group of five transcription factors related to the 
Rel/NFκB family (NFAT 1-5).  Normally, NFAT proteins are phosphorylated and 
reside in the cytoplasm in resting cells.  NFAT 1-4 are regulated by Ca2+ and the 
Ca2+/calmodulin-dependent serine phosphatase calcineurin; upon stimulation 
these NFAT proteins are dephosphorylated by calcineurin, exposing a NLS, and 
translocate to the nucleus.  Here they become transcriptionally active, providing 
a direct link between intracellular Ca2+ signalling and gene expression (Figure 5) 
(Hogan et al., 2003).  
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Figure 5.  Mechanism of action of CsA.  CsA binds to Cyclophilin (CypB).  The CsA-
CypB complex binds to regulatory subunit of calcineurin.  Calcineurin is positively 
regulated by Ca
2+
 and negatively regulated by an endogenous inhibitor (CAIN).  In 
immune cells, calcineurin dephosphorylates NFAT regulating expression of cytokines, 
their receptors and ion channels.  NFAT complex is composed of NFAT proteins and 
AP-1 transcription factor activated via Ras/PKC/MAPK pathway.  JNK (c-Jun N 
terminal MAP kinase) and GSK3β phosphorylate NFAT proteins counteract effects of 
calcineurin (modified from Kaminska et al, 2004 (Kaminska et al., 2004)). 
 
NFAT acts synergistically with AP-1 but also with other transcription factors 
other than Fos and Jun (Hogan et al., 2003).  NFAT activates transcription of a 
large number of genes during an effective immune response including IL-2, IL-
3, GM-CSF, TNFα and Fas ligand (Rao et al., 1997). When Ca2+ entry is 
prevented or calcineurin activity is inhibited, NFAT is rephosphorylated by NFAT 
kinases and rapidly leaves the nucleus, terminating NFAT gene expression 
(Figure 5) (Hogan et al., 2003). 
 
Thus, CsA inhibits calcineurin and prevents IL-2 production which is required for 
T cell activation. 
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3.2 Cyclosporine A in inflammatory skin disease 
Since 1979, CsA has been used as effective treatment for psoriasis.  Since 
then, it has been used effectively for atopic eczema (Figure 6) and for a number 
of other dermatoses such as pyoderma gangrenosum, lichen planus, Darier’s 
disease, Hailey-Hailey’s disease and autoimmune bullous disease (Griffiths et 
al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Clinical improvement of atopic eczema with CsA therapy.  Example of (i) 
clinical improvement at 4 weeks and (ii) reduction in the total disease severity score 
(SASSAD) in response to CsA therapy (4mg/kg), with kind permission from NJ 
Reynolds. 
 
However, its precise mechanism of action in skin and in particular psoriasis and 
atopic eczema is not completely understood.  Both conditions are accompanied 
by a T-cell predominant inflammatory infiltrate.  In psoriasis, a Th1 cytokine 
predominates within the plaques, thus cyclosporin may exert its effects here by 
inhibiting T cell activation via a reduction in IL-2 expression (Griffiths et al., 
2006).   
 
There is good evidence that suggests that CsA exerts effects in the skin that are 
independent of its action on T-cells.  CsA has been shown to inhibit proliferation 
of cultured keratinocytes from psoriatic plaques at concentrations that are 
(ii) 
(i) 
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therapeutically relevant (Fisher et al., 1988).  CsA inhibits 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) induced epidermal hyperplasia, leukocyte infiltration 
and keratinocyte-derived TG activity and inhibits TPA induced inflammation in 
SCID mice in the absence of functioning T cells (Reynolds et al., 1998).  CsA 
also induces hair growth indicating a direct epidermal effect (Taylor et al., 
1993).  CsA has also been shown to inhibit epidermal IL-1 and IL-8 expression 
in psoriatic skin before clinical improvement is seen and suggests that CsA also 
modulates keratinocyte cytokine expression (Prens et al., 1995). 
 
Furthermore, the expression of the calcineurin/NFAT pathway has been shown 
in cultured human keratinocytes and in normal and psoriasis skin in vivo 
(Barrandon and Green, 1987; Al-Daraji et al., 2002).  CsA binding protein 
cyclophilin A and tacrolimus binding protein FKBP12, calcineurin and NFAT 
were all expressed predominantly in the keratinocytes of normal and psoriatic 
skin.  Increased nuclear localization of NFAT1 in suprabasal keratinocytes of 
psoriatic epidermis was observed indicating calcineurin activation.  In addition, 
calcineurin is functionally active by demonstration of nuclear translocation of 
endogenous NFAT in  human keratinocytes which have been exposed to 
differentiation stimuli, specifically TPA, TPA plus ionomycin and raised [Ca2+]o 
that is inhibited by CsA and tacrolimus in a dose dependent manner and at 
doses that are therapeutically relevant (Al-Daraji et al., 2002).  
 
Activation of calcineurin/NFAT by agonists that induce keratinocyte 
differentiation suggest that this pathway may play a role in regulating 
keratinocyte differentiation.  Regulation of transcription of mouse keratinocyte 
differentiation markers and the cyclin-dependent kinase inhibitor p21WAF1 via 
calcineurin has been shown to occur through a mechanism involving an 
interaction between NFAT1/NFAT2 and the Sp1/Sp3 transcription factors 
(Santini et al., 2001). 
 
These data indicate that inhibition of NFAT in keratinocytes by CsA may 
contribute to its therapeutic effects in psoriasis and that the calcineurin/NFAT 
pathway may play a role in epidermal differentiation. 
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Chapter 4.  Cyclophilin B  
 
4.1 The immunophilins  
Three enzymes subfamilies, the cyclophilins, FK506 binding proteins (FKBPs) 
and parvulins, are collectively termed immunophilins on the basis of their affinity 
for immunosuppressive ligands. They are highly conserved and ubiquitous 
proteins, the majority of which possess the ability to catalyze the cis-trans 
isomerization of peptidyl-prolyl bonds.  The cyclophilins were the first subfamily 
of immunophilins to be discovered in bovine thymocytes as ligands for the 
immunosuppressant drug CsA. FKBPs bind macrolides such as FK506 
(tacrolimus) and rapamycin(sirolimus), that are structurally distinct from CsA.  
Parvulins bind Juglone (5-hydroxy-1,4-napthoquinone, an organic brown 
compound found in leaves, husk and barks of trees) (M. T. Ivery, 2000a; Galat 
and Bua, 2010). 
 
A large number of isoforms of both cyclophilins and FKBPs have been isolated, 
varying primarily by their molecular weight and tissue distribution.  All are 
characterised by their highly conserved ligand binding domain.  Immunophilins 
are ubiquitous and occur in every compartment both as free cytosolic and 
membrane bound species.  Their peptidyl-prolyl cis-trans isomerase (PPIase) 
activity is important for protein folding, assembly and trafficking.  There is 
growing evidence to suggest that immunophilins perform other important 
functions within a range of organisms and cell types although their exact 
function remains to be elucidated (M. T. Ivery, 2000a). 
 
Cyclophilins and FKBPs have structurally distinct PPIase domains that are 
unrelated in their amino acid sequence.  The drugs bind to the catalytic pocket 
of the PPIase domain and inhibit their PPIase activity.  In addition, the drug-
immunophilin complexes, CyP-CsA and FKBP-FK506, inhibit calcineurin and 
subsequently block activation and proliferation of T-cells, the basis of 
immunosuppression. Although their drug-dependent functions which gave rise 
to their name have clinical relevance, this interaction does not appear, so far, to 
have any physiological relevance (McCaffrey et al., 1993; Kumari et al., 2012). 
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4.2 The Cyclophilins 
Cyclophilins are found in most cellular compartments in mammals, plants, 
insects, fungi and bacteria.  There are 7 major cyclophilins in humans, CypA, 
CypB, CypC, CypD, CypE, Cyp40 and CypNK, with a total of 16 cyclophilin 
proteins identified so far.  Their structure is conserved throughout evolution and 
all cyclophilins share a common central domain of approximately 10 amino 
acids, the cyclophilin core domain which includes the PPIase catalytic site and 
the CsA binding site (Wang and Heitman, 2005).  In mammals, CypA and 
Cyp40 are cytosolic whereas CypB and CypC have amino-terminal signal 
sequences that target them to the ER protein secretory pathway. CypD has a 
signal sequence that directs it to the mitochondria; CypE has an amino-terminal 
RNA-binding domain and is localised in the nucleus, Cyp40 has a c-terminal 
tetratricopeptide repeat domain (TPR) and is located in the cytosol. Human 
CypNK is the largest cyclophilin, with a large, hydrophilic and positively charged 
carboxyl terminus, and is located in the cytosol (Wang and Heitman, 2005). 
 
CypA and CypB are the most abundant isoforms of the cyclophilins (Wang and 
Heitman, 2005).  The first characterized isoform of cyclophilin was cyclophilin A 
(CypA) and is an abundant cytosolic isoform recognised as the host cell 
receptor for CsA (Takahashi et al., 1989; Edlich and Fischer, 2006).  Cyclophilin 
B (CypB), a second CsA binding protein, was then characterised and was found 
to have a 10 times higher affinity for CsA than CypA and was distinguishable 
from CypA as an ER residential protein (Figure 7) (Hasel et al., 1991; Spik et 
al., 1991; Mikol et al., 1994). 
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Figure 7.   Three-dimensional structures of (A) CypA and (B) CypB.  Visualized 
models with WinMGM program using the coordinate files (A) ICWA and (B) ICYN.  
CsA is represented with the yellow balls.  The residue W121 is involved in the CsA 
binding site of CypA and W128A is involved in the CsA binding site of CypB.  Taken 
from Carpentier el al, 2000 (Carpentier et al., 2000). 
 
a) b) 
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4.3 Characteristics of Cyclophilin B 
CypB (also known as peptidylprolyl isomerise B or PPIB) is a 21kDa protein 
mapped to 15q21-q22.   
 
Sequence alignment and comparison of human CypB (hCypB) to human CypA 
(hCypA), yeast CypB (yCypB) and rat cyclophilin-like protein (rCyLP), reveals 
domains with various degrees of conservation (E. R. Price et al., 1991).  Human 
CypB (Figure 8) contains 5 domains:  Domain I, made up of 33 amino acids, at 
the N-terminal containing characteristic ER directed signal sequences and 
nuclear localisation sequence, absent from CypA;  Domain II, III and IV 
(containing 61, 77 and 27 amino acids respectively) make up the CyP core 
domain; Domain V contains 10 amino acids  which are not found in the CypA 
family (Figure 8b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Schematic structure of CypB.  a) Schematic showing domain structure of 
human CypB (modified from Price et al (E. R. Price et al., 1991) and Fearon et al 
(Fearon et al., 2011) b) Schematic comparison of hCypB to yCypB and hCypA.  For 
each domain the percentage of amino acid identity between hCypB and a particular 
homologue is displayed (modified from Price et al (E. R. Price et al., 1991)). 
 
CypB accumulates in the ER and in complexes on the cell surface.  It has a 
cleavable N-terminal signal sequence that directs the protein to the ER 
(Schumacher et al., 1994).  Regulation of protein expression during cell life and 
differentiation is reliant on the mechanisms operating in the ER and in the 
a) 
b) 
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downstream compartments of the secretory pathway (Ellgaard et al., 1999) 
(Ellgard et al, 1999).  CypB lacks the C-terminal KDEL ER-retention signal 
found in most ER resident proteins but interacts with plasma membrane 
proteins in the ER via the VEKPFAIAKE motif at the C-terminus of CypB.  The 
ER retention sequence (AIAKE) is proteolytically clipped in the ER enabling 
secretion of CypB into the extracellular environment (E. R. Price et al., 1991; 
Arber et al., 1992; E.R. Price et al., 1994).  The variable C-terminal domain is 
isoform specific.  CsA causes a specific and rapid translocation of CypB from 
the ER to more distal portions of the secretory pathway (E.R. Price et al., 1994).  
Within the N-terminus, CypB contains a nuclear translocation motif 
(DEKKKGPKV) (Figure 9) (E. R. Price et al., 1991). 
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Figure 9.  Nucleotide and amino acid sequence of CypB.  a) Nucleotide and amino 
acid sequence of hCypB and b): Amino acid sequence alignment showing homologies 
between human CypA (165 amino acid residues), human CypB (208 residues), yeast 
CypB (206 residues) and rat CyP-like protein (rCyLP) (231 residues) lower case letter 
indicate insertions relative to hCypA at the N-terminus (cleavable N-terminal sequence 
directing CypB to the ER), dots indicate deletions, and hyphens indicate identities, 
taken from Price et al (E. R. Price et al., 1991). 
a) 
b) 
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4.4 Functions of Cyclophilin B 
Increasing evidence reveals CypB to be involved in both intracellular and 
intercellular activity (Figure 10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Schematic summarising intercellular and intracellular functions of 
CypB. 
 
 
4.4.1 Intracellular functions of Cyclophilin B 
 
PPIase activity and Protein folding and assembly 
The PPIase activity of cyclophilins are important in protein folding and in the 
assembly of multidomain proteins.  Peptide bonds can exist in two distinct 
isomeric forms – cis and trans.  The trans peptide bond is a lower energy state 
with side chains at 180 degrees opposite to each other.  These are sterically 
favoured and it is thought that the ribosome synthesizes peptide bonds in this 
form.  In proline containing peptides, 10% of the peptidyl-prolyl bonds are in the 
unusual cis conformation where the side chains are adjacent to each other.  
CyPs stabilise the cis-trans transition state and accelerate isomerization (Figure 
11). 
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Figure 11.   Cis-trans isomerization of a peptidyl-prolyl bond (Gothel and Marahiel, 
1999). 
 
This process is considered important not only in protein folding but also during 
the assembly of multidomain proteins (Gothel et al., 1996). 
 
CsA blocks the PPIase activity of cyclophilins but the prolyl isomerase activity of 
these proteins is not essential for their immunosuppressive effects (Gothel and 
Marahiel, 1999). 
 
Kim et al have shown that CypB expression is activated during ER stress via an 
ER stress response element and suppresses ER stress mediated apoptosis.  
Overexpression of CypB, but not the catalytically (PPIase) inactive mutant, 
protected cells against ER stress by preventing abnormal calcium leakage, 
ROS generation and mitochondrial membrane depolarization.  Conversely, 
CypB knockdown increased the sensitivity of cells to ER stress.  These studies 
show that CypB is required for cell survival in response to ER stress via its 
PPIase activity (J. Kim et al., 2008). 
 
Recently, mutations in the PPIB gene have been shown to contribute to a small 
percentage of individuals with oseogenesis imperfecta.  It is thought that 
excessive post-translational modification of type1 procollagen results in 
phenotypes that range from lethal osteogenesis imperfecta in the perinatal 
period to severe deforming osteogenesis imperfecta and that normally the 
PPIase activity of CypB is required to produce effective type 1 procollagen 
(Pyott et al., 2011).  However, a lack of CypB in osteogenesis imperfecta has 
also been associated with normal collagen folding but that there is a delay in 
folding due to the unavailability of CypB (Barnes et al., 2010). 
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Protein chaperones 
An important role for CyPs is as chaperones for protein trafficking and 
macromolecular assembly.  For example CypA and CypB assist viral 
replication.  CypB interacts with the HCV RNA-dependent RNA polymerase 
(NS5B) required for viral replication.  HCV replication is compromised if the 
CypB-NS5B interaction is competitively inhibited by CsA or mutation of NS5B 
which prevents its binding to CypB (Watashi et al, 2005).  CypA promotes the 
formation and infectivity of HIV via its interaction with HIV-1 GAG (Galat, 1993; 
Stremlau et al, 2004).  Non-immunosuppressive anolgues of CsA, namely 
Debio-025 and SCY-635 may alter certain replication steps of HCV (Fernandes 
et al., 2010; Puyang et al., 2010). 
 
Calcium signalling 
CypB has been implicated in Ca2+ signalling. Stimulation of T cells with CypB at 
varying concentrations induced Ca2+ mobilization which did not occur when 
CypB was preincubated in the presence of CsA (Denys et al., 1998a). 
 
In the search for potential homologues of CsA, calcium modulating cyclophilin B 
ligand protein (CAML) was identified.  Overexpression of CAML in Jurkat T cells 
constitutively activated an NFAT reporter in cells co-stimulated with phorbol 
ester (Bram and Crabtree, 1994; Holloway and Bram, 1998).  NFAT requires a 
Ca2+ influx signal for activation which is usually provided following T cell 
receptor stimulation.  This can be mimicked pharmacologically by treating cells 
with thapsigargin, a specific inhibitor of Ca2+/APTase (SERCA) pumps (Hogan 
et al., 2003).  CAML localizes to SERCA2-containing vesicles and 
overexpression of CAML markedly depleted internal Ca2+ stores and shifted the 
dose response of thapsigargin to lower concentrations.   
 
Thus CAML may act by directly releasing intracellular Ca2+ and leading to 
consequent NFAT activation through the capacitative Ca2+ pathway (Holloway 
and Bram, 1998). 
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Receptor trafficking  
CypB may be important in receptor recycling.  CAML deficient mouse epithelioid 
cells had severely impaired proliferative responses to EGF. In these cells, EGF 
induced activation of signalling intermediates and internalization of the EGF 
receptor (EGFR) were normal, but recycling of the internalized receptor to the 
plasma membrane was defective leading to reduced surface accumulation.  
Enhanced recycling of surface receptors effectively leads to augmented ligand-
induced proliferation by continuously replenishing surface receptor levels 
necessary for prolonged signalling (Tran et al., 2003).   
 
Transcription induction 
CypB has been shown to potentiate prolactin (PRL) driven proliferation, cell 
growth and nuclear retrotransport of PRL.  PRL is necessary for mammary 
growth and differentiation and its pleotrophic actions are mediated by signalling 
through the PRL receptor.  In addition to activation of signalling cascades, the 
PRL receptor is also associated with ligand internalisation via an endosomal like 
pathway across the ER and nuclear envelope known as nuclear 
retrotranslocation.  The retrotranslocation of peptide hormones also appears to 
be widespread as several other peptide hormones such as EGF, growth 
hormone and insulin are also noted in the nucleus.  CypB has been shown to 
potentiate PRL-driven proliferation and this was accompanied by a dramatic 
increase in nuclear retrotranslocation of PRL.  Removal of the NLS in the N 
terminus of CypB abrogated the potentiation in PRL proliferation and the 
enhancement of PRL nuclear transport indicating a necessary role for CypB in 
these functions.  Furthermore, PPIase activity of CypB is required for the 
potentiation of PRL-driven proliferation but not for PRL nuclear retrotransport 
(Rycyzyn et al., 2000).  The PRL/CypB complex interacts directly with Stat5, a 
member of the signal transducers and activators of transcription (STATs) which 
comprise a family of several transcription factors that are activated by a variety 
of cytokines, hormones and growth factors. STATs are activated through 
tyrosine phosphorylation, mainly by JAK kinases, which lead to their 
dimerization, nuclear translocation and regulation of target genes expression 
(Rycyzyn and Clevenger, 2002; Valentino and Pierre, 2006).  The interaction of 
the PRL/CypB complex with Stat5 results in the removal of the stat-repressor 
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protein inhibitor of activated Stat3 (PIAS3), enhancing Stat5 DNA-binding 
activity and PRL-induced Stat5 mediated gene expression (Rycyzyn and 
Clevenger, 2002). 
 
CypB levels are increased in malignant breast epithelium and have been shown 
to play an important role in cancer progression, cell proliferation and cell growth. 
They are also implicated in the regulation of the above genes which are 
implicated in the pathogenesis of breast cancer (Fang et al., 2009). Knockdown 
of CypB decreases cell growth, proliferation and migration.  Prolactin is 
increasingly appreciated as having a key role in the pathogenesis of breast 
cancer.  CypB knockdown was shown to impair the patterns of gene expression 
induced by prolactin in breast cancer cells and that targeting both PRL-induced 
signals and CypB may have a synergistic potential in the treatment of breast 
cancer. 
 
4.4.2 Intercellular functions of Cyclophilin B 
CypB is the major component of the extracellular pool of cyclophilins.   
Appreciable quantities of CypB of up to 150ng/ml have been found in serum 
and breast milk (Allain et al., 1995; Mariller et al., 1996).  CypB can also be 
released from chondrocytes by activated matrix metalloproteinases (MMPs) (De 
Ceuninck et al., 2003).  In vitro, extracellular CypB interacts with two types of 
receptor at the surface of the T-lymphocytes. 
 
The first type, known as Type I binding sites, were identified as CD147 (also 
known as Basigin or EMMPRIN) initially in T cells, but are now known to be 
expressed by epidermal keratinocytes, human skin mast cells and melanoma 
cells (Denys et al., 1997; Ghannadan et al., 1998; Kanekura et al., 2002; 
Yurchenko et al., 2010). Type I binding sites are involved in an endocytosis 
process and have been shown to be essential for cyclophilin-initiated signalling 
events (Denys et al., 1998a).  The type I receptor-binding site region on CypB is 
highly conserved containing the CsA binding pocket– its interaction is inhibited 
by CsA.  The PPIase activity of CypB is not required for receptor binding but are 
required for promoting cellular adhesion (Carpentier et al., 2002).   
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The second, Type II binding sites, are highly specific and correspond to  
glycosaminoglycans (GAGs) of the heparin family. The type II receptor-binding 
site is located in the N-terminal extension of CypB which is not present in CypA.  
In T-cells the interaction of CypB with GAGs does not only serve to increase the 
local concentration near the type I receptors but also affects the biological 
activity. The binding regions of CypB are located on opposite sides of the 
molecule (Denys et al., 1998a; Yurchenko et al., 2001; Carpentier et al., 2002). 
 
T-Cell chemotaxis and adhesion 
CypB induces chemotaxis and integrin mediated adhesion of T cells to the ECM 
and appears to target memory CD4+ T cells predominantly in vitro which 
suggests that CypB may recruit specific populations of T cells into infected 
tissue in vivo thus playing a role in inflammation.  CypB induced T-cell adhesion 
to the ECM in vitro was by its ability to bind to Type II GAGs receptors (Allain et 
al., 2002).    
 
4.5  Cyclophilin B and inflammation 
Accummulating data have implicated extracellular CypB (as well as CypA) as 
an intercellular mediator in inflammation.  High levels of cyclophilins have been 
observed in inflammatory disorders such as sepsis, rheumatoid arthirits and 
atherosclerosis and systemic lupus erythematosus (Billich et al., 1997; Tegeder 
et al., 1997).  CypB is constituitively secreted by tissue-resident cells (eg 
fibroblasts, chondrocytes and keratinocytes) and accumulates within the 
extracellular matrix (Gonzalez-Cuadrado et al., 1996; De Ceuninck et al., 2003; 
Fearon et al., 2011).  It is released intact by heparanase and MMPs suggesting 
it can participate in tissue inflammation.  CypB contributes to leukocyte 
infiltration during the acute phase of inflammation.  In addition it is able to trigger 
chemotaxis and integrin activation in T lymphocytes (Marcant et al., 2012). 
 
4.6  Cyclophilin B and keratinocyte differentiation 
SDS/PAGE immunoblot of cyclophilin and quanitifcation of cyclophilin mRNA in 
human epidermal cells revealed that CyP isoforms were consistently expressed 
throughout normal differentiating human keratinocytes but their function in the 
keratinocyte remains elusive (Chatellard-Gruaz et al., 1994; Steele et al., 2002).  
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CyP is found in normal human skin, lesional psoriatic skin and in non-
differentiating and differentiating keratinocytes (Griffiths et al., 1990; Chatellard-
Gruaz et al., 1994).  The presence of two isoforms, a major and minor form of 
CyP were found in cultured human keratinocytes and in normal and psoriatic 
skin.  The major CyP form was found in vivo and in vitro at similar levels in all 
samples but the minor form was expressed at significantly lower levels in 
psoriatic plaques as compared with normal skin.  Inducing cultured 
keratinocytes to differentiate and stratify in the presence of 1.2mM [Ca2+]o 
increased levels of the minor form of CyP by 5.8 fold (p<0.2) (Chatellard-Gruaz 
et al., 1994).  These results strongly indicate that CyP may be an important 
factor in keratinocyte differentiation.   
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Chapter 5. Aims 
 
As described above, CypB has been shown to be expressed and secreted by 
keratinocytes.  However, the functional role of CypB in the skin has not yet been 
determined.  In addition, CsA is an effective therapeutic option for patients with 
inflammatory skin disease.  CypB is therefore an interesting protein to study in 
the skin and is a potential therapeutic target as: 
 
a) Cyclophilins have been shown to increase in differentiating keratinoctyes. 
b) CypB binds to CsA with 10 times greater efficiency than CypA. 
c) CypB is secreted in response to CsA. 
d) CypB has been shown to play a role in regulating the inflammatory 
response in a variety of other tissues/systems. 
 
The work undertaken has been to investigate the hypothesis that a) CypB, a 
key intracellular receptor for CsA, regulates growth and differentiation of human 
keratinocytes and that b) CsA exerts a direct therapeutic effect on the epidermis 
in patients with atopic eczema through its effect on CypB. 
 
The aims of this research were to: 
1. Determine whether CypB influences growth, proliferation and differentiation in 
normal human epidermal keratinocytes and whether this effect is driven by 
intracellular or extracellular pathways. 
2.  Understand the functional and clinical significance of CypB and its role in 
mediating effects of CsA by studying a) skin equivalents overexpressing CypB 
and following CypB knockdown and b) skin biopsies obtained from patients with 
atopic eczema before and during the early phases of treatment with CsA.    
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Chapter 6. Materials and Methods 
 
6.1   Human skin biopsies 
Local ethical committee approval for the study was obtained (Ref: 2003/199).  
Patients were recruited having met the following criteria: 1) UK modification of 
Hanifin and Rajka’s diagnostic criteria for atopic eczema (Williams et al., 1994), 
2) Have been routinely prescribed CsA treatment, 3) 18 years old, 4) Over 18 
years old, 4) Given informed consent to the study; 5) Have not used immune 
modifying drugs, topical calcineurin inhibitors, systemic eczema treatments, 
UVB, UVA, PUVA, sun-beds or significant exposure to sunlight for 3 months 
prior to inclusion; 6) Have not used very potent topical steroids for two weeks 
prior to inclusion.   
 
5mm punch biopsies were taken under local anaesthesia from patients with 
atopic dermatitis before and during treatment with CsA.  The severity of eczema 
was measured using the six area, six sign in atopic dermatitis (SASSAD) 
severity score for atopic eczema. 
 
6.1.1  Preparation of skin biopsies 
The tissue was embedded in OCT (Optimal Cutting Temperature compound) on 
a tissue chuck with the dermo-epidermal junction at 90o to the chuck and 
completely covered in OCT.  The chuck, but not the tissue, was immersed in 
liquid nitrogen to freeze the tissue.  The frozen OCT embedded tissue was then 
placed onto a cork base and stored at -80oC.  Tissue sections were cut using 
the Leica CM 1900 rapid sectioning cryostat (Leica Microsystems, Milton 
Keynes, UK) and placed onto superfrost microscope slides coated with 
TESPA/APES (2% aminopropyltriethoxy-silane in dry acetone) or Supafrost 
Plus microscope (Thermo Scientific, UK). 
 
6.1.2  Immunohistochemical analysis of skin biopsies 
Five micron frozen sections of human skin biopsies were analysed for CypB 
FLG and CD147 expression.  Rabbit polyclonal antibody to CypB (1:500, PA1-
027A, ABR affinity BioReagents, USA), was used.  This antibody is a synthetic 
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peptide corresponding to residues C(194) GKIEVEKPFAIAKE(208) of human 
CyPB. This sequence is almost completely conserved between human, mouse, 
rat, bovine, and chicken.  This sequence is not found in CypA.  Mouse 
monoclonal antibodies to FLG (1:100 Neomarkers, USA) and CD147 (1:750 BD 
Biosciences, USA) were used for FLG and CD147 expression.  Substitution of 
the primary antibody with isotype-specific IgG and omission of the primary 
antibody served as negative controls.  The secondary antibody used for CypB 
immuohistochemistry was Goat anti-Rabbit Oregon Green (1:300) and for FLG 
was Goat anti-Mouse Oregon Green (1:300). Tissue sections were defrosted at 
room temperature and fixed in acetone for 10 minutes.  Sections were washed 
with Tween 20 (0.05%) in PBS (PBS/Tween).  Each washing step was repeated 
3 times with PBS/Tween.  Cells were permeabilised with Triton X-100 (0.2%) for 
10 minutes and then washed.  Blocking buffer (NGS 1:60 in 1% BSA in PBS) 
was applied for 10 minutes, tipped off and the primary antibody applied for 1 
hour at room temperature.  Sections were washed and the secondary antibody 
applied for a further hour at room temperature.  After washing, the nuclear stain 
toto-3 iodide was added (1:7000 in PBS) for 15 minutes and then washed for 
the last time.  A coverslip was attached with Vectasheild ® (Vectalabs, UK) 
mounting medium, sealed with nail polish and stored at 4oC. 
 
For CD147, labeled StreptAvidin Biotin (LSAB) method was used.  Tissue 
sections were defrosted at room temperature and fixed in acetone for 10 mins.  
Sections were washed and permeabilised as above.  Tissue sections were 
blocked with horse serum. Avidin D was applied for 15 minutes, slides washed 
and then Biotin block applied for 15 minutes.  Following a further wash, the 
primary antibody was applied for 1 hour at room temperature, washed and 
biotinylated Horse anti-Mouse (1:300) applied for 1 hour.  Following a further 
wash, Streptavidin Oregon Green (1:300) was applied for 30 minutes followed 
by the nuclear stain toto-3 iodide was added (1:7000 in PBS) for 15 minutes 
and then washed for the last time.  A coverslip was attached with Vectasheild ® 
(Vectalabs, UK) mounting medium, sealed with nail polish and stored at 4oC. 
 
Oregon Green 488 and Toto-3-iodide (642/660) were excited using the 488nm 
line supplied by the Argon ion laser and the 633 nm line supplied by the Helium 
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red neon laser, respectively.  Images were captured using a Leica TCS SP II 
confocal laser microscope (Leica Microsystems, Milton Keynes, UK) and 
processed using Adobe Photoshop 6.0 and CS, USA. 
 
6.2   Cell Culture 
6.2.1    Cell culture of primary human keratinocytes 
Primary human keraintocytes were cultured from skin samples obtained from 
urological and paediatric surgical procedures from the Royal Victoria Infirmary 
(RVI) following informed consent and ethical committee approval (Ref: 
08/H0906/95).  These tissue samples would have otherwise been discarded.  
Tissue samples were delivered in universal containers containing transport 
medium (Keratinocyte culture medium) and were stored at 40C and processed 
promptly. 
 
Primary human keratinocytes were grown in EpilifeTM   (Invitrogen, UK) 
supplemented with penicillin  G (5 IU/ml) and streptomycin (5µg/ml) and Human 
keratinocyte Growth Supplement (Invitrogen, UK) and incubated at 370C with 
5% CO2 in a humidified incubator. 
 
To prepare the skin the hypodermis was trimmed off with sterile scissors.  The 
sample was then scored and placed in a universal container with phosphate 
buffered saline (PBS) and penicillin G (5 IU/ml), streptomycin (5µg/ml) and 
dispase (2mg/ml).  Dispase, a protease, separates the dermis from the 
epidermis.  The sample was stored at 40C.  After 24 hours the epidermis was 
peeled off from the dermis with sterile forceps and incubated for 5 minutes at 
370C with 5ml trypsin (0.05% trypsin and 0.02% EDTA, Lonza, UK) in a 
universal to separate the basal keratinocytes.  The trypsin was neutralised with 
2% FCS and the contents of the universal placed in a T75 or T175 flask with 
10ml or 25mls respectively of EpilifeTM  and incubated at 370C with 5% CO2 in a 
humidified incubator overnight.  The cells were washed with PBS and re-fed 
and incubated.  Keratinocytes were fed every 2-3 days.  Once 80% confluent 
the cells were either passaged or seeded for experiments.  Primary 
keratinocytes were usually passaged up to 3 – 4 times. 
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6.2.2   Cell culture of cell lines 
Cell lines used were the HaCaT, Retroviral Phoenix Amphoteric (RPA), 293T 
cells and 3T3 mouse fibroblast cell lines.  All four cell lines were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Cambrex, UK), supplemented 
with 10% fetal calf serum (FCS) (Biosera, UK), penicillin  G (5 IU/ml) and 
streptomycin (5µg/ml).  The cells were incubated at 370C with 5% CO2 in a 
humidified incubator. 
 
The HaCaT cell line is an immortalised aneuploid human keratinocyte cell line 
which was a kind gift from Professor NE Rusenig [Heidelburg, Germany 
(Boukamp et al., 1988)]. The RPA cells are a retroviral packaging cell line and a 
kind gift from Dr G Nolan (Stanford, USA).  The 293 cells are a lentiviral 
packaging cell line and were a kind gift from Dr O Heidenreich (NICR, 
Newcastle, UK).  The 3T3 mouse fibroblasts were a kind gift from Dr J Reichart 
(ICM, Newcastle UK). 
 
6.2.3   Passaging and seeding cells 
The cells were washed with PBS and then detached with trypsin incubated at 
370C with 5% CO2.  The cells were viewed regularly so that trypsin 
neutralisation can occur as soon as the cells have detached.  DMEM was used 
for trypsin neutralisation. A 1 in 10 dilution of trypsin to neutralising medium was 
used.  The medium containing the cells were transferred to a universal 
container and centrifuged at 1200rpm for 5 mins to obtain a cell pellet and 
supernatant discarded.  For primary keratinocytes, the pellet was resuspended 
in 10mls EpilifeTM and for RPA cells, the cells were reseeded in complete 
DMEM. 
 
For passaging, keratinocytes were reseeded into tissue culture flasks incubated 
and allowed to grow until 80-90% confluency.  In order to seed keratinoctyes, 
20µl was removed from the suspension in order to measure the concentration of 
cells using a haemocytometer.  The required numbers of cells were then 
seeded into appropriate cell culture plates. 
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6.3   Retroviral Transduction 
6.3.1   Retroviral Gene Transfer 
Retroviral gene transfer allows for long-term, stable expression of introduced 
genetic elements.  Retroviruses are able to integrate into the DNA of the host 
chromosome following which the retroviral promoter directs high-level, efficient 
expression of genes encoded within its genome. 
 
The plasmid used as the retroviral vector was pLEGFP-N1 (Clontech, US).  A 
second plasmid pLEGFP-C1 was also available (Figure 12).  pLEGFP-N1 and 
pLEGFP-C1 facilitate the retroviral delivery and expression of enhanced green 
fluorescent protein (EGFP) or the amino-(N1) or carboxy-(C1) terminal fusions 
of EGFP protein of interest.   
 
EGFP is a red-shifted variant of wild-type green fluorescent protein (GFP) of the 
jelly fish Aequorea Victoria.  EGFP has a brighter fluorescence and higher 
expression in mammalian cells (excitation maximum = 488nm; emission 
maximum = 507nm). 
 
pLEGFP derivatives expressing EGFP fusions to the gene of interest are stably 
transfected into a packaging cell line to allow the production of infectious viral 
particles.  The packaging cell line used was the retroviral phoenix amphoteric 
(RPA) cell line, a generous gift from Dr G Nolan (Nolan’s lab, Stanford 
University, USA).  The RPA cells include the structural gag, pol, env genes to 
allow retroviral infection and delivery.  pLEGFP transcripts produced in the 
packaging cell contain the RNA signal Ψ+, the neomycin gene, transcription and 
processing elements and the gene of interest.  EGFP or an EGFP fusion is 
expressed from the human cytomegalovirus (CMV) immediate early promoter 
(PCMV).  The vectors do not contain the structural gag, pol and env genes that 
are required for retroviral particle formation and replication, but are stably 
integrated in the packaging cell genome.  In the cell, RNA from the vector is 
packaged into high-titer, infectious, replication-incompetent retroviral particals 
and thus can infect target cells and transmit the EGFP or EGFP-fusion gene, 
but cannot replicate within these cells since the cells lack the viral structural 
genes (BD Biosciences Clontech, US). 
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Figure 12. Restriction map and multiple cloning sites (MCS) of pLEGFP-N1 
retroviral vector (Clontech, 2002). 
 
6.3.2   Wild type CypB and W128A mutant CypB retroviral vectors 
(pLEGFP-CypBWT and pLEGFP-CypBW128A) 
The wild type CypB (CypBWT) and W128A mutant CypB (CypBW128A) were a 
kind gift from Dr F Allain ([Lille, France;(Carpentier et al., 1999)].  CypBWT and 
CypBW128A had already been cloned into the pLEGFP retroviral vector and 
stably transfected into the RPA packaging cell line in the Reynolds lab by 
amplifying full length human CypB from keratinocyte complementary DNA and 
cloned into the pLEGFP-N1 vector between the HindIII and BamHI restriction 
sites to generate C-terminal fusion proteins forming the pLEGFP-CypBWT 
construct.  The pLEGFP-CypBW128A was generated by subcloning a region 
containing the W128A mutation from the vector CypBW128A (Carpentier et al., 
1999).  The same primers used to generate full-length wild-type CypB was used 
to amplify the insert and the PCR product was cloned into pLEGFP-CypBWT 
between the Apa1 and BamH1 sites, replacing the wild-type CsA-binding site 
with the mutated one. 
 
RPA cells transfected with pLEGFP-CypBWT and pLEGFP-CypBW128A were 
stored in cryovials in liquid nitrogen for long term storage. 
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6.3.3   Retroviral particle production and collection 
RPA cells transfected with pLEGFP-CypBWT and pLEGFP-CypBW128A were 
defrosted and grown to 90-100% confluence in complete DMEM in T75 flasks at 
37oC with 5% CO2 in a humidified incubator.  The medium was replaced gently 
with complete DMEM and the cells transferred to 32oC with 5% CO2 in a 
humidified incubator.  After 48 hours the medium containing the virus particles 
is harvested and stored in a sterile 15ml or 50ml Falcon conical tube at -80oC. 
 
6.3.4   Retroviral transduction of keratinocytes 
Retroviral transduction was performed in 6 well and 12 well plates.  Primary 
human keratinocytes were seeded into 6 well and 24 well plates respectively. 
When the cells were at least 50-60% confluent, the medium was removed and 
they were transduced by adding 2mls per well of medium containing virus 
particles together with 10µl of hexadimethrine bromide (Polybrene, 5µg/ml) 
(Sigma, UK) and centrifuged at 1500rpm for 90 mins.  Polybrene, a cationic 
polymer reduces the electrostatic repulsion between the negatively charged 
surfaces of the viruses and the cells or alternatively, may induce viruses to 
flocculate and form complexes, which due to their large size rapidly sediment 
onto the target cells, increasing the rate of gene transfer but can only be used at 
low concentrations (e.g., 2–20 μg/ml in most cases) due to their cytotoxicity 
(Davis et al., 2004; Landazuri et al., 2006). 
 
After transduction they were washed with PBS and EpilifeTM   (Invitrogen, UK) 
supplemented with penicillin  G (5 IU/ml) and streptomycin (5µg/ml) and Human 
keratinocyte Growth Supplement (Invitrogen, UK) was added and the plates 
were incubated at 370C with 5% CO2 in a humidified incubator. 
 
6.3.5   Retroviral transduction efficiency. 
Live cells were imaged on the Leica upright fluorescent microscope (Leica 
Microsystems, UK) to assess transduction efficiency.  Alternatively, keratinocyte 
seeded onto coverslips and retrovirally transduced were fixed using 2ml GFP 
fixative per well for 15 minutes.  The fixative is then aspirated off and the cells 
washed twice with 150nM Tris.  The coverslips are mounted onto slides using 
Vectashield® (Vectorlabs, UK) and the edges sealed with nail varnish and 
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stored at 4oC until ready to visualise.  GFP was excited using the 488nm line 
supplied by the Argon ion laser and images captured using a Leica TC SP II 
confocal laser microscope (Leica Microsystems, Milton Keynes, UK) and 
processed using Adobe Photoshop 6.0 or CS (Adobe, USA). 
 
6.4   Lentiviral Transduction 
6.4.1   Lentiviral Gene Transfers  
Lentiviruses belong to the group, retroviruses, and are thus able to integrate 
into the host genome and direct highly efficient gene expression.  Unlike 
retroviruses, which only infect dividing cells, lentiviruses can infect actively 
dividing as well as resting and differentiated cells and thus are more effective 
for long-term gene expression (Manjunath et al., 2009). 
 
GIPZ Lentiviral shRNAmir viral vector (Figure 13) was used for shRNA 
knockdown.  A cyclophilin B (PPIB) mouse GIPZ lentiviral shRNAmir clone was 
purchased in a glycerol stock (Open Biosystems, Thermo Scientific, UK).  The 
DNA was extracted using the Qiagen Maxi Prep kit and used to transfect 293T 
cells for virus production.  At the time of purchase, only one GIPZ lentiviral 
shRNAmir construct for CypB was available.  This lentiviral system contains 
turbo GFP (tGFP) to mark cells expressing shRNAmir and was thus chosen.  A 
non-silencing-GIPZ lentiviral shRNAmir control an pGIPZ lentiviral empty vector 
control were used (Open Biosystems, Thermo Scientific, UK). 
 
 
 
 
 
 
Figure 13. GIPZ Lentiviral shRNAmir vector  (Open Biosystems, Thermo Scientific) 
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6.4.2   Co-transfection of 293T cells.  
DNA transfections were performed using the Calcium phosphate coprecipitation 
technique (Graham and van der Eb, 1973).  The day prior to co-transfection, 
293T cell were seeded into 100mm tissue culture dishes in 10mls of complete 
DMEM for cells to be 50-60% confluent on the day of transfection.  Prior to 
transfection the cells were re-fed with complete DMEM.  On the day of 
transfection 20µg of the lentviral transfer vector is mixed with 5µg of envelope 
plasmid (pMD2.G) and 15µg of packaging plasmid (pCMVdeltaR8.91) in a 
sterile endotoxins-free epindorf.  The envelope and packaging plasmids were 
kind gifts from Dr O Heidenreich (NICR, Newcastle, UK) and the protocol for co-
transfection and particle collection, outlined below, developed by his laboratory.  
Special Water (125µl of 1M HEPES (ph7.3) to 50ml deionized water and 
solution sterilized using 0.22 µm filter and stored at 40C) was added to the 
plasmid mixture and the volume made up to 250µl.   To this, 250µl of 0.5M 
CaCl2 solution was added and mixed well.  The plasmid/CaCl2 mixture was 
added drop-wise, slowly onto 500µl HeBS while mixing by air bubbling.  Prior to 
mixing, pre-warming of the special water, CaCl2 solution and 2X HeBS to room 
temperature or in a water bath to 37oC was important to standardise the 
precipitate characteristics.  The mixture was allowed to stand for 30 minutes 
(maximum of 40mins) on the bench at room temperature, a critical time for the 
formation of a fine precipitate. The precipitate was slowly added, drop-wise, 
onto the cell monolayer while gently shaking the plate to ensure the precipitate 
was mixed well.  The cells were incubated at 37oC with 5% CO2 in a humidified 
incubator.  After 16-18 hours, a fine sandy precipitate was seen over the whole 
plate except on the cells and immediately around them.  The reason for this was 
that DNA-calcium co-precipitate mixture formed strongly binds to the surface of 
the cell monolayer and enhances uptake of DNA by the cells (Graham and van 
der Eb, 1973).  The medium was then carefully aspirated and the cells gently 
washed with warmed PBS.  The cells were gently re-fed with complete DMEM 
and the dish incubated at 37oC with 5% CO2 in a humidified incubator for 3 
days.   
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6.4.3   Lentiviral particle collection 
Three days post co-transfection the lentiviral containing supernatant was 
harvested by collecting the supernatant into a sterile 15ml – 50ml Falcon 
conical tube.  The collected supernatant was centrifuged at 3000 rpm for 14 
mins to pellet cell debris.  The viral supernatant was then filtered through a 
0.45µm filter to remove any remaining cell debris.  The viral particles were 
stored in Falcon conical flasks at -80oC.  
 
6.4.4   Lentiviral transduction of keratinocytes 
Lentiviral transduction was performed in 6 plates.  Keratincoytes were seeded 
into 6 well plates respectively. When the cells were at least 50-60% confluent 
they were transduced by adding 1mls per well of medium containing virus 
particles and 1ml of complete DMEM together with 20µl of hexadimethrine 
bromide (Polybrene, 5µg/ml) (Sigma, UK) and centrifuged at 1500rpm for 90 
mins.   
 
6.4.5   Lentiviral transduction effeciency. 
Live cells were imaged on the Leica upright fluorescent microscope (Leica 
Microsystems, UK) to assess transduction effeciency.   
 
6.5   Cell Viability and proliferation assays 
6.5.1   Sulforhodamine B (SRB) Assay 
The SRB assay is widely used for cell proliferation and chemosensitivity testing.  
SRB is a bright pink aminozanthene dye with two sulfonic groups.  Under mildly 
acidic conditions, SRB binds to protein basic amino acid residues in 
trichloracetic acid (TCA) fixed cells to provide and index of cellular (cytoplasmic) 
protein content.  It does not stain cell debris.  The relationship between 
absorbance and cell number is linear and the colorimetric end-point is non-
destructive.  SRB strongly fluoresces with laser excitation at 488nm and can be 
measured quantitatively by static fluorescence cytometry (Skehan et al., 1990). 
  
3 x 103 HaCaT cells in 200µl medium were seeded per well into 96well plates.  
Retroviral transduction with pLEGFP-CypBWT and pLEGFP-CypBW128A and 
pLEGFP-empty vector was performed the following day.  The SRB assay was 
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performed on day1, day 5 and day 7 following retroviral transduction.  Cells 
were fixed in 10% TCA for 1 hour at 4oC.  Plates were washed by immersion in 
tap water, 5 times, and the excess water flicked off and the plates drained.  The 
plates could be strored at 4oC until all time points were ready to assay.  Fixed 
cells were stained with 0.4% SRB dissolved in 1% glacial acetic acid for 30 
minutes at room temperature.  At the end of the staining period the SRB was 
removed and the plates rinsed four times with 1% glacial acetic acid and the 
excess flicked off.  The plates were then completely dried either overnight at 
room temperature or for 1 hour at 60oC.  The bound dye was solubilisd with 200 
µl 10mM unbuffered Tris base (ph10) for 5-10 minutes on a gyratory shaker.  
The optical density (OD) was measured using a spectrophotometer 
(SpectraMax 250, Molecular Devices, USA).  Linear readings occurred with dye 
concentrations below 1.8 OD units.  The most appropriate wavelength chosen 
was 490nm to ensure linear readings. 
 
6.5.2   Colony forming Assays 
Colony forming assays or clonogenic assys have been considered to be the 
optimal assay method for determining cell proliferation and survival following 
treatment of cells with various agents.  It relies upon the ability of cells to form 
viable colonies derived from a single clone (Banasiak et al., 1999).  Human 
epidermal cells in culture form three distinct types of colony (Barrandon and 
Green, 1987).  The holoclone has the greatest reproductive capacity.  Less than 
5% of the colonies formed by cells of a holoclone terminally differentiate and 
thus form large rapidly growing colonies.  These cells represent the epidermal 
stem cells.  The paraclone consists of cells which have a short proliferative life 
span and stop dividing after a few cell divisions to differentiate, thereby 
producing small but uniform colonies.  The meroclone, the third type of clone, 
contains a mixture of cells with different growth potential and represents a 
transitional stage between a holoclone and a paraclone (Barrandon and Green, 
1987; Roh et al., 2005).   
 
The use of a non-proliferating feeder layer of mitomycin C-treated murine 3T3 
fibroblasts was used to enhance the culturing of keratinocytes and formation of 
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colonies and was described by Rhinewald in 1975 (Rheinwald and Green, 
1975). 
 
Primary human keratinocytes were grown in 6 well plates and when at least 50-
60% confluent were transduced with pLEGFP-CypBWT and pLEGFP-CypBW128A 
and pLEGFP-empty vector.  Cells were grown until 80% confluent and 
visualised under a fluorescent microscope to ensure effective transduction 
efficiency.  Keratinocytes were removed with trypsin-EDTA and neutralised as 
described in chapter 2.3.  200 cells were seeded onto mitomycin C treated 
mouse 3T3 fibroblasts in 60mm Petri dishes in quadruplet in 4mls EpilifeTM per 
dish.   
 
Prior to use, the 3T3 mouse fibroblasts were grown in T75 tissue culture flasks 
to 70-80% confluency and then treated with Mitomycin C (10µl/ml) for 2 hours.  
The fibroblasts were then trypsinised as described in Chapter 6.2.3 and seeded 
into petri dishes and allowed to attach for 1 hour before adding the 
keratinocytes.   
 
Once the keratinocytes were seeded onto the mitomycin C treated mouse 3T3 
fibroblasts, the Petri dishes were incubated at 37oC with 5% CO2 for 14 days.  
The medium was changed every 2 – 3 days.  The Petri dishes were then fixed 
in Carnoy’s fixative (75% methanol and 25% acetic acid) for 5 minutes, washed 
briefly with water and then stained using crystal violet (0.4% crystal violet in 
water).  The plates were left to dry after rinsing off excess crystal violet with 
water.  The numbers of colonies were counted by hand.  A colony was defined 
as having at least 10 cells.    
 
6.5.3   CellTitre-Glo® Assay Luminescent Cell Viability Assay (Promega®) 
The CellTitre-Glo® assay Luminescent Cell Viability Assay is a homogeneous 
method which determines the number of viable cells in culture by quantifying 
the amount of the ATP present.  ATP signals the presence of metabolically 
active cells. The procedure involves adding a single reagent (CellTiter-Glo® 
Reagent) directly to cells cultured in serum-supplemented medium.   This 
reagent results in cell lysis and generation of a luminescent signal proportional 
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to the amount of ATP present.  The amount of ATP is directly proportional to the 
number of cells present in culture in.  The CellTiter-Glo® Assay relies on the 
properties of a proprietary thermostable luciferase (Ultra-Glo™ Recombinant 
Luciferase), which generates a stable “glow-type” luminescent signal.  
 
5 x 103  primary human keratinocytes retrovirally transduced with  pLEGFP-
CypBWT and pLEGFP-CypBW128A and pLEGFP-empty vector for overexpression 
studies or with CypB GIPZ lentiviral shRNAmir, non-silencing-GIPZ lentiviral 
shRNAmir control or  pGIPZ lentiviral empty vector shRNA knockdown studies, 
were seeded in 100µl  EpilifeTM per well into a white 96 well plate with clear 
bottoms suitable for luminescence detection.  After 24 hours, the cells were 
treated with either vehicle or Dithranol (5µM) as a negative control.  Following a 
further 24 hours, the assay was performed according to the manufacturer’s 
instructions:  at the end of the experiment duration the plates were equilibrated 
at room temperature for 30 mins.  100µl of CellTitre-Glo® reagent, equilibrated 
to room temberature, was added to each well and mixed for 2 mins on an orbital 
shaker to induce cell lysis.  After, a further 10 minute incubation period the 
luminescence was quantified using a luminometer (Microbeta® Trilux, 
PerkinElmer Precisely, Canada). 
 
6.5.4    CytoTox FluorTM cytotoxicity assay (Promega®) 
1 X 104 primary human keratinocytes were seeded into black 96 well plates with 
clear bottoms suitable for fluorescence detection and cultured in 100µl Epilife 
medium (Invitrogen, UK) supplemented with human keratinocyte growth serum 
(Invitrogen, UK) together with 5IU/ml penicillin G and 5µl/ml streptomycin at 
37oC with 5% CO2.  When the cells had reached 80-90% confluency, they were 
treated with either 0.5µM Ciclosporin (CsA) (Calbiochem, USA) or 1µM CsA for 
24 hours. As a postitive control for cell death 5µM Dithranol was used.  The 
Cytotox-Fluor® cytotoxicity assay (Promega, UK) was used to detect ‘dead cell 
activity’. 20 µl of cytotoxicity reagent was added to each well and briefly mixed 
on an orbital shaker for 30 seconds.  The plate was incubated for 1 hour at 
37oC prior.  The assay measures a distinct protease activity released from cells 
that have lost membrane integrity using a fluorogenic peptide substrate (bis 
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AAF-R110). The bis-AAF-R110 substrate cannot cross the intact membrane of 
live cells and therefore gives no signal from live cells.  
 
The signal intensity was measured using a Cary Eclipse fluorometer (Varian, 
Southampton, UK) using an excitation wavelength of 485nm and emission 
wavelengths of 520±2.5 nm (Promega, UK).    
 
6.6   Differentiation Assays 
6.6.1   Transglutaminase Luciferase assays 
The 2.2 kb transglutaminase (TG) promoter-luciferase (TG-Luc) construct was a 
generous gift from Dr R Rice [California, USA (Mariniello et al., 1995)].  This 
construct, designated pTG-2.2LUC was made by generating a fragment 
including +70 to -2,210bp, counting upstream from the transcription start site in 
the 5’-flanking regions of the gene encoding TG.  The construct was cloned into 
the pGL3-promoter vector (Promega, USA) and could be excised using KpnI 
and BglII restriction enzymes.  The backbone of the pGL3 Luciferase Reporter 
Vectors is designed for increased expression, and contains a modified coding 
region for firefly (Photinus pyralis) luciferase that has been optimized for 
monitoring transcriptional activity in transfected eukaryotic cells. The pGL3-
Promoter Vector (Figure 14) contains an SV40 promoter upstream of the 
luciferase gene (Promega, www.promega.com). 
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Figure 14.  The pGL3-Promoter Vector circle map: luc+, cDNA encoding the 
modified firefly luciferase; Ampr, gene, conferring ampicillin resistance in E.coli; f1 
ori,origin of replication derived from filamentous phage; ori, origin of replication in 
E.coli.  Arrows within luc+ and the Ampr gene indicate the direction of transcription; 
the arrow in f1 ori indicates the direction of ssDNA strand synthesis (Promega). 
  
Dual Luciferase® Reporter Assay system (DLRTM, Promega) 
The DLRTM measures the activities of firefly (Photinus pyralis) and Renilla 
(Renilla reniformis, also known as sea pansy) sequentially from a single 
sample.  The term ‘dual reporter’ refers to the simultaneous expression and 
measurement of two individual reporter enzymes within a single system.  The 
‘experimental’ reporter correlates with the effect of the specific experiment and 
the activity of the co-transfected Renilla ‘control’ reporter provides an internal 
control that serves as a baseline response.  The activity of the experimental 
reporter is normalised to the activity of Renilla thus minimizing experimental 
variability caused by differences in cell viability or transfection efficiency 
(Promega, www.promega.com).  
 
Transfection of keratinoctyes 
Keratinocytes were transfected 1 hour following retroviral transduction at 
approximately 50-60% confluence per well in 24 well plates.  Cells were 
transfected with 1µg total plasmid DNA (ie TG-Luc) and 0.05µg of Renilla as 
control, using LipofectamineTM and PlusTM reagents, per well (Invitrogen, 
www.invitrogen.com).  For each well, 1µg of plasmid DNA, 0.05µg of Renilla as 
control, 2µl Plus reagent and 100µl antibiotic and serum free EpilifeTM were 
placed in one falcon and in another 2 µl Lipofectamine and 100µl antibiotic and 
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serum free EpilifeTM was added.  Each falcon was mixed and incubated at room 
temperature for 15 minutes then both falcons were mixed together and 
incubated for a further 15 minutes at room temperature.  The transfection 
mixture was added to each well and made up to 1ml with antibiotic and serum 
free medium and incubated at 37oC with 5% CO2 for 4 hours.  After this time 
point, the medium was aspirated and cells washed with PBS.  1ml of complete 
medium was added to each well and incubated.  Medium was changed after 2 
days.  On day 4 the cells were lysed using 100ul 1X Passive Lysis Buffer per 
well and placed on a rocker and gently agitated for 20 minutes.  The plates 
could be stored at -20oC until the DLRTM assay was ready to be performed.  
 
DLRTM assay 
In preparation of the DLRTM assay, the plates were defrosted whilst gently 
agitated on a rocker.  40µl of each sample was placed into a well of a 96-well 
solid bottomed white plate for reading luminescence.  The firefly luciferase 
reporter was measured first by adding 65µl Luciferase Assay Reagent II 
(LARII).  The firefly luminescence was quantified using a luminometer 
(Microbeta® Trilux, PerkinElmer Precisely, Canada).  65µl of the Stop & Glo 
Reagent was then added to the same well which quenches the firefly luciferase 
reaction and simultaneously initiates the Renilla luciferase reaction and the 
luminescence again quantified.   
 
6.6.2   Cadaverine incorporation technique 
Cadaverine is a polyamine, which can serve as an amine donor for 
transglutaminase reactions in place of lysine residues.  Lysine residues are 
highly expressed in various protein differentiation markers such as involucrin 
and loricrin.  Glutamine and lysine residue crosslinking is important in the 
formation of cornified envelopes during epithelial terminal differentiation and the 
enzymes responsible for carrying out this reaction are transglutaminase I and III 
(Candi et al., 2005).  Cadaverine derivatives have been used experimentally as 
transglutaminase substrates and fluoroscein cadaverine has been shown to 
incorporate into the membrane proteins of epithelial cells and provide a 
quantitative and qualitative measurement of epidermal terminal differentiation 
(Gray et al., 1999). 
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In view of the presence of GFP labelled CypB used in our experiments, Texas 
Red® labelled cadaverine (Invitrogen) was used for measurement of epidermal 
differentiation studies. 
 
Primary human keratinocytes were grown in 6 well plates and, when at least 50-
60% confluent, were transduced with pLEGFP-CypBWT and pLEGFP-CypBW128A 
and pLEGFP-empty vector.  Cells were grown until 80% confluent and 
visualised under a fluorescent microscope to ensure effective transduction 
efficiency.  Keratinocytes were removed with trypsin-EDTA and neutralised as 
described in Chapter 6.2.3. 
 
1-2 x 104 cells were seeded per well into black 96 well plates with clear 
bottoms, suitable for fluorescence detection in EpilifeTM medium.   1µM Texas 
Red® cadaverine (TRC) was added to the cells the following day and 1.2mM 
Calcium chloride added to control wells as a positive control for differentiation.  
Medium was changed every 2-3 days and after 6 days the assay performed. 
When the plate was ready the cells were washed twice with PBS and 100µl 
PBS added to each well.  Signal intensity was measured using a Cary Eclipse 
fluorometer (Varian, Southampton, UK) using a excitation wavelengths of 
550±10nm and emission wavelengths of 610±10nm.  The cells were then fixed 
in 100µl fixative solution (acetic acid:ethanol:water  - 1:49:50, by vol) and air 
dried.  Cell protein content was determined using the kenacid blue method 
adapted from Knox et al. (1986): 150 µl kenacid blue stain (12mls acetic 
acid:88ml kenacid blue stock solution – 0.4g Coomassie Brillian Blue+250ml 
ethanol+ 630ml distilled water) added per well and plates shaken on a rotatest 
shaker for 2-3 hours. The stain was removed and cells washed x 2 for a minute 
each in 200µl washing solution (glacial acetic acid:ethanol:distilled water – 
5:10:85 by volume).  Cells were washed a third time and shaken for 20mins.  
The washing solution was then replaced with 150 µl desorb solution and 
agitated for 20 mins.  The solution was diluted 1:5 in order to ensure a linear 
Optical Density (OD) reading within 0.4-1.2 range.   The OD value was used to 
represent the protein content and data presented as fluorescence/OD value. 
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6.7   Plasmid DNA Preparation 
The bacterial vector containing the plasmid of interest was streaked to 
encourage growth of single colonies onto an agar plate containing ampicillin 
(100µg/ml) – the desired antibiotic for selection of the plasmids used.  The plate 
is incubated upside down at 37oC overnight.  A colony is picked and put into 
200ml Luria-Bertani (LB) broth supplemented with ampicillin (100µg/ml) and 
grown overnight in an incubator shaker at 37oC for 14-16 hours.   
 
Purified plasmid DNA was obtained with Qiagen’s HiSpeed Maxi Kit (Qiagen) 
according to the manufacturers’ instructions.  Following bacterial culture, a 
bacterial pellet is obtained by centrifuging the LB cuture at 5000 x g for 15 mins 
at 4oC.  The bacterial cells then undergo alkaline lysis and are poured into the 
barrel of a QIA filter Cartridge which are special filter units designed to 
completely remove SDS precipitates and clear bacterial lysates.   A plunger is 
inserted into the cartridge and the cell lysate is filtered into an equilibrated 
HiSpeed Tip.  The HiSpeed tips contain an anion-exchange resin which allows 
for purification of nucleic acid.  The HiSpeed tip is washed and the DNA within, 
eluted.  The plasmid DNA is then precipitated by adding isopropanol to the 
eluted DNA, mixed and incubated at room temperature for 5 mins.  The 
eluate/isopropranolol mixture is then filtered throught a QIA precipitator using 
constant pressure.  The QIAprecipitator traps the precipitated DNA while the 
isopropanolol-buffer mixture flows through. The DNA is then eluted from the 
QIA precipitator into a microcentrifuge tube with TE buffer. 
 
Restriction enzyme digest followed by agarose gel electrophoresis was 
performed to confirm the size of the plasmid and construct. 
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6.8   Formation of Human Epidermal Skin Equivalents 
Human epidermal skin equivalents are formed from primary human 
keratinocytes cultured at high cell density in high calcium medium for 14 days 
on an inert polycarbonate filter (Millipore®) at the air-liquid interface (Poumay et 
al., 2004). 
 
Primary human keratinocytes were grown in 6 well plates and when at least 50-
60% confluent were transduced with pLEGFP-CypBWT or pLEGFP-CypBW128A or 
pLEGFP-empty vector for overexpression studies or with CypB GIPZ lentiviral 
shRNAmir, non-silencing-GIPZ lentiviral shRNAmir control or  pGIPZ lentiviral 
empty vector shRNA knockdown studies.  Cells were grown until 80% confluent 
and visualised under a fluorescent microscope to ensure effective transduction 
efficiency.  Keratinocytes were then transferred to T75 flasks and allowed to 
proliferate to at least 80% confluency.   
 
8.5 x 105 keratinocytes in Epilife™ were seeded onto the polycarbonate filter of 
an organotypic culture insert (Millipore®, Merck, Millipore, UK).  Each insert was 
placed in a well of a 6 well plate.  2mls complete EpilifeTM was added to each 
well so that the cells were nourished from below the filter.  The following day, 
the cells were switched to an air-liquid interface.  The medium within the inserts 
was carefully aspirated so that the cells were dry and the medium below was 
replaced with 2ml Epilipfe TM containing 1.5mM Ca2+ and 5µl/ml vitamin C.  The 
medium was changed in the wells every other day using freshly prepared 
EpilifeTM medium containing 1.5mM Ca2+ and 5µl/ml vitamin C.  After 14 days 
the equivalents were differentiated.   
 
The membrane was carefully removed from the insert using a scalpel blade and 
Each organotypic culture was divided into three: (i) snap frozen for lysate 
production and Western blotting, (ii) formalin fixed and paraffin embedded for 
H&E staining, (iii) OCT embedded and frozen for immumohistochemistry.   
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6.9   Preparation of organotypic culture for immunohistochemistry. 
After the skin equivalent has been harvested, a third of the sample is fixed in 
OCT.  The skin equivalent was embedded in OCT on a tissue chuck with the 
dermo-epidermal junction at 90o to the chuck and completely covered in OCT.  
The chuck, but not the tissue, was immersed in liquid nitrogen to freeze the 
tissue.  The frozen OCT embedded tissue was then placed onto a cork base 
and stored at -80oC.  Tissue sections were cut using the Leica CM 1900 rapid 
sectioning cryostat (Leica Microsystems, Milton Keynes, UK) and placed onto 
superfrost microscope slides coated with TESPA/APES (2% 
aminopropyltriethoxy-silane in dry acetone) or Supafrost Plus microscope 
(Thermo Scientific, UK). 
 
6.9.1   Immunohistochemical analysis of skin epidermal equivalents 
5 micron frozen sections of the skin equivalents were analysed for CypB and 
FLG for skin equivalents formed from non transduced primary keratinocytes and 
for GFP in skin equivalents formed from retrovirally or lentivirally transduced 
skin equivalents.  Mouse monoclonal antibody to FLG (1:100, Neomarkers, 
USA) were used.  Substitution of the primary antibody with isotype-specific IgG 
and omission of the primary antibody served as negative controls.  Secondary 
antibody used for FLG was Goat anti-Mouse Oregon Green (1:300).  Tissue 
sections were defrosted at room temperature and fixed for 10 minutes in 
acetone for for FLG detection.  For GFP detection, GFP fixative was used to fix 
the sections for 10 minutes.   Sections were washed with Tween 20 (0.05%) in 
PBS (PBS/Tween).  Each washing step was repeated 3 times with PBS/Tween.  
Cells were permeabilised with Triton X-100 (0.2%) for 10 minutes and then 
washed.  For those sections in which CypB and FLG were assessed, blocking 
buffer (NGS 1:60 in 1% BSA in PBS) was applied for 10 minutes, tipped off and 
the primary antibody applied for 1 hour at room temperature.  Sections were 
washed and the secondary antibody applied for a further hour at room 
temperature. After washing, the nuclear stain Toto-3 iodide (1:7000 in PBS) or 
ToPro (1:1000 in PBS) was added for 15 mins or 10mins respectively to all 
sections following 15 mins RNAase (1 in 1000) and then washed for the last 
time.  A coverslip was attached with Vectasheild ® (Vectalabs, UK) mounting 
medium, sealed with nail polish and stored at 4oC.   
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Oregon Green 488 and Toto-3-iodide (642/660) were excited using the 488nm 
line supplied by the Argon ion laser and the 633 nm line supplied by the Helium 
red neon laser, respectively.  Images were captured using a Leica TCS SP II 
confocal laser microscope (Leica Microsystems, Milton Keynes, UK) and 
processed using Adobe Photoshop 6.0 and CS, USA. 
 
6.9.2   Specimen processing for Haematoxylin and Eosin staining of Skin 
Equivalents 
After the skin equivalent has been harvested, a third of the sample was fixed in 
formalin (10% formaldehyde in water).  Using forceps, the sample was carefully 
wrapped in histology tissue (kindly donated by Histopathology Department, 
Royal Victoria Infirmary (RVI), Newcastle-upon-Tyne) and sandwiched between 
two biopsy foam pads.  This was then transferred to a histology cassette and 
immersed in 70% ethanol ready for tissue processing.  Tissue processing was 
performed by the histopathology laboratory at the RVI, Newcastle-upon-Tyne.  
Here the tissue was dehydrated by immersing the cassette, multiple times in 
progressively more concentrated ethanol baths.  The tissue then undergoes 
clearing with xylene, a solvent which fully miscible with both ethanol and 
paraffin wax.  Xylene replaces the ethanol so that the tissue will then be able to 
be infiltrated with paraffin wax. Hot paraffin wax then replaces the xylene in the 
tissue and once cooled to room temperature, solidifies.   
 
Once processed the tissue was ready for embedding.  The processed tissue is 
removed from the cassette and set in a paraffin block, using additional paraffin, 
and attached to the outside of the cassette on ice using the Leica EG1160 
embedding centre (Leica, UK) courtesy of the RVI, histopathology department. 
 
5 µm sections were cut from the paraffin block and placed into a water bath set 
at 37oC to smooth out any wrinkles.  The sections were lifted out onto a glass 
microscope (Superfrost Plus) and placed into a rack and were dried at 60oC for 
1hour.  Once dried the slides were immersed successively, first in 90% ethanol 
and then 100% ethanol for 2 seconds each and then deparaffinised for 15 
minutes in Histo-ClearTM.  They were re-immersed, first in 100% ethanol and 
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then in 90% ethanol for 2 seconds each.  Following this the slides were stained 
with haematoxylin solution for 2 minutes and then immersed in tap water for 10 
minutes, with a change of water midway.  The slides were counterstained in 1% 
eosin for 10-15 seconds and rinsed in water and then consecutively immersed 
in 90% ethanol, then 100% ethanol each for 2 seconds, and cleared for 5 
minutes in Histo-ClearTM.  The slides were mounted with DPX mounting medium 
and stored at room temperature. 
 
The slides were imaged using 10x and 40x (0.75 NA) on a Zeiss AxioImager Z2 
microscope (http://www.zeiss.com/) and images captured on the AxoVision 4.8 
software, and processed in PowerPoint. 
 
The thickness of the epidermal equivalent was measured from the image by 
hand using a ruler and taken from the top of the polycarbonate membrane to 
the base of the stratum corneum, and converted to micrometers. 
 
6.9.3   Specimen preparation for Western Blotting 
The final third of the skin equivalent was snap frozen in an eppendorf and 
stored at -80oC until analysis by Western blotting.   The samples were place on 
ice and the polycarbonate membrane was removed from the sample with 
forceps.  100µl RIPA buffer (see Chapter 6.10.3) was added to the eppendorf 
and the segment of the skin equivalent fully immersed.  A glass homogeniser 
was cooled in Liquid nitrogen and then inserted into the eppendorf.  The sample 
was homogenised, refrozen and the process repeated.  The glass homogeniser 
was cleaned with ethanol between samples.  Once homogenised each sample 
was sonicated at 8Hz for 4 seconds, 3 times.  The samples were centrifuged at 
-2oC, at 23000rcf.  The protein content was determined using the BCA assay 
and 10µg for protein prepared for Western blotting.    
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6.10   Western Blotting 
Western blotting (or immunoblotting) is an important tool to study the presence, 
relative abundance, relative molecular mass, post translational modification and 
also specific interaction of proteins (MacPhee, 2010).  Proteins, obtained from 
tissue or cell lysis are separated eletrophoretically on a polyacrylamide gel and 
transferred to a membrane – a Western blot, which represents a replica of the 
separated proteins.  This method was developed by two laboratories (Towbin et 
al., 1979; Burnette, 1981) and named Western blotting (Burnette, 1981; Kurien 
et al., 2011) following Southern blotting, the process transferring nucleic acids 
from an agarose gel to a membrane, through capillary action and Northern 
blotting , the capillary transfer of RNA from an electrophoresis gel to a blotting 
membrane (Kurien et al., 2011).  Following this, antibodies are directed against 
the membrane bound proteins and detected via chemiluminescence and 
captured on film or electronically (MacPhee, 2010). 
 
6.10.1   Preparation of cell lysates and medium for Western blotting 
1x105 primary human keratinocytes were seeded into each well of a 6 well plate 
and were transduced with either pLEGFP-CypBWT and pLEGFP-CypBW128A and 
pLEGFP-empty vector for overexpression studies or with CypB GIPZ lentiviral 
shRNAmir, non-silencing-GIPZ lentiviral shRNAmir control or pGIPZ lentiviral 
empty vector shRNA knockdown studies.  Cells were grown for 24hrs, 48hrs, 
72hrs and 96hrs.  To determine the effect of CsA, cells were treated with 1µM 
CsA, equating to a therapeutic level. 
 
6.10.2   Preparation of culture medium 
At the end of the experiment, the culture medium was removed (approx 2mls) 
and concentrated using Amicon centrifugal filter units (Merck Millipore, UK).  
10µl of sample was retained to measure protein concentration.  The samples 
were stored at -20oC.   
 
6.10.3   Preparation of cell lysates 
The medium was removed and processed as described above.  The cells were 
washed in 1ml ice cold PBS per well of 6 well plate.  100µl ice-cold modified 
radioimmunoprecipitation (RIPA) lysis buffer was prepared (50nM Tris-HCl 
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(pH7.5), 150mM NaCl, 0.25% (wt/v) sodium deoxycholate, 1% Nonidet P-40 
(NP-40), 1mM NaF, 5mM β-Glycerophosphate, 1 tablet of Complete protease 
inhibitor cocktail tablet (Roche Applied Sciences,UK), made to a volume of 50ml 
ddH20 and stored at -20
oC) and completed by adding 5µl sodium orthovanadate 
and 5µl of 200nM PMSF just prior to adding to the cells and incubated on ice for 
5 minutes.  The cells were scraped off the surface using a cell scraper and 
transferred to a 1.5ml eppendorf on ice.  The samples were centrifuged for a 
maximum of 10 minutes to a speed of 10,000rpm.  10µl of sample was removed 
to measure protein concentration. The samples were stored at -20oC. 
 
6.10.4   Protein quantification using the Pierce® BCA protein assay kit  
The amount of protein in each sample was quantified using the Pierce® BCA 
protein assay kit (Thermo Scientific, UK).  This assay is a detergent-compatible 
formulation based on bicinchoninic acid (BCA) which allows for the colorimetric 
detection and quantification of total protein.  The first step is the chelation of 
copper with protein in an alkaline medium which reduces Cu2+ to Cu+ (the biuret 
reaction – based on the reaction between the organic compound biuret, NH2-
CO-NH-CO-NH2 and the cupric ion to form a light blue tetradentate complex) 
The intensity of colour produced is proportional to the number of peptide bonds 
in the reaction.  Single amino acids and dipeptides do not give the biuret 
reaction but tripeptides and larger polypeptides or proteins reat to produce a 
light blue – violet complex.  The second step is the colorimetric detection of the 
cuprous cation (Cu+) that was formed in step 1, using a reagent containing 
bicinchoninic acid.  The chelation of two molecules of BCA with one cuprous ion 
forms a purple-coloured reaction product which is water soluble and exhibits a 
strong absorbance at 562 nm that is nearly linear with increasing protein 
concentrations over a broad working range (20-2000 µg/ml).  The reaction that 
leads to BCA colour formation is also influenced by the presence of any of four 
amino acid residues (cysteine, cystine, tyrosine, tryptophan) in the amino acid 
sequence of the protein, and a single amino acid residue in the sample may 
result in the formation of a coloured BCA-Cu+ chelate. 
 
Protein quantification was determined using the Pierce® BCA protein assay kit 
according to the manufacturers guidelines.  Protein samples were prepared in 
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duplicate and diluted 1 in 5 in H20 to 10µl.   The standard BCA Protein Assay 
detects protein concentrations from 20 to 2,000μg/mL and is provided with 
Reagent A (carbonate buffer containing BCA Reagent) and Reagent B (cupric 
sulphate solution). A working solution (WS) is prepared by mixing 50 parts of 
BCA Reagent A with 1 part of BCA Reagent B (50:1, Reagent A:B). The 
working solution is an apple green colour that turns purple after 30 minutes at 
37°C in the presence of protein.   The plate was cooled to room temperature 
and the absorbance measured at 562nm on a spectrophotometer (SpectraMax 
250, Molecular Devices, USA).   
 
6.10.5   Sample preparation for Gel Ecectrophoresis 
Samples were defrosted on ice and the volume for 10 µg of protein was mixed 
into an eppendorf with 2.5 µl NuPAGE ® LDS Sample Buffer (4x) ( Invitrogen), 
1 µl NuPAGE® Reducing Agent (10x), made up to 10 µl deionised H20 and 
heated to 70oC for 10 minutes.  LDS (Lithium Dodecyl Sulfate) maintains 
polypeptides in denatured state following heating.  The reducing agent contains 
500 mM dithiothreitol (DTT) which breaks disulfide bonds to remove secondary 
and tertiary structure.    
 
6.10.6   Gel Electrophoresis 
Gel Electrophoresis was performed using the  NuPAGE® (Invitrogen) 4-12% 
Bis-Tris gradient precast polyacrilamide gel cassettes were used to separate 
proteins.  The comb from the gel cassette was removed and each well was 
flushed with deionised water.  The gel cassette was inserted into the 
electrophoresis chamber of an XCell4SureLockTM after peeling off the tape 
covering the slot on the back of the gel cassette.    The gel cassette was locked 
into place, the upper buffer chamber filled with 1X NuPAGE® MES SDS running 
buffer and 500 µl NuPAGE® Antioxidant and checked for leakage.  The protein 
samples were loaded into the wells and a molecular weight marker (Novex® 
Sharp Protein Standard, Invitrogen) was also loaded to allow visualisation of the 
protein moleucar weight ranges and evaluation of western transfer efficiency.  
Two gel cassettes could be used in each  XCell4SureLockTM electrophoresis 
chamber. The Lower Buffer Chamber was filled and the lid placed on the so that 
the (-) and (+) electrodes are properly aligned.  The electrode cords are 
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connected to the power supply and electrophoresis performed at 200V Constant 
for 40 minutes. 
 
6.10.7   Protein Transfer to Nitrocellulose membrane 
Following electrophoresis, the cassettes were removed and opened.  The plates 
of the cassette were separated and the plate without the gel was discarded.  A 
wet piece of blotting paper was layed over the gel and the gel carefully removed 
from the remaining plate using a gel knife to loosen the gel.  The blotting paper, 
with the gel overlying it, was placed onto a wet transfer pad.  The nitrocellulose 
membrane was cut and dampened and placed onto top of the gel.  Another 
piece of blotting paper was placed over the nitrocellulose membrane.  This and 
the gel were sandwiched between two pieces of blotting paper and two blotting 
pads and placed into a Novex transfer cassette.  The cassette is placed into a 
Mini Trans-Blot Electrophoretic Transfer Cell (Bio Rad Laboratories) which can 
take two cassettes, thus transferring two gels together.  The cell was filled with 
cold transfer buffer (1X NuPAGE transfer buffer, 10% methanol, 0.1% 
antioxidant at 40C) and an ice pack inserted.  The lid was positioned and 
transfer performed at 100V Constant for 1 hour, ensuring that the protein runs 
from the gel to the nitrocellulose membrane from cathode to anode. 
 
6.10.8   Immunodetection 
Immunodetection is achieved in three steps: 1) blocking, to eliminate  non-
specific interactions of the antibody with the membrane, 2) probing, to detect 
the protein of interest using a specific primary antibody, following which a 
secondary antibody linked to the reporter enzyme, peroxidise is directed against 
the species-specific portion of the primary antibody, and 3) detection, using a 
chemiluminescent agent as a substrate that will luminesce when exposed to the 
peroxidise on the secondary antibody and captured digitally or using film.  The 
nitrocellulose membrane is removed and washed in TBS-Tween 20 (TBS-T: 
100mls 10X TBS (24.2g Tris Base, 80g NaCl made up to 1L deionised H20, pH 
7.6), 1ml Tween 20, 899ml deionised H2O).  The membrane is placed in 5% 
non-fat milk powder in 1X TBS-Tween 20 to block non-specific binding sites, at 
room temperature 1 hour whilst gently agitated on a rotary shaker .  The 
membrane was washed for 5 minutes in TBS-T.  The membrane was placed in 
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a 50 ml Falcon and 4mls of the primary antibody, CypB 1:500 (ab16045, 
Abcam, UK - a synthetic peptide conjugated to KLH (keyhole limpet 
haemocyanin) derived from within residues 150 to the C-terminus of human 
Cyclophilin B.) in 5% non-fat milk powder in 1X TBS-T, was added.  This was 
placed on a tube roller at room temperature for 1 hour.  The membrane was 
washed 3 x 5 mins in TBS-T and then the secondary antibody, Anti-rabbit 
(Sigma) 1:2000  in 5% non-fat milk powder in 1X TBS-T added for 1 hour at 
room temperature.  The membrane was washed 3 x 5 mins in TBS-T before 
detection.  Chemiluminescence detection was performed using AmershamTM 
ECLTM Plus western blotting detection reagents (GE Healthcare, UK) according 
to the manufacturer’s instructions. 40 parts of ECL Plus solution A to 1 part ECL 
Plus solution B (40:1 solution A: solution B) were mixed at room temperature for 
15 minutes.  After removing excess liquid, the membrane was laid on Saran 
wrap and the ECL Plus mixture pipetted equally over the membrane.  This was 
covered from light for 10 minutes, after which the excess liquid was blotted off 
and placed on a piece of clean glass and covered with Saran wrap, taking care 
to remove any air bubbles.  The membrane was then exposed on a 
phosphoimager.  The ECL Plus detection reagents generate an intense long-
lasting chemifluorescent signal which was detected on a phophorimager and 
digitally captured as a Tiff image using image analysis software .  The 
membrane was washed in TBS-T and wrapped in Saran wrap and stored at -
20oC.  Anti β-actin anti-mouse (Sigma Aldrich) or anti GAPDH anti-mouse were 
used as loading controls in order to compare the band intensity of the target 
protein to this (www.gelifesciences.com, (Penna and Cahalan, 2007)). 
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6.11 TIRF imaging 
Molecular events such as cell adhesion, secretion of neurotransmitters or 
cytokines often occur at the cell surface.  If a protein bound to a fluorophore is 
excited, the resulting fluorescence bound to the surface is often overwhelmed 
by the background fluorescence.  Total internal reflection fluorescence 
microscopy (TIRFM) was developed to overcome this problem.  Total internal 
reflection is an optical phenomenon that occurs when a ray of light strikes a 
medium boundary at an angle larger than a particular critical angle with respect 
to the normal to the surface.  If the refractive index is lower on the other side of 
the boundary, no light can pass through and all of the light is reflected.  The 
critical angle is the angle of incidence above which the total internal reflection 
occurs (Figure 15). 
 
1x104 primary human keratinocytes were seeded per well into a 6 well plate and 
transduced with either pLEGFP-CypBWT and pLEGFP-CypBW128A and pLEGFP-
empty vector.  Following transduction they were washed and trypsinised and 
seeded into glass bottom WillCo-dishes® for 24 hours.  TIRF Images were 
acquired using an Evolve 512 EM CCD camera (Photometrics) mounted on a 
Nikon Eclipse TiE microscope.  Samples were illuminated by 488 nm laser light 
(Argon) collected by a Plan Apochromat 60×/1.49 NA objective (Nikon).  Images 
were acquired at a rate of 2 frames per second.  Acquisition was controlled by 
Elements software (Nikon). 
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Figure 15. Total internal reflection fluorescence microscopy (TIRFM). When light 
strikes the interface between two  materials, usually between a specimen and a glass 
coverslip or tissue culture container,  at a sufficiently high angle, termed the critical 
angle, its refraction direction becomes parallel to the interface (90 degrees relative to the 
normal), and at larger angles it is reflected entirely back into the first medium.  An 
induced evanescent wave or field is produced immediately adjacent to the interface 
between the two media having different refractive indices and this decays exponentially. 
As excitation of fluorophores in the bulk of the specimen is avoided, confining the 
secondary fluorescence emission to a very thin region, a much higher signal-to-noise 
ratio is achieved compared to conventional widefield epifluorescence illumination. This 
enhanced signal level makes it possible to detect single-molecule fluorescence by the 
TIRFM method (Ross et al.). 
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Chapter 7. Results 
 
7.1   Expression of CypB in human keratinocytes and effect of CsA 
CypA and CypB are the most abundantly found cyclophilins.  Cyclophilins have 
been shown to be expressed by human keratinocytes via PAGE radiobinding 
assay, immunohistochemistry and  PCR (Chatellard-Gruaz et al., 1994; Al-
Daraji et al., 2002; Steele et al., 2002) and so far CypA, CypB and CypD have 
been documented to be expressed in keratinocytes (Al-Daraji et al., 2002; 
Fearon et al., 2011; Ji et al., 2012).  CypA has been shown to be expressed in 
the cytoplasm of the basal layer of human epidermis by the Reynolds lab (Al-
Daraji et al., 2002).  The Reynolds lab have shown that CypB is secreted in 
response to CsA in normal human keratinocytes (Fearon et al., 2011) but the 
distribution of CypB in human epidermis has not, to our knowledge, been 
previously published.  CD147 has been  recognised as the Type 1 receptor for 
both CypA and CypB (Yurchenko et al., 2001; Ji et al., 2012). CD147 has been 
shown to be expressed in the basal and suprabasal layers of the epidermis 
(DeCastro et al., 1996).  As CypB binds to CsA with 10 times greater efficiency 
than CypA, is secreted in response to CsA and has proinflammatory properties, 
we were interested to investigate its physiological role in human epidermis and 
its potential role in mediating the effects of CsA in atopic eczema (see section 
7.6). 
 
7.1.1  Immunohistochemical analysis of CypB and CD147  in normal skin. 
To determine the expression of CypB and CD147 in normal skin, confocal 
images were taken of normal skin immunostained with CypB and CD147 (Type 
1 receptor) antibodies.  FLG was used to define the granular cell layer.  
Immunohistochemistry of FLG in normal skin was seen, as expected, in the 
granular layer of the differentiating epidermis in normal skin.  CypB showed 
strong cytosolic expression within granular layer of the differentiating epidermis 
(Figure 16).  There was an inverse gradient towards the basal layer where 
expression was much less than in the granular cell layer.  Thus, the expression 
of CypB was highly distinct compared to CypA.  CD147 was expressed in the 
cytoplasm and at the cell membrane of keratinocytes and expression was seen 
consistently from the basal layer of the epidermis throughout the suprabasal 
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layers as previously described (DeCastro et al., 1996), but also to some extent, 
in the granular layer of the epidermis (Figure 16).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16:  Localisation of CypB, CD147 and FLG in normal human skin.  
Confocal images of frozen sections of normal epidermis immunostained with FLG, 
CypB and CD147 antibodies (Oregon green) and nuclear Toto-3 (red).  Bar = 50µm. 
 
 
FLG, CypB and CD147 expression in eczematous skin from patients with atopic 
eczema before and after two weeks of CsA treatment will be detailed in section 
7.6. 
 
7.1.2   Western blot analysis for CypB in normal human keratinocytes and 
in response to CsA 
To investigate the physiological role of CypB, we utilised normal human 
keratinocytes cultured in monolayer and also studied 3-D epidermal equivalents 
(see section 7.5).  Western blotting of normal human keratinocyte (NHEK) 
lysates detected a 21KDa band using a polyclonal antibody to CypB, as 
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previously established by the Reynolds lab (Fearon et al., 2011).  Since our 
previous work, conditions for culturing human keratinocytes have been modified 
to include use of Epilife™ (Invitrogen, UK) keratinocyte culture medium.   We 
therefore confirmed that CsA reproducibly induced secretion of CypB under 
these conditions: analysis of conditioned medium from NHEKs treated with and 
without CsA (1µm) was performed to detect any changes in CypB secretion in 
response to CsA.   Primary human keratinocytes were treated for 24 and 48 hrs 
with CsA (Figure 17a). 
 
Endogenous CypB was present in both vehicle and CsA treated keratinocyte 
whole cell lysates.  Secretion of endogenous CypB into the medium increased 
in the presence of CsA which was present in a clinically relevant concentration 
(1 uM)  (Fearon et al., 2011).  In order to ensure that CsA was not inducing cell 
death, which could explain the appearance of CypB in the medium, a 
cytotoxicity assay was performed.  NHEKs were treated with up to 1µm CsA for 
24 hrs.  This confirmed that no significant cell death occurred in the presence of 
CsA (Figure 17b). 
 
 
  
 
 
 
 
 
Figure 17:  Secretion of CypB, an intracellular protein, increases in the presence of 
CsA.  (a)Western blotting of keratinoyte whole cell lysates and concentrated medium 
(CM) collected from NHEKs, treated with 1µm CsA for 24 and 48 hrs (representative 
Western blot results shown from one of two donors).  (b) Cytotoxicity was measured by 
detecting a fluorogenic protease released by dead cells.  Bar chart showing no difference 
between the vehicle treated cells and those treated with CsA (n=9 wells from 3 
independent experiments, **p<0.0001 compared with vehicle, one-way analysis of 
variance (ANOVA). 
 
 
  
a b 
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7.2   Retroviral transduction of normal human keratincytes with pLEGFP-
CypBWT and pLEGFP-CypBW128A. 
 
In order to investigate the effects of CypB on keratinocyte proliferation and 
differentiation, wild type CypB (CypBWT) and mutant W128A CypB mutation 
(CypBW128A) tagged at the C-terminus with green fluorescent protein (GFP) into 
the pLEGFP-N1 vector, already established in the Reynolds lab, were 
overexpressed in NHEKs by retroviral transduction.  The CypBW128A  mutation 
reduces the affinity of CypB for CsA by about 97%, with minimal effect on its 
PPIase activity (Carpentier et al., 2000), allowing us to establish functionality of 
the CsA binding region and CsA binding.  The retroviral system was used to 
efficiently introduce stable expression of CypB and the expression of the 
enhanced green fluorescent protein allowed visualization of the protein within 
the cell.   
 
7.2.1   Intracellular distribution and secretion of pLEGFP-CypBWT and 
pLEGFP-CypBW128A in normal human keratinocytes following retroviral 
transduction and response to CsA 
Previous work by the Reynolds lab (Fearon et al., 2011) had confirmed via 
Western blotting and confocal imaging, that pLEGFP-CypBWT was expressed in 
NHEKS, and that pLEGFP-CypBW128A was expressed in HaCaTs following 
retroviral transduction.  In view of the changes in keratinocyte culture as 
described above in section 7.1.2, the intracellular distribution of GFP tagged 
CypB, and its response to CsA was confirmed in NHEKs following transducation 
with pLEGFP-CypBWT and pLEGFP-CypBW128A, treated with 1µm CsA and 
grown over 7 days.  Live cell imaging and Western blot analysis of whole cell 
lysates were used to determine the intracellular distribution of pLEGFP-CypBWT 
and pLEGFP-CypBW128A compared to pLEGFP-empty vector control. Western 
blot analysis of conditioned medium was used to confirm if pLEGFP-CypBWT 
was secreted into the medium as seen with endogenous CypB and whether any 
differences were seen between pleGFP-CypBWT and pleGFP-CypBW128A 
compared to pleGFP-empty vector control. 
 
Both live cell and confocal imaging of fixed cells confirmed the high efficiency of 
retroviral transduction (Figure 18a and b).  pLEGFP-empty vector showed both 
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nuclear and cytoplasmic localisation compared to pLEGFP-CypBWT and 
pLEGFP-CypBW128A which mainly show a cytoplasmic localisation on live cell 
imaging and when visualised using confocal microscopy following cell fixation 
(Figure 18a).  pLEGFP-CypBW128A showed a reduced intracellular signal on live 
cell imaging compared to pLEGFP-CypBWT, in the vehicle treated cells, 
suggesting less pLEGFP-CypBW128A  present intracellular, however, western 
blot analysis revealed the presence of both pLEGFP-CypBWT and pLEGFP-
CypBW128A in the lysates from 48 hrs to day 4.   Both pLEGFP-CypBWT and 
pLEGFP-CypBW128A were present in the medium at 48 hrs and day 4. At 48 hrs, 
western blot analysis revealed that more pLEGFP-CypBW128A was present in the 
medium compared to pLEGFP-CypBWT.  By day 4, intracellular levels of both 
pLEGFP-CypBWT and pLEGFP-CypBW128A  increased in vehicle treated NHEKs 
compared to 48hrs on western blot.  The levels of intracellular pLEGFP-CypBWT 
shown on western blot appear to be higher than pLEGFP-CypBW128A in vehicle 
treated cells at both 48hrs and 4 days.  Following CsA treatment, intracellular 
pLEGFP-CypBWT is lower compared to cells treated with vehicle after 48 hrs 
and also at day 4 on live cell imaging and this is confirmed on the western blot.  
After 4 days secretion of both pLEGFP-CypBWT and pLEGFP-CypBW128A 
increase compared to 48hrs.  This appears to be temporal and not just due to 
an increase in cell number.  Together these data suggest that CsA induces 
secretion of CypB such that the intracellular concentration of CypB is decreased 
and that the rate of CypB production is insufficient to replenish levels and this 
can be seen to occur 24 hrs after treatment.  Price et al demonstrated that CsA 
depleted CypB from the ER in HeLa cells and caused secretion of CypB (E.R. 
Price et al., 1994). These data also indicate that CsA not only causes secretion 
of CypB into the medium, but that the CsA binding site is important in regulating 
the cellular distribution and secretion of CypB (Figure 18b and c).   
 
CypB secretion was detected via western blot as this is a robust method of 
detecting the presence and abundance of proteins (MacPhee, 2010) and was 
used to validate the live cell images visualised using Confocal microscopy, 
determining the presence of CypB extracellularly in the medium.  Measurement 
of CypB in the medium relied on the assumption that CypB is not protein bound 
to soluble receptors, carrier proteins or affected by inhibitors (Sullivan et al., 
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2000).  Although  detecting immunofluorescence using live cell imaging 
indicated differences between pLEGFP-CypBWT, pLEGFP-CypBW128A compared 
to pLEGFP-empty vector and each other, number of cells in each image was 
not known whereas, western blot allowed assessment of equal amounts of 
protein which was assessed by comparing the band intensity given using the 
loading control b-actin between samples and the band intensity of the target 
protein between the lysates and medium, following cell proliferation.  B-actin 
bands show that loading for detection of CypB in lysates transduced with 
pLEGFP-CypBWT and pLEGFP-CypBW128A and treated with CsA was greater 
than for those treated with vehicle alone at 48hrs.  Despite this we can still 
conclude that CsA secretion does increase over time as the western blots 
suggest less protein loaded in the day 4 samples but greater pLEGFP-CypBWT 
and pLEGFP-CypBW128A secretion compared to 48 hrs.  Techniques such as 
ELISA would allow quantification of the amount of CypB present in the samples.  
Furthermore, using FACS to count the number of cells in a sample would be 
helpful to accurately identify how much protein is being produced by a known 
number of cells. 
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Figure 18.  Localisation of pLEGFP-CypBWT and pLEGFP-CypBW128A in NHEKs 
and response to CsA.  (a) Live cell imaging and confocal images following cell 
fixation of NHEKs following retroviral transduction with  pLEGFP-empty vector 
control, pLEGFP-CypBWT and pLEGFP-CypBW128A . (b) Live cell imaging of primary 
human keratinocytes, transduced with pLEGFP-CypBWT and pLEGFP-CypBW128A and 
treated with CsA, grown over 7 days.   d) Western blotting of cells and concentrated 
medium at 48 hours and day 4, β-actin acts as a cytoplasmic protein control.    
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7.2.2  TIRF Microscopy (TIRFM) of keratinocytes transduced with GFP 
tagged CypB 
In order to study the process of secretion of CypB within NHEKs, primary 
human keratinocytes were transduced with pLEGPF-empty vector, pLEGFP-
CypBWT and , pLEGFP-CypBW128.   Live cell images were taken using TIRFM 
which allows viualisation of molecular events occurring at the cell surface (see 
enclosed CD of images).   
 
A series of stills are shown below in Figures 19-21.  In the keratinocyte shown 
transduced with pLEGFP-empty vector, keratinocyte pseudopodia, (as indicated 
by the white arrows) were seen and GFP was expressed homogenously 
throughout the cytoplasm and nucleus (Figure 19).  Consistent with the ER 
localisation of CypB, a reticular pattern was observed in keratinocytes 
transduced with pLEGFP-CypBWT but also with pLEGFP-CypBW128 (Figure 20 
and 21).  In the NHEKs transduced with pLEGFP-CypBWT dynamic activity 
occurring within the ER was seen in stills 1-3 (as indicated by the white arrows).   
In stills 4 and 5 a secretory vesicle (containing CypB, indicated by a white 
arrow) is shown moving from the cell to the extracellular space or over the glass 
interface.  Towards the end of the series, in stills 8 and 9, new strands of ER 
containing CypB were seen to form. In NHEKs transduced with pLEGFP-
CypBW128A (Figure 21) multiple secretory vesicles were seen moving rapidly 
within the keratinocyte (Figure 21a) and between the two keratinocytes shown 
(Figure 21b) which are not seen in the NHEK transduced with pLEGFP-CypBWT. 
These vesicles correspond to secreted CypB.  Visualisation of the dynamic 
changes are clearly seen in the movies in the DVD attached to the back cover 
of the thesis. 
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Figure 19.  TIRFM stills of primary human keratinocytes overexpressing 
pLEGFP-empty vector.  NHEKs transduced with pLEGFP- vector and imaged over 
0.04 seconds shows diffuse pLEGFP empty vector expression. New keratinocyte 
pseudopodia are seen occurring in still 2 (not seen in still 1) and in still 5 ( just seen to 
develop in still 4) marked with white arrows, Bar = 10µm. 
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Figure 20. TIRFM stills of primary human keratinocytes overexpressing pLEGFP-
CypBWT.  NHEKs transduced with pLEGFP-CypBWT and 9 stills taken from live cell 
imaging over 0.04 seconds.  A reticular pattern indicates ER residence of pLEGFP-
CypBWT. White arrows in stills 1-3 identify change in pattern indicating dynamic 
activity of CypB on the ER.  White arrow in stills 4 and 6 shows a secretory vesicle 
moving from the cell to the extracellular space or over the glass interface.  In stills 8-9 
there are new areas of ER formation not seen in 7, indicating CypB binding. Bar = 
10µm. 
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Figure 21 (a). TIRFM stills of primary human keratinocytes overexpressing 
pLEGFP-CypBW128A.  Nine stills taken every second of primary human keratinocytes 
transduced with pleGFP-CypBW128A and imaged over 9 seconds using TIRFM showing 
reticular distribution of pleGFP-CypBW128A. Bleaching occurs over time. White arrows 
indicates movement of a CypB secretory vesicle within the cell that appears in 5 and 
moves down the cell through stills 6-9.  There is a high degree of dynamic activity 
within the cells with GPF positive vesicles appearing and moving rapidly across the 
cells.  This activity is clearly seen on the movie. Bar - 10µm 
a 
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Figure 21(b) TIRFM stills of primary human keratinocytes overexpressing pLEGFP-CypBW128A.  Movement of secretory vesicle (as 
indicated by white arrows) from lower cell to cell above, over 0.02 seconds shown in stills 1-8.  The secretory vesicle forms in still 1 and 
moves to the edge of the cell, shown in stills 4-5.  It is released from the cell, shown in still 6 and taken up by the upper cell shown in stills 
7-8. Bar = 5µm. 
b 
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7.3   Overexpression of pLEGFP-CypBWT and pLEGFP-CypBW128A and 
effect on keratinocyte proliferation. 
To investigate whether CypB played a role in keratinocyte differentiation we 
overexpressed CypB in both HaCaT cells and NHEKs with pLEGFP-CypBWT 
and pLEGFP-CypBW128A, by retroviral transduction, and assessed cell growth, 
proliferation and clonality.  In addition, we assessed whether extracellular CypB 
was involved in cell growth and proliferation. 
. 
7.3.1   Overexpression of pLEGFP-CypBWT and pLEGFP-CypBW128A in 
HaCaT cells and effect on cell growth and proliferation. 
In order to assess the influence of overexpressing CypB on keratinocyte 
proliferation we initially investigated the influence of CypB on HaCaT cells, an 
immortalized keratinocyte cell line.  An SRB assay was performed which 
revealed that both CypBWT and CyPBW128A significantly influenced keratinocyte 
growth and proliferation (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  Overexpression of CypB in HaCaT cells significantly increases growth 
and proliferation.  SRB in HaCaT keratinocytes growth over 7 days.  By Day 5 and 7 
HaCaT cells transduced with CyPBWT and CypBW128A showed significantly more 
growth compared to control, ***p<0.001, one way ANOVA, Neuman Keuls post test, 
n=36, results shown as the means ± SEM. 
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7.3.2   Overexpression of pLEGFP-CypBWT and pLEGFP-CypBW128A in 
primary human keratinocytes and effect on colony forming assays  
In order to investigate the effect of CypB in primary human keratinocytes, 
NHEKs were transduced with pLEGFP-CypBWT and pLEGFP-CypBW128A and 
seeded onto mitomycin C treated mouse 3T3 fibroblasts and grown for 14 days 
to allow colony formation13 (Figure 23). 
 
Significantly, more colonies were formed in those keratinocytes overexpressing 
CypB.   In our clonogenic assays, keratinocytes transduced with pLEGFP-
CypBWT grew more colonies than pLEGFP-CypBW128A.  Interestingly some 
donors showed more clonality than others and colonies were formed from some 
keratincytes passaged up to 4 times.   Further, observations of the clones in 
one donor showed that colonies formed in those keratinoctyes overexpressing 
CypB were more likely to be holoclones (Figure 23c).  In this donor (shown in 
the upper most panel in Figure 23b) the different colonies were easy to identify.  
In the other 3 donors (2 of which are shown in the lower panels of Figure 23b) 
colony size was smaller and therefore the different colonies were more difficult 
to distinguish, but this would suggest that the majority were, therefore, 
paraclones.  These observations may suggest that CypB could influence the 
switch from keratinocytes proliferation to differentiation.   
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Figure 23.  Overexpression of CypB in primary human keratinoctyes significantly 
increases colony formation.   (a) Retroviral transduction of NHEKs with pLEGFP-
CyPBWT  and pLEGFP-CyPBW128A significantly increased colony formation compared 
to pLEGFP empty vector (EV) by 1.4 fold and 1.15 fold respectively, results shown as 
the means ±SEM, **p<0.001, *p<0.05 n=16 in 4 independent experiments, from 4 
different donors, one-way ANOVA, Neuman-Keuls post test analysis.  (b) 
Representative images of colonies formed in 6mm petri dishes after 14 days of culture 
from 3 donors.  (c) Bar chart showing the types of colonies formed in one donor, results 
shown as the means ±SEM. 
b 
c 
a 
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7.3.3   Overexpression of pLEGFP-CypBWT and pLEGFP-CypBW128A in 
primary human keratinocytes and effect on cell growth and proliferation. 
In order to further validate these observations, NHEKs were transduced with 
and grown in 96 well plates. In addition, CypBWT knockdown via lentiviral 
shRNA CypBWT transduction was achieved in primary human keratinocytes. Cell 
growth was measured after 48 hours using a cell proliferation assay as 
described in Chapter 6.5.3 (Figure 24).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24.  Overexpression of CypB in primary human keratinoctyes significantly 
increases cell growth and proliferation using the CellTitre-Glo® cell proliferation 
assay.    (a) A significant increase in cell proliferation was seen in keratinocytes 
transduced with pLEGFP-CyPBWT  by 1.9 fold and pLEGFP-CypBW128A  by 2.7 fold 
when compared to pLEGFP empty vector, *p<0.05 and **p<0.001 respectively, n=20, 
in 4 independent experiments, one-way ANOVA, Neuman-Keuls post test.  (b) 
Conversely, transduction of keratinocytes with shRNA CypBWT  (shRNACyPB) 
resulted in reduced cell proliferation which was significant when compared with non-
silencing (NS) and empty vector GFP control (eGFP),  **p<0.001 and *p<0.05 
respectively, n=36, in 4 independent experiments, one-way ANOVA.  Results shown as 
the means ± SEM (c) Western blotting of primary human keratinocyte lysates shows 
shRNA CyPBWT knockdown.   
 
Keratinocyte proliferation was seen to significantly increase in those 
keratinocytes overexpressing CypB.    To further validate the role of CypB in 
b a 
c 
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keratinocyte proliferation, we used shRNA to knockdown CyPB in keratinocytes.  
Western blotting confirmed CypB knockdown (Figure 24c).  In addition this data 
showed that a significant reduction in keratinocyte proliferation occurred 
compared to normal controls when CypB knockdown was achieved. 
 
Together, these experiments confirm that CypB influences keratinocyte growth 
and proliferation. 
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7.3.4   Effect of extracellular CypB induces keratinocyte growth and 
proliferation 
In order to confirm whether intracellular or extracellular CypB is important for 
keratinocyte growth and proliferation,  primary human keratinocytes, transduced 
with pLEGFP-CypBWT and pLEGFP-CypBW128A in 6 well plates, were seeded 
into T75 flasks and expanded until 80% confluent the following day and the cells 
fed with complete Epilife® medium.  Conditioned medium was collected after 
two further days of growth in T75 flasks because CypB accumulates in the 
medium, as shown previously.  Conditioned medium was concentrated and 
100µl added to naïve primary human keratinocytes (seeded the previous day) in 
96 well plates and incubated for 48 hours.  Cell growth in naïve NHEKs treated 
with concentrated conditioned medium was measured after 48 hours using a 
cell proliferation assay (Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25:  Extracellular CypB influences cell growth and proliferation using the 
CellTitre-Glo®proliferation assay.  An increase in cell proliferation was seen in 
keratinocytes treated with conditioned medium from primary human keratinocytes 
transduced with pLEGFP-CyPBWT  by 1.32 fold (*p<0.01)  , one-way ANOVA, and 
from cells transduced with pLEGFP-CypBW128A  by 1.17 fold when compared to 
pleGFP empty vector control, n=36, in 3 independent experiments from 3 separate 
donors,  results shown are the means ±SEM.   
 
These experiments provide evidence that extracellular CypB influences growth 
and proliferation.     
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7.4   Overexpression of pLEGFP-CypBWT and pLEGFP-CypBW128A in 
primary human keratinocytes and effect on keratinocyte differentiation. 
As CypB is expressed in the granular layer of the epidermis we determined 
whether it played a role in regulating keratinocyte differentiation by assessing 
transglutaminase promoter luciferase activity and cadaverine incorporation in 
primary human keratinocytes transduced with CypBWT and CypBW128A (Figure 
26).  
 
 
 
 
 
 
 
 
 
Figure 26.  Overexpression of CypB regulates keratinocyte differentiation.   (a) An 
increase in transgluatminase promoter activity was seen after 4 days in pLEGFP-
CypBWT  and pLEGFP-CypBW128A when compared to pLEGFP-empty vector, n=34, 4 
independent experiments (b) Increased transglutaminase activity measured by 
cadaverine incorporation (a substrate for transglutaminase) was seen after 6 days in 
pLEGFP-CypBWT  and pLEGFP-CypBW128A  transduced  keratinocytes when compared 
to pLEGFP-empty vector control, n=23, 3 independent experiments.  
 
Using two different assays, keratinocytes overexpressing CypB showed an 
increase in transglutaminase activity which, although not statistically significant, 
is consistent with its presence in the differentiating layers of the epidermis. 
However, together these data suggest that CypB exerts a more profound effect 
on keratinocyte profileration and colony formation ability and that extracellular 
CypB may exert an important paracrine effect in this regard. 
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7.5  Organotypic cultures from primary human keratinocytes  
To investigate the functional role of CypB we investigated the phenotype of 
organotypic cultures grown from NHEKs overexpressing CypB and following 
CypB knockdown.  Skin equivalents were formed on a polycarbonate 
membrane allowing the formation of a fully differentiated cultured epidermis that 
is easily reproducible and therefore an important model for the study of human 
skin. The epidermal layers in these organotypic skin cultures display the same 
morphology as well as similar chemical and physical properties to normal 
human skin but are comprised of keratinocytes and do not contain melanocytes, 
Langerhan’s cells or Merkel cells which are the other cells found in human 
epidermis (Poumay et al., 2004).     
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7.5.1  CypB andFLG expression in organotypic culture formed from 
primary human keratinocytes 
Skin equivalents formed form NHEKs were confirmed to express CypB and FLG 
(Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27.   Localisation of CypB and FLG in skin equivalents.   Confocal images of 
organotypic culture from one donor expressing CypB, FLG and nuclear Toto (red); SG 
= Straturm Granulosum , PFM= Polycarbonate filter membrane. 
 
Organotypic cultures were observed to form basal, suprabasal, differentiating 
layers and a straturm corneum on light microscopy.  Immunohistochemical 
analysis confirmed that these skin equivalents expressed FLG and CypB in the 
differentiating layer as expected. 
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7.5.2  Overexpression of CypBWT and CypBW128A and formation of 
epidermal organotypic cultures 
We assessed the functional role of CypB by transducing primary human 
keratinocytes with pLEGFP-CypBWT and pLEGFP-CypBW128A and using these 
keratinocytes to generate epidermal equivalents, as described in Chapter 6.8.   
Each organotypic culture was divided into three: (i) snap frozen for lysate 
production and Western blotting, (ii) formalin fixed and paraffin embedded for 
H&E staining, (iii) OCT embedded and frozen for immumohistochemistry 
(Figure 28). 
 
The presence of GFP tagged CypB in addition to endogenous CypB in the 
epidermal equivalents was confirmed by western blotting and confocal imaging 
of the organotypic cultures. There was reduced expression of pLEGFP-
CypBW128A compared to pLEGFP-CypBWT, in keeping with lysates from 
monolayer experiments (Figure 28a). When examined using confocal 
microscopy, there was confirmation of GFP expression within the granular later 
of the epidermis in those organotypic cultures formed from keratinocytes 
overexpressing CypB (Figure 28c). 
 
H&E sections of the organotypic cultures revealed the presence of a basal 
layer, supra-basal and differentiating layers together with the formation of a 
stratum corneum.  Examination of the H&E sections suggest that in those 
epidermal equivalents formed from keratinocytes overexpressing CypB, the 
stratum corneum was more compacted in keeping with parakeratosis.  
Parakeratosis is often seen in psoriasis where there is overproliferation of the 
keratinocyte (Figure 28b and d). 
 
The thickness of the epidermal equivalents were measured from the base of the 
basal layer to the top of the granular layer and revealed that those transduced 
with pleGFP-CyPBWT produced a thicker epidermis when compared to those 
organotypic cultures grown from keratinocytes transduced with empty vector 
control (Figure 29e),  although this did not reach statistical significance. 
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Figure 28.  Organotypic culures formed from NHEKs overexpressing pLEGFP-
CyPBWT and pLEGFP-CypBW128A.   a) Western blotting of skin equivalents showed 
the presence of GFP tagged CypB in addition to endogenous CypB in equivalents 
formed from  keratinocytes transduced with pLEGFP-CyPBWT and pLEGFP-CypBW128A 
whereas those equivalents formed from  keratinocytes transduced with pLEGFP control 
showed presence of endogenous CypB alone. As in keeping with lysates from 
monolayer experiments, there was reduced expression of CypBW128A compared to 
CypBWT.  Western blot from one donor shown as a representative of experiments 
performed in triplicate.  b) H&E sections of organotypic cultures formed from 
keratinocytes transduced with pLEGFP-CyPBWT and pLEGFP-CypBW128A and pLEGFP 
control show basal layer of keratinocytes, supra-basal and differentiating layers and 
stratum corneum formation. c) Confocal images of organotypic cultures formed from 
keratinocytes transduced with pLEGFP-CyPBWT and pLEGFP-CypBW128A and pLEGFP 
control showing GFP expression in green and nuclear stain with ToPro in red.  d) H&E 
sections of skin equivalents.  Skin equivalents formed from keratinocytes from three 
different donors transduced with pLEGFP-empty vector and pLEGFP-CyPBWT. e) 
Measurement of the thickness (measured from the base of the basal layer to the top of 
the granular layer) of each organotypic culture revealed those transduced with pLEGFP-
CyPBWT produced a thicker epidermis when compared to those organotypic cultures 
grown from keratinocytes transduced with empty vector control (n=144, from 3 
different donors - 48 measurements taken for each equivalent using 20x images shown 
in d) and measured manually); Bars=50µm. 
 
a c 
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7.5.3   Organotypic cultures from keratinocytes following lentiviral shRNA 
CypBWT. 
Primary keratinocytes were transduced with lentiviral shRNA CypBWT and 
allowed to proliferate in monolayer culture initially and then transferred into 
inserts and grown as epidermal equivalents before being processed as 
described above.  Western blotting and H&E staining was performed (Figure 
30).   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Organotypic culures formed from NHEKs following shRNA CypB 
knockdown.  (a) Skin equivalents from 3 different donors (labelled 1,2 and 3)  
following shRNA knockdown of CypB.  (b)  Western blotting of epidermal equivalents 
following shRNA knockdown, Bar=50µm. 
 
Epidermal equivalents from keratinocytes from 3 different donors (labelled 1,2 
and 3) and transduced with shRNA CypBWT did not show a normal skin 
phenotype. However although western blotting from monolayer cultures showed 
some reduction in CypB following shRNA knockdown, epidermal equivalents did 
not show a reduction in expression of CypB.  This may reflect a lack of stable 
transfection or that those cells with continued CypB production were able to 
proliferate and produce an equivalent resembling an epidermis. 
a 
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Patient Sex Age
Hanifin and 
Rajka Diagnostic Criteria 
for Atopic Dermatitis
Biopsy site 
(pre CsA)
Biopsy site 
(post CsA)
Previous 
treatments Co-morbidities
1 F 26 Y buttock buttock
2 F 30 Y lower back lower back  UVB
iron deficiency, 
asthma, hayfever
3 M 54 Y abdomen abdomen
4 M NA Y NA NA
5 M 71 Y arm buttock
Photosensitive 
eczema
6 F NA Y buttock buttock
7 F 42 Y lower back lower back
8 F NA
Y
lower back lower back
9 F 42 Y lower back lower back
topical tacrolimus, 
UVB 
asthma
10 F 30 Y buttock buttock
11 M 31 Y
lower/mid 
back
lower/ mid 
back
UVB
asthma, 
pneumonia
12 M 37 Y lower back lower back
7.6   Immunohistochemical analysis of skin biopsies from patients with 
atopic eczema treated with Cyclosporine A (CsA)  
In order to understand the clinical significance of CypB and its functional role in 
the epidermis we studied skin biopsies from eczematous skin of patients with 
atopic eczema before and after two weeks of CsA treatment at a dose of 
4mg/kg.  A summary of the patient details is shown in table 1 below.  We 
reasoned that by studying changes in the epidermis of eczematous skin early 
during the treatment course, we were more likely to identify direct effects of CsA 
on atopic eczema rather than secondary changes that occur as a result of 
eczema clearance or as a result of barrier repair.   Skin biopsies were taken and 
processed as described in chapter 6.1.  We analysed the intensity of expression 
(intensity) of CypB, FLG and CD147 (Type I binding site (extracellular receptor) 
for CypB) in skin biopsies from patients with atopic eczema using confocal 
microscopy.  The intensity for each protein was calculated by measuring its 
fluorescence intensity within the whole epidermis per 100µm of epidermis using 
image analysis software (Velocity, Perkin-Elmer, UK).  Parameters were set to 
exclude background fluorescence. 
 
Table 1: 12 patients with atopic eczema donated skin biopsies for 
immunohistochemical analysis before and after treatment with CsA ( M=male, 
F=female, Y=Yes, UVB=UVB phototherapy, NA= not available, CsA=ciclosporin) 
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7.6.1  CypB expression in skin biopsies from patients with atopic eczema 
treated with Cyclosporine A (CsA) 
Immunohistochemical analysis of CypB undertaken in nine patients who had 
been treated with CsA at 4mg/kg for two weeks is shown in Figure 33.  The fold 
change in the intensity of expression of CypB from pre treatment levels together 
with changes in the SASSAD scores for each patient pre-treatment and two 
weeks into CsA therapy is summarised below in Figure 30 and Table 2.   Skin 
biopsies were taken as described in chapter 6.1.  The normalised intensity 
measurements are shown in Figure 33.  Any value less than 1 indicates that the 
intensity was reduced compared to the normal control for that image.  The 
normal intensity was taken as the mean intensity measured from two normal 
controls (one representative image is shown).  In the scatter plot (Figure 30), 
eight of the nine patients’ data are shown.  This is because in patient 3, who 
showed an increase in CypB intensity following CsA treatment in eczematous 
skin, had pre-treatment intensity levels calculated at zero due to the parameters 
set and thus the change in intensity could not be subsequently calculated.   
 
Overall, there is no clear relationship between CypB expression within the 
epidermis and eczema severity.  Seven out of nine patients showed a reduction 
in CypB expression in eczematous skin at baseline (prior to CsA treatment) 
compared to normal controls.  In five of these patients, an increase in CypB 
expression was seen following 2 weeks of CsA treatment, but not to above that 
of the normal control.  All patients showed an improvement in their SASSAD 
score.  The remaining two of the nine patients had a higher CypB expression in 
their lesional skin compared to normal control but a decrease in expression was 
seen following CsA treatment.  In patient 4, who showed a decrease in CypB 
expression following CsA treatment, diffuse CypB staining was seen throughout 
the epidermis pre CsA treatment, but following CsA treatment CypB expression 
was seen in the granular layer and present in similar levels to normal skin 
control.   
  
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  Scatter plots to show changes in epidermal CypB expression in atopic 
eczema skin following 2 weeks of CsA treatment.  9 patients with atopic eczema were 
analysed for CypB expression. a) CypB epidermal intensity and SASSAD scores shown 
for 9 patients with atopic eczema prior to CsA therapy. b) CypB epidermal intensity and 
SASSAD scores shown for 9 patients with atopic eczema after two weeks of CsA 
therapy.  c)  5 patients showed an increase in expression following CsA treatment from 
pre-treatment levels (as indicated by fold change values above 1, except for 1 patient 
(patient 3) where an increase in CypB expression was seen but pre-treatment intensity 
levels were calculated at zero due to the parameters set and thus the change in intensity 
levels is shown as zero).  4 patients showed a decrease in expression following CsA 
treatment from pre-treatment levels (as indicated by fold change values below 1), y-axis 
intersects x-axis at 1.  All patients showed an improvement in atopic eczema as 
indicated by the % improvement in SASSAD score. 
 
a b 
c 
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7.6.2   FLG expression in skin biopsies from patients with atopic eczema 
treated with Cyclosporine A (CsA)  
Immunohistochemical analysis of skin biopsies from patients with atopic 
eczema who had been treated with CsA at 4mg/kg for two weeks to detect FLG 
expression was undertaken in 12 patients (Figure 34a and b). The normalised 
intensity measurements are shown in Figure 34 (any value less than 1 indicates 
that the intensity was reduced compared to the normal control for that image; 
where two images are shown, the intensity given is the mean of the two 
images).  The normal intensity was taken as the mean intensity measured from 
two normal controls for all patients 1, 2, 4, 5, 7 and 10.  For patients 3, 6, 8, 9, 
11 and 12 the normal intensity was measured from one normal control.  One 
representative image of the normal control is shown. 
 
The fold change in intensity of expression following 2 weeks of CsA from pre 
treatment levels, together with changes seen in the SASSAD score are 
summarised below in Table 2 and in a scatter plot in Figure 31.   
 
In 11 of the 12 atopic eczema patients, FLG expression was lower in lesional 
(baseline) skin compared to normal control except for patient 6 who had a 
higher expression of FLG in lesional atopic skin compared to the normal control.  
Following CsA treatment, FLG expression increased in 10 patients, all of whom 
had lower expression compared to the normal control, pre treatment.  In seven 
of these 10 patients, the expression of FLG was higher following CsA treatment 
compared to normal control.  In 9 of these 10 patients an improvement in 
SASSAD score was seen (SASSAD scores were unavailable for patients 10.   
FLG expression was lower following CsA treatment in the other two patients: 
patient 6 who had higher FLG expression compared to normal control pre 
treatment and an improvement in SASSAD, and patient 11 who had reduced 
FLG expression compared to normal skin pre CsA treatment and a decrease in 
FLG expression following 2 weeks of CsA treatment.  However, the SASSAD 
score for patient 11 indicated particularly severe eczema which had minimally 
improved following 2 weeks of CsA treatment.   
b a 
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Figure 31.  Scatter plots to show changes in epidermal FLG expression in atopic 
eczema skin following 2 weeks of CsA treatment.   12 patients with atopic eczema 
were analysed for FLG expression, 11 of the 12 patients analysed for FLG expression 
are shown above as SASSAD score for patient 10 not available.  a) FLG epidermal 
intensity and SASSAD scores shown for 11 patients with atopic eczema prior to CsA 
therapy. b) FLG epidermal intensity and SASSAD scores shown for 11 patients with 
atopic eczema after two weeks of CsA therapy.  c)  9 of the 11 patients shown showed 
an increase in expression following CsA treatment from pre-treatment levels (as 
indicated by fold change values above 1, r
2
=0.3704, p+0.0469, linear regression 
analysis).  2 patients showed a decrease in expression following CsA treatment from 
pre-treatment levels (as indicated by fold change values below 1), y-axis intersects x-
axis at 1.  All patients showed an improvement in atopic eczema as indicated by the % 
improvement in SASSAD score.  Solid line representing linear regression analysis with 
dotted lines representing 95% confidence intervals. 
 
 
 
c 
r2 0.3704, p=0.0469 
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7.6.3   CD147 expression in human keratinocytes and atopic eczema. 
CD147 has been identified as the Type I binding site for CypB and is known to 
be expressed on keratinocytes (Denys et al., 1997; Ghannadan et al., 1998; 
Kanekura et al., 2002).  We analysed CD147 expression in 6 patients with 
atopic eczema pre and post CsA treatment using confocal microscopy (Figure 
35a and b) and analysed intensity of CD147 expression using velocity software 
(Perkin Elmer, UK). The normalised intensity measurements are shown in 
Figure 35 (any value less than 1 indicates that the intensity was reduced 
compared to the normal control for that image).  The normal intensity was taken 
as the mean intensity measured from two normal controls (one representative 
image is shown).  Table 2 and the scatter plot below (Figure 32) summarises 
the fold change seen in CD147 expression following 2 weeks of CsA therapy.  
 
CD147 is expressed throughout the normal epidermis. The intensity of CD147 
expression increased in four of the six patients investigated.  A change in 
distribution of CD147 following treatment with CsA in patients with atopic 
eczema was seen (Figure 35).  In patient 2 there was reduced expression of 
CD147 throughout the epidermis of atopic eczema in both pre and post CsA 
sections.   In patients 4 and 7 the distrubtion of CD147 was found to change 
from being greatest at the basal layer, pre CsA treatment, to showing a greater 
intensity in the differentiating layers after two weeks of CsA therapy.  In patient 
6 the intensity of CD147 increases throughout the epidermis after two weeks of 
treatment.  In patient 8 the intensity of CD147 expression increases in the basal 
layer of the epidermis. 
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Figure 32.  Scatter plots to show changes in epidermal CD147 expression in atopic 
eczema skin following 2 weeks of CsA treatment.   6 patients with atopic eczema 
were analysed for CD147 expression.  a) CD147 epidermal intensity and SASSAD 
scores shown for 6 patients with atopic eczema prior to CsA therapy. b) CD147 
epidermal intensity and SASSAD scores shown for 6 patients with atopic eczema after 
two weeks of CsA therapy.  c) Of the 6 patients analysed, 4 patients showed an increase 
in expression following CsA treatment from pre-treatment levels as indicated by fold 
change values above 1).  2 patients showed a decrease in expression following CsA 
treatment from pre-treatment levels (as indicated by fold change values below 1), y-axis 
intersects x-axis at 1.  All patients showed an improvement in atopic eczema as 
indicated by the % improvement in SASSAD score. 
  
b a 
c 
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Figure 33.  Localisation of CypB in frozen skin sections from patients with atopic 
eczema pre and post CsA treatment. Immunohistochemistry of eczematous skin 
revealed CypB expression throughout the epidermis, but mainly in the granular layer.  
For CypB expression one representative image is shown.  The calculated normalised 
intensity is shown for each image.  One representative image from two normal controls 
is shown.  Bar = 100µm.
0.008232 0.163422 0.007145 0.188508 0 0.236723 
1.659606 0.304703 0.481529 0.176416 0.080519 0.060713 
0.012575 0.728764 0.019453 0.062942 6.953113 0.551073 
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Figure 34 (a).  Localisation of FLG in frozen skin sections from patients 1-6 with atopic eczema pre and post CsA treatment.   
Immunohistochemistry of frozen skin sections from patients 1-6 with atopic eczema pre and post 2 weeks of CsA treatment.  FLG 
expression is seen in all patients but has a more patchy expression pre CsA treatment.  Note FLG expression at baseline compared to 
normal control. An increase in FLG expression is seen in patients 1-5 following treatment.  In patient 6 a decrease in FLG expression was 
seen pre CsA in atopic skin compared to normal and following 2 weeks of CsA therapy.  Two representative images from skin sections for 
both pre and post CsA are shown except for patients 6 where one representative image is shown.   Expression was quantified by measuring 
the intensity of green fluorescent signal measured per 100µm of epidermis, using velocity software (Perking Elmer) and the average 
intensity measured from the two images, except for patient 6.  The calculated normalised intensity for each patent is shown.  Where two  
representative images are shown, the calculated normalised intensity is the mean of the two images, Bar = 25µm.  
a 
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Figure 34 (b).  Localisation of FLG in frozen skin sections from patients 7-12 with atopic eczema pre and post CsA treatment. 
Immunohistochemistry of frozen skin sections from patients 7-12 with atopic eczema pre and post CsA treatment. FLG expression is seen 
in all patients but has a more patchy expression pre CsA treatment.  An increase in FLG expression is seen in  patients 7, 8, 9, 10, 12 
patients following treatment to above that of normal except in patients 9 and 10.  Two representative images from skin sections for both pre 
and post CsA are shown except for patients 8 and 12 where one representative image is shown).   Expression was quantified by measuring 
the intensity of green fluorescent signal measured per 100µm of epidermis, using velocity software (Perking Elmer) and the average 
intensity measured from the two images, except for patients 8 and 12.  The calculated normalised intensity for each patent is shown.  Where 
two representative images are shown, the calculated normalised intensity is the mean of the two images,  Bar  = 25µm. 
b 
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Figure 35 (a). Localisation of CD147 in frozen skin sections from patients 2,4,and 5 with atopic eczema.   Immunohistochemistry of 
frozen skin sections from patients 2,4 and 5 with atopic eczema pre and post CsA treatment. CD147 expression is seen throughout normal 
epidermis.  An increase in CD147 expression is seen in patient 4, following treatment.  One representative image from skin sections for 
both pre and post CsA are shown.   Expression was quantified by measuring the intensity of green fluorescent signal measured per 100µm 
of epidermis, using velocity software (Perking Elmer).  Distribution of CD147 can be seen in the basal layer in patient 2, and is more 
apparent in both basal and differentiating layers for patients 4 and 5.  The calculated normalised intensity is shown for each image.  One 
representative image from two normal controls is shown, Bar  = 50µm. 
a 
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Figure 35 (b). Localisation of CD147 in frozen skin sections from patients 6,7 and 8 with atopic eczema.   Immunohistochemistry of 
frozen skin sections from patients 6,7 and 8 with atopic eczema pre and post CsA treatment. An increase in CD147 expression is seen in 
patients 6,7 and 8, following treatment.  One representative image from skin sections for both pre and post CsA are shown.   Expression 
was quantified by measuring the intensity of green fluorescent signal measured per 100µm of epidermis, using velocity software (Perking 
Elmer).  Distribution of CD147 is more apparent in both basal and differentiating layers for patients 6,7 and 8 (Bar  = 50µm).  
b 
b 
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7.1.4   Summary of FLG, CypB and CD147 expression in skin biopsies 
from patients with atopic eczema treated with CsA 
 
Table 2. Summary of changes seen in expression of FLG, CypB and CD147 in 
patients  with atopic dermatitis following CsA treatment. Values above 1 indicate an 
increase in expression (green cells); Values below 1 indicate a decrease in expression 
(orange cells) Improvement of eczema is indicated by % change in SASSAD score with 
green cells indicating an improvement in atopic eczema. Increase* - an increase in 
CypB expression was seen in patient 3 but pre-treatment intensity levels were calculated 
at zero due to the parameters set and thus the change in intensity could not be 
subsequently calculated.   
 
 
In summary and notably, these results indicate that in all patients where an 
increase in CypB was seen following CsA treatment, an increase in FLG was 
also observed.  However, of the four patients who had a decrease in CypB, 
three showed an increase in FLG expression and one showed a decrease in 
FLG expression.  Further information may be gleaned if further biopsies were 
taken continually during treatment:  in the patients where an increase in both 
CypB and FLG was seen post treatment, the SASSAD score fell to below 20 
(except for patient 7), whereas they remained above 20 in those where there 
was a decrease in CypB following treatment, indicating that in these patients 
Patient Fold 
change in 
CD147 
expression 
following 2 
weeks CsA 
treatment 
Fold 
change in 
CypB 
expression 
following 2 
weeks CsA 
treatment 
Fold 
change in 
FLG 
expression 
following 2 
weeks CsA 
treatment 
SASSAD 
pre CsA 
SASSAD 
post 
CsA 
% 
improvement 
in SASSAD 
score 
1 UNA 19.85 2.60 37 19 49 
2 0.51 26.38 13.81 45 19.5 57 
3 UNA Increase* 2.49 23 14 39 
4 1.69 0.18 4.03 47.5 31 35 
5 0.59 0.37 7.98 41 23.5 43 
6 1.25 0.75 0.45 41 29 29 
7 1.45 57.96 3.67 30 26 13 
8 9.33 3.24 8.20 33 15 55 
9 UNA 0.08 7.96 38 24 37 
10 UNA UNA 1.64 UNA UNA UNA 
11 UNA UNA 0.89 81 80 1 
12 UNA UNA 6.62 30 23.5 22 
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improvement of eczema was not as marked.  Changes in FLG expression may 
be seen earlier than in CypB expression during treatment.  Further 
investigations are required to confirm this speculation.  In addition, changes in 
CD147 expression are seen pre and post CsA treatment.  CD147 expression is 
seen throughout the epidermis but an increase in basal and granular layer 
expression is seen.   
 
FLG expression does increase in 10 out of 12 patients treated with CsA which 
suggest CsA may play a direct role in barrier repair.  In all 5 patients with an 
increase in CypB expression following CsA treatment, FLG expression was also 
seen to increase.  These observations and the changes in CD147 expression 
that were observed in the epidermis before and during CsA treatment need 
further investigation. 
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Patient
Average pixel 
intensity per 
10000 pixels 
pre CsA 
treatment 
Average 
pixel 
intensity per 
10000 pixels 
post CsA 
treatment
Fold change in 
FLG 
expression 
following 2 
weeks CsA 
treatment
SASSAD 
pre CsA
SASSAD post 
CsA
% 
Improvement 
in SASSAD 
score
1 2.16 3.77 1.75 37 19 49
2 2.45 11.31 4.62 45 19.5 57
3 4.63 6.55 1.41 23 14 39
4 1.47 4.64 3.16 47.5 31 35
5 2.2 4.37 1.98 41 23.5 43
6 10.44 12.95 1.24 41 29 29
7 1.56 3.17 2.03 30 26 13
8 22.07 23.09 1.05 33 15 55
9 3.04 4.87 1.60 38 24 37
10 5.61 7.33 1.31 UNA UNA UNA
11 3.95 2.79 0.71 81 80 1
12 1.89 3 1.59 30 23.5 22
7.1.5 Reanalysis of FLG expression in skin biopsies from patients with 
atopic eczema treated with Cyclosporine A (CsA)  
In order to validate the results seen previously, the FLG data was reanalysed so 
that the FLG intensity for each patient was normalised to internal nuclear (Toto-
3) staining as the control, before and after CsA treatment. 12 patients with 
atopic eczema were reanalysed for FLG expression using Image J software.  
The average pixel intensity for each area of protein expression (FLG being 
expressed in the stratum granulosum and Toto-3 expressed between the 
stratum basale and stratum granulosum) was calculated/ 10000 pixels.  FLG 
intensity was normalised to internal Toto-3.  11 out of 12 patients showed an 
increase in expression following CsA treatment from pre-treatment levels.  
Table 3 summarises the results.  This data is shown as scatter plots in Figure 
36. 
 
 
Table 3: Summary of changes seen in expression of FLG in patients with atopic 
dermatitis following CsA treatment following reanalysis.  Values above 1 indicate an 
increase in expression (green cells); values below 1 indicate a decrease in expression 
(orange cells).  Improvement of eczema is indicated by % change in SASSAD score 
with green cells indicating an improvement in atopic eczema. UNA=unavailable. 
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Figure 36:  Reanalysis of FLG expression in skin biopsies from patients with atopic 
eczema treated with Cyclosporine A (CsA).  Scatter plots to show changes in 
epidermal FLG expression in atopic eczema skin following 2 weeks of CsA treatment 
following reanalysis.  11 of the 12 patients analysed for FLG expression are shown 
above as SASSAD score for patient 10 was not available. a) FLG epidermal intensity 
and SASSAD scores shown for 11 patients with atopic eczema prior to CsA therapy.  b) 
FLG epidermal intensity and SASSAD scores shown for 11 patients with atopic eczema 
after two weeks of CsA therapy.  c) Chart to show fold change in FLG expression 
following CsA treatment in 11 patients reanalysed: 11 out of 12 patients showed an 
increase in expression following CsA treatment from pre-treatment levels – values 
above 1 indicate an increase in FLG expression and values below 1 indicate a decrease 
in expression. Patient 10 whose SASSAD score is not available and therefore not 
plotted showed an increase in FLG expression following CsA therapy All patients 
shown had an improvement in atopic eczema indicated by the % improvement in 
SASSAD score.  Solid line representing linear regression analysis with dotted lines 
representing 95% confidence intervals.   
  
c 
r
2
 0.1974, p=0.17 
a b 
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Chapter 8: Discussion 
 
CsA has been recognised as an effective and rapidly acting drug for the 
treatment of atopic eczema for many years but its mechanism of action remains 
unclear in the skin.  Although CsA binds to cyclophilin A and inhibits calcineurin 
in T cells, the relative contribution of this mechanism to the effects of CsA in 
inflammatory skin disease is incompletely understood.  CsA has been shown to 
directly act on keratinocytes and moreover CsA inhibits inflammation and 
affects keratinocyte differentiation in SCID mice that lack functional T- cells 
(Fisher et al., 1988; Reynolds et al., 1998).  In addition to the effect of the CsA-
CypA complex on calcineurin, CsA interacts with other cyclophilins. CypB is 
highly expressed in T-cells and binds with high affinity to CsA (Hasel et al., 
1991; E. R. Price et al., 1991; Spik et al., 1991; Denys et al., 1997; Denys et al., 
1998b).  Moreover, over the last few years, CypB has been increasingly found 
to play an important role in a number of intracellular and extracellular functions 
in different cell types (Fang et al., 2009; Galat and Bua, 2010; Kumari et al., 
2012).   The studies reported in this thesis investigated the potential role of 
intracellular CypB, as well as CypB that is secreted by keratinocytes in 
response to CsA and their role in mediating the therapeutic effects of CsA in 
inflammatory skin disease.  The studies show that CypB promotes keratinocyte 
proliferation and differentiation through both intra- and extracellular mechanisms 
and underscore the role of CypB in keratinocyte biology as well as the direct 
cutaneous effects of CsA that are independent of T cells.  
 
Our studies confirm that CypB and its type I receptor CD147 are both 
expressed in human epidermis with the greatest expression of CypB found in 
the differentiating granular layer.  CD147 has been recognised as the functional 
type 1 receptor for CypB which is involved in endocytosis and cyclophilin-
initiated signalling in T-cells (Denys et al., 1998a; Yurchenko et al., 2001; Allain 
et al., 2002).  Positioned on the opposite side of CypB is its type II binding site 
and the location of type I and type II binding sites on opposing sides of the 
CypB molecule suggests that interactions with both types of binding can occur 
simultaneously (Carpentier et al., 1999).  Type II binding of CypB serves to 
increase CypB concentration near the type I receptors as well as affecting the 
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biological activity of the protein which has been described in T-cells (Carpentier 
et al., 2002). 
   
Our western blotting studies confirmed that CypB is secreted by human 
keratinocytes and that secretion is enhanced by CsA.  In addition, using live cell 
imaging of GFP-tagged CypB constructs, we were able to visualise for the first 
time the actual secretion process of CypB secretion in keratinocytes and its 
uptake by adjacent keratinocytes in culture.  We had previously shown that the 
addition of a GFP tag did not affect the distribution or behaviour of CypB in 
keratinocytes (Fearon et al., 2011).  We verified in NHEKs that secretion of 
CypB in response to CsA was not due to CsA-induced cell death.  Importantly, 
our studies have shown for the first time that CypB plays a role in regulating 
keratinocyte proliferation and differentiation.  We established this by first 
overexpressing CypB-GFP in keratinocytes and then showing that CypB 
significantly promotes keratinocyte cell growth and proliferation using three 
different assays.  Conversely, transduction with shRNA CypBWT resulting in 
knockdown of CypBWT reduced NHEK proliferation.  Using conditioned media 
experiments we were able to provide evidence that extracellular CypB 
significantly promoted cell growth and proliferation in keratinocytes.  Taken 
together, these results strongly suggest that CypB has an autocrine and/or 
paracrine role in promoting cell growth.  In addition, we found that formation of 
skin equivalents produced from NHEKs overexpressing CypB formed a thicker 
epidermis supporting our observations that CypB plays a role in keratinocyte 
proliferation.  Furthermore, using two different assays, overexpression of CypB 
in NHEKs positively increased transglutaminase activity, which is consistent 
with its expression in the differentiating layer of the epidermis.   
 
Since CsA has been shown to exert a direct effect in keratinocytes we sought to 
investigate the relevance of the CypBW128A  mutation (which substitutes alanine 
for tryptophan at residue 128 in the CsA-binding site) on keratinocyte 
proliferation and differentiation as this mutation reduces CsA binding by 97%, 
but does not have a significant effect on its PPIase activity (Carpentier et al., 
1999).  We found CypBW128A to be more readily secreted than CypBWT in 
primary keratinocytes, as shown via western blotting, and intracellular secretory 
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vesicles of CypBW128A were seen to be very prominent on TIRFM imaging in 
NHEKs.  Previous work by the Reynolds lab has shown that the CsA-binding 
site of CypB is required for retaining CypB within the ER (Fearon et al., 2011):  
confocal imaging studies using the GFP-tagged CypBWT and CypBW128A 
revealed that CypBW128A showed significantly less colocalisation with an ER 
marker than CypBWT and that CsA reduced colocalisation of CypBWT but not 
CypBW128A with the ER (Fearon et al., 2011).  In addition, an optical isomer of 
CsA lacking cyclophilin-binding activity (cyclosporin H) did not induce secretion 
of CypB which further supports evidence that the CsA site regulates CypB 
secretion.  Furthermore, Fearon et al showed that the CsA binding site affects 
the speed and mobility of intracellular CypB.  Following photobleaching in 
HaCaT cells, the completeness of recovery was significantly longer for 
CypBW128A compared to CypBWT, and the addition of CsA also reduced the 
recovery of CypBWT but not CypBW128A.  This confirmed that the mutation in the 
CsA binding site reduced the speed and mobility of CypB suggesting that CypB 
had been directed out of the ER into secretory vesicles (Fearon et al., 2011).  In 
our studies, using TIRFM live cell imaging, we were able to further study CypB 
localisation and motility within NHEKs. 
 
Live cell imaging of primary human keratinocytes following transduction with 
GFP tagged CypBWT and GFP-tagged CypBW128A using TIRFM allowed us to 
visualise the differences between CypBWT and CypBW128A.  These images 
showed that both proteins localised to an interconnected network consistent 
with the ER.  Moreover we observed the presence of much dynamic activity 
occurring within the ER.  However, in the cells overexpressing wild type CypB, 
there was a much clearer reticular pattern seen than in those cells 
overexpressing GFP tagged CypBW128A.  This provided further evidence that 
CypBWT is able to bind to the ER, as expected.  In addition, we were able to 
visualise formation of reticulate strands indicating active binding of CypBWT to 
the ER.  Moreover, a secretory vesicle was seen to be released from the cell 
indicating secretion of CypBWT.  These secretory vesicles could be seen to a 
greater extent in the NHEKs overexpressing CypBW128A.  In these cells, a much 
greater number of secretory vesicles could be seen actively moving within the 
keratinocytes compared to CypBWT.  We were able to show the release of a 
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secretory vesicle from one cell and its uptake into the neighbouring cell.  This 
further confirms that the presence of the CsA binding site mutation interferes 
with CypB binding to the ER and that a greater number of secretory vesicles 
containing CypB are therefore available within the keratinocyte.  Taken 
together, these data suggest that under normal physiological conditions CypB 
may bind other proteins via the CsA-binding site to ER-binding partner(s) to 
retain CypB in the ER (Fearon et al., 2011) and/or that other cellular CypB-
binding proteins interact with the CsA binding site to release CypB from the ER 
so that CypB may be biologically available.  In the search for a potential 
homologue for CsA, CAML (calcium modulating cyclophilin B ligand protein) has 
been found to be involved in Ca2+ signalling, activates the calcium driven 
activation of NFAT and has been shown to be required for EGF receptor 
recycling to the cell surface (Bram and Crabtree, 1994; Holloway and Bram, 
1998; Tran et al., 2003).  In preliminary results we have identified CAML RNA 
(via RT-PCR) from cultured human keratinocytes.  It would be interesting to 
investigate if CAML plays a role in human keratinocytes as CAML has been 
shown to be associated with CypB and Ca2+ signalling and the ER provides an 
important store for calcium.  In addition, CAML has been found to bind to the 
prolactin receptor during prolactin stimulation and participates in the receptor 
signalling and prolactin dependent proliferation of breast cells (Lim et al., 2011).  
As it is ubiquitously expressed, CAML may therefore play an interacting role in 
CypB signalling pathways but this is speculation and needs to be determined 
experimentally. 
 
We hypothesised that CypB may play a role in keratinocyte proliferation and 
differentiation in keratinocytes.  Although CypB protein was seen to be 
expressed throughout the human epidermis, we found the greatest expression 
in the granular layer. This observation suggests that CypB might regulate 
keratinocyte differentiation.  On the other hand, the fact that CypB is known to 
be secreted (E.R. Price et al., 1994; Mariller et al., 1996; Billich et al., 1997), 
and may regulate proliferation in other cell types (Rycyzyn et al., 2000; Rycyzyn 
and Clevenger, 2002), raises the possibility that CypB secreted from 
keratinocytes in the granular cell layer might regulate the proliferation of stem 
and transit-amplifying keratinocytes in the basal and suprabasal layers.  CD147 
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was previously shown to be expressed at the protein level within the basal and 
suprabasal layers by DeCastro et al (DeCastro et al., 1996), although it was not 
appreciated by these authors that CD147 may be the type 1 receptor for CypB.  
The work in this thesis extends these observations by demonstrating expression 
throughout human epidermis.  This difference in expression may have been 
observed due to different antibodies used for detection.  Moreover, these data 
provide a plausible biological mechanism and add further weight to the concept 
that CypB secreted in the granular cell layer may exert physiological effects on 
keratinocytes in basal and suprabasal layers of human epidermis.   
 
We showed that overexpressing CypBWT and CypBW128A both significantly 
increased cell growth and proliferation in HaCaT and NHEK cells but also had a 
positive role in keratinocyte differentiation.   For our cell growth and proliferation 
studies we performed an SRB assay on HaCaT cells which determines cell 
number and a cell viability assay in NHEKs which determines the number of 
viable cells in culture by quantifying the amount of ATP present.  Both assays 
showed similar results – overexpression of both CypBWT and CypBW128A 
significantly expressed keratinocyte proliferation compared to normal control.  In 
these experiments overexpression of CypBW128A was seen to influence 
keratinocyte proliferation to a greater extent compared to CypBWT (although this 
was only statistically significant in the cell growth and proliferation assay 
performed in NHEK cells).  In addition, overexpression of both CypBWT and 
CypBW128A  increased the number of colonies formed in NHEK culture 
suggesting that CypB regulates keratinocyte stem cell proliferation and that this 
effect is independent of the CsA binding site.  In our colony forming 
experiments, overexpression of wild type CypB was seen to influence colony 
formation above that of CypBW128A overall.  Secretion of CypB increases over 
time.  If there is a depletion of intracellular CypB and the amount of extracellular 
CypB available is low (as would most likely be the case in colony forming 
assays as there are much fewer cells), there may be less CypBW128A overall 
compared to CypBWT which may explain why less colonies were seen to form in 
those keratinocytes overexpressing CypBW128A than in those overexpressing 
CypBWT.  Certainly, extracellular CypB does play a significant role in regulating 
NHEK proliferation as shown by our conditioned media experiments which 
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revealed that both extracellular CypBW128A and CypBWT influenced keratinocyte 
growth and proliferation compared to normal control.  Here again, cells treated 
with conditioned medium derived from cells overexpressing CypBWT (containing 
CypBWT in the medium) significantly influenced cell growth and proliferation of 
NHEKs) whereas cells treated with conditioned medium derived from CypBW128A 
expressing cells showed less cell growth.  These observations overall suggest 
that the W128A mutation does not modulate the ability of CypB to regulate 
keratinocyte proliferation per se but rather that the CsA binding site is important 
in regulating distribution and secretion of CypB and may affect the availability of 
CypB both intracellularly and extracellularly.   
 
With regard to the colony forming assays, we observed that in one donor, which 
was able to produce the largest number of colonies and therefore cells overall, 
we were able to identify the different types of colonies produced and found that 
holoclones were the largest type of colonies formed by NHEKs overexpressing 
CypBWT and CypBW128A.  This supports our observations that CypB influences 
keratinocyte growth and proliferation as the holoclones represent proliferating 
stem cells (although this was an observation in one donor in the NHEK cells, we 
also observed this in preliminary HaCaT cell data, results not shown).  
Furthermore, our skin equivalent experiments showed that organotypic cultures 
formed from NHEKs overexpressing CypBWT formed a thicker epidermis 
compared to the normal control, again supporting our hypothesis that CypB 
influences keratinocyte growth and proliferation such as seen in conditions such 
as psoriasis, where increased epidermal proliferation occurs resulting in 
epidermal hyperplasia (thickening).  Although our conditioned media studies 
provide persuasive data supporting that extracellular CypB plays an important 
role in keratinocyte cell growth and proliferation, due to lack of time we were 
unable to further validate this role.  Specifically, in future studies, we will aim to 
confirm and validate these observations by performing immune-depletion 
studies and looking at the effects of blocking CypB binding via cell surface 
CypB binding sites (Type I and II binding with CsA and protamine, respectively).   
Carpentier et al have shown that the CypBW128A mutation interferes with type 1 
binding (a 7-fold higher concentration of CypBW128A was required to displace 
50% of radiolabeled ligand [125I]-CypB bound to the type I sites but that 
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CypBW128A was as efficient as CypBWT  in inhibiting the binding of [
125I]-CypB to 
the type II binding sites) (Carpentier et al., 1999). T-cell adhesion to CypB 
occurs via complex mechanisms. Type II binding, via the N-terminal GAG 
clusters of CypB, is required for T cells to bind to CypB.  However, when T-cell 
adhesion to the ECM component fibronectin is required, type I binding, type II 
binding and the PPIase site of CypB are necessary in order for biological 
activity to occur (Carpentier et al., 2002).  Similar complex mechanisms may be 
involved in the role CypB plays in keratinocytes but the relative contribution of 
type I and type II binding sites in mediating the effects of extracellular CypB in 
keratinocytes requires further delineation and study.   
 
Type II binding sites for CypB have been shown to be via GAGs, namely 
heparin sulphate proteoglycans (HSPG).  Many biological functions mediated 
through cell surface proteoglycans are dependent on the interaction with 
extracellular mediators through their heparin sulphate moieties and the 
participation of their core proteins in signalling events (Allain et al., 2002).  The 
syndecans are cell-surface HSPGs.  Syndecan-1 has been shown to be 
associated with CD147 in CypB induced p44/p42 MAPK activation and 
consequent migration and adhesion of T-cells (Allain et al., 2002). Our results 
have shown that extracellular CypBWT significantly increased keratinocyte 
growth and proliferation but that there was also a trend towards positive 
regulation of keratinocyte growth and proliferation by extracellular CypBW128A.   
These results indicate that Type I binding is probably not involved in 
keratinocyte proliferation.   
 
In keratinocytes, GAGs have been shown to be synthesised and expressed at 
the level of the cell surface by proliferating human keratinocytes in culture (K. 
W. Brown and Parkinson, 1983; Roberts and Jenner, 1983).  GAGs including 
the HSPGs have been shown to modulate the fate of several signalling 
molecules (growth factors and cytokines) implicated in epidermal homeostasis 
and repair (Ojeh et al., 2008).  Syndecan-1 is strongly expressed in the 
suprabasal and differentiating layers with lower levels in the basal proliferating 
cells.  However, its expression is upregulated in the wound edge keratinocytes 
upon wounding and has been shown to be an important modulator in mice of 
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epidermal cell proliferation with overexpression of syndcan-1 in basal 
keratinocytes promoting keratinocyte proliferation. (Elenius et al., 2004; Bartlett 
et al., 2007; Ojeh et al., 2008).  Syndecan-1 expression has been shown to be 
expressed in full thickness normal skin with the strongest reaction observed in 
the spinous and granular layer, whereas in psoriatic skin the strongest 
expression occurred in the basal and suprabasal layers and diminished through 
the spinous layer (Tomas et al., 2008).  CypB may thus exert some of its 
biological functions in keratinocyte proliferation via type II binding or via another 
mechanism which may explain why we do see proliferation occurring in 
keratinocytes overexpressing both CypBWT and the CypBW128A mutation.  
However, we have no direct evidence for type II binding of CypB in 
keratinocytes, although further experiments blocking type II binding with 
Protamine or using CypB mutants corresponding to the protein(s) modified 
within its N-terminal that interacts with heparin and the type II binding sites 
(Carpentier et al., 1999), could be used to establish whether type II binding 
occurs in keratinocytes.  Observing whether Syndecan-1 expression is present 
in lesional skin of patients with atopic dermatitis and whether there are any 
changes in its expression during treatment of CsA would be of interest. 
 
Proliferation of cultured keratinocytes from psoriatic plaques has been shown to 
be inhibited by CsA at therapeutically relevant levels (Fisher et al., 1988).  In 
addition, proliferation of cultured keratinocytes inhibited by CsA has been 
shown to correlate with blockade of the keratinocyte cell cycle at the G0/G1 
phases (Karashima et al., 1996). Our results also confirmed that NHEKs treated 
with CsA at therapeutically relevant levels did not proliferate and in addition the 
lack of growth was confirmed not to be due to cell death.  The action of CsA on 
keratinocytes is to block keratinocyte proliferation but a mutation in the CsA 
binding site does not inhibit keratinocyte proliferation. This may be because the 
actual CsA-CypB complex inactivates CypB but the mutation in the CsA binding 
site does not and the protein is still able to interact with other proteins.  Further 
experiments to determine the effect of CsA on keratinocytes overexpressing 
CypBWT and CypBW128A may help to clarify these observations. 
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We used two different techniques to study the effect of CypB on 
transglutaminase activity and thus keratinocyte differentiation.  Both confirmed 
that overexpression of CypB increased transglutaminase activity, with CypB 
W128A showing a greater trend than wild type CypB in influencing keratinocyte 
differentiation.  This supports our observations that secreted CypB plays an 
important role in cellular activities but that the mutation in the CsA binding site 
does not inhibit keratinocyte differentiation.  This may be due to the fact that a 
mutation in the CsA binding site increases secretion of CypB and allows for 
more intracellular bioavailability of CypB as well as an increase in extracellular 
CypB.  Due to the complexities of these experiments, where NHEKs were 
subjected to retroviral transduction using spin transduction and then transfected 
for transglutaminase luciferase promoter activity assay or the addition of 
cadaverine post transduction and timing of experiments, the addition of CsA 
further complicated the assays.  Due to lack of time we were unable to further 
pursue alternative methods for assessing differentiation, but the effects of CsA 
on keratinocyte differentiation and the effects of CypB on calcium influx and 
differentiation would be important areas to investigate.  A rise in intracellular 
Ca2+ is a critical trigger for keratinocytes to switch from proliferation to 
differentiation.  Yurchenko et al have also shown that CypB induced neutrophil 
chemotaxis and Ca2+ flux in CD147 expressing CHO cells (Yurchenko et al., 
2001).  As we have found CypB to positively regulate keratinocyte differentiation 
it maybe that it is involved in raising intracellular calcium levels via CAML or 
releasing Ca2+ from the ER, activating NFAT or interacting with CD147.  It is 
possible that a naturally occurring homologue to CsA may bind to CypB, such 
as CAML, in order to regulate its activity.   
 
Another possible mechanism of action by which CypB influences keratinocyte 
proliferation and differentiation might be via the calcineurin-NFAT pathway as 
evidence that CsA inhibits the expression of keratinocyte terminal differentiation 
markers and inhibits calcineurin and NFAT1 nuclear translocation has been 
shown in nude and depilated normal mice (Gafter-Gvili et al., 2003).  In these 
mice, it was shown that the expression of p21waf/cip1 and p27kip1, two cyclin 
dependent kinase inhibitors usually induced with differentiation were blocked by 
CsA treatment (Gafter-Gvili et al., 2003).  Santini et al showed that calcineurin 
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regulated the expression of differentiation markers and the activity of p21waf1 in 
cultured mouse keratinocytes in a pathway involving the interaction of 
NFAT1/NFAT2 and the Sp1/Sp3 transcription factors (Santini et al. 2001).  Al-
Daraji et al have confirmed that calcineurin/NFAT1 translocation to the nucleus 
in response to differentiation stimuli in normal human keratinocytes was 
inhibited by CsA (Al-Daraji et al, 2002).  However, the CsA binding site is 
important in its interaction with calcineurin and the CypBW128A mutant does not 
significantly interact with calcineurin (Carpentier et al., 2000).  In addition, 
Carpentier et al have found that in the absence of CsA there is no significant 
interaction between CypB and calcineurin (unpublished results (Carpentier et 
al., 2000)).  In view of this, it seems unlikely that CypBWT and CypBW128A are 
exerting their effects on keratinocyte growth and differentiation via the 
calcineurin and suggests that CypB is promoting keratinocyte differentiation via 
an alternative pathway to the calcineurin-NFAT pathway.   
 
If CypB does regulate keratinocyte proliferation and differentiation it must have 
some influence on transcription of genes involved in cell growth, proliferation 
and differentiation.  Secreted factors and cell surface receptors can be 
internalised by endocytosis and translocated to the cytoplasm and nucleus 
(Planque, 2006) and we have confirmed that CypB is secreted by keratinocytes.  
By immunofluorescence and confocal studies, we found CypB was present in 
the nucleus of cultured NHEKs and in the nucleus of keratinocytes in skin 
biopsies of patients with atopic eczema treated with CsA.  Overall, nuclear 
CypB was observed more in the basal and suprabasal layer compared to the 
differentiating layer in normal skin and atopic eczema skin, but this was not 
quantified.  In breast cells, CypB has been shown to enhance prolactin (PRL) 
nuclear retrotranslocation: the PRL receptor is associated with ligand 
internalisation and the PRL/CypB interacts directly with STAT5 and thus 
potentiating PRL driven proliferation (Rycyzyn et al., 2000).  Removal of the 
NLS in the N-terminus of CypB abrogated the potentiation of PRL driven 
proliferation and nuclear retrotransport.  However, removal of the PPIase 
activity of CypB affected potentiation of PRL-driven proliferation but not nuclear 
retrotransport (Rycyzyn et al., 2000).  STAT5a has been implicated to be 
involved in involucrin induction via PPARγ.  The PPARs (proliferator-activated 
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receptors) bind to exogenous or endogenous ligands, form heterodimers with 
the retinoid X receptor (RXR), recruit a coactivator and facilitate transcription of 
target genes involved in many cellular functions including differentiation.  All the 
PPAR members have been identified in keratinocytes and shown to play a 
physiological role in keratinocyte proliferation and differentiation (Dai et al., 
2007).  As CypB is found in the nucleus keratinocytes (Fearon et al., 2011) it 
may be involved in transcription of genes involved in cell growth and 
proliferation which then alters as keratinocytes differentiate.   
 
As previously described, in healthy epidermis, keratinocytes undergo a carefully 
orchestrated programme of proliferation in the basal layer and differentiation in 
the suprabasal layers.  However, once exposed to injury they are quickly 
activated to repair damaged tissue.  The most common initiators are IL-1α and 
IL-1β.  Once the keratinocyte is activated, further proinflammatory cytokines are 
released such as TNF-α, EGFR and ICAM-1 which in turn activate the 
MAPK/ERK signalling cascade pathway (Freedberg et al., 2001).  CypB 
contributes to leukocyte infiltration during inflammation, triggers chemotaxis and 
integrin activation in T-cells and is released intact by heparanase and MMPs, all 
of which suggest it participates in tissue inflammation (Marcant et al., 2012).  
CypB has been shown to activate ERK signalling through CD147, together with 
increased ERK phosphorylation (Yurchenko et al., 2001; K. Kim et al., 2012).  
CypB is therefore a candidate as an additional pro-inflammatory cytokine, 
particularly as it is actively secreted and it would be interesting to investigate its 
potential role in wound healing.   
 
During the early stages of CsA treatment in patients with atopic eczema, we 
found that the level and pattern of CypB expression within epidermis changed 
and this varied between patients.  Individual variability to the 
immunosuppressive effects of CsA is well established (Klintmalm et al., 1985; 
Sander et al., 1986).  Consistent with this, although all of our patients showed 
clinical improvement after 2 weeks of CsA therapy, we observed a wide range 
in % improvement in SASSAD scores.  Denys et al showed that although there 
is individual variability in the clinical response to CsA, CypB potentiated the 
activity of CsA in blood mononuclear cells and that extracellular CypB modified 
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CsA distribution between plasma, erythrocytes and lymphocytes in a dose 
dependent manner by retaining the CypB-CsA complex extracellularly as well 
as promoting its accumulation intracellularly.  Thus, the changes in CypB 
expression seen in our patients, may be related to individual variation but also 
due to dynamic changes occurring extra- and intracellularly.   
 
Finally, we showed that FLG expression increased in 10 out of the 12 patients 
with atopic eczema after two weeks of CsA treatment and notably there was a 
significant positive correlation between the increase in FLG expression and 
clinical improvement following 2 weeks of therapy with CsA, suggesting that 
CsA may play a direct role in mediating barrier repair. 
 
From our observations, it is not clear how CypB in atopic eczema skin treated 
with CsA is modulated by CsA therapy.  Seven out of nine patients showed a 
reduction in CypB expression in eczematous skin at baseline (prior to CsA 
treatment) compared to normal controls.  In five of these patients, an increase in 
CypB expression was seen following 2 weeks of CsA treatment, but not to 
above that of the normal control.   The remaining 4 patients showed a decrease 
in CypB expression following CsA treatment despite all patients showing 
improvement in their eczema as indicated by the reduction in SASSAD scores. 
The presence of CypB in normal epidermis and its increased expression in the 
granular layer, changes seen in CypB expression in eczematous skin compared 
to normal skin and changes seen in CypB expression before and after CsA 
treatment all warrant further investigation.  Our patient numbers are 
unfortunately small, but do illustrate that the expression of CypB is altered in 
atopic dermatitis and changes during treatment with CsA.  Extracellular levels of 
CypB have correlated with an increased patient response to 
immunosuppression (Denys et al., 1998b; Fearon et al., 2011).  In addition, the 
availability of CypB in the ECM may allow it to associate with its receptors, 
internalise and be directed to its intracellular functions.  Secreted molecules 
such as growth factor and protein hormones, have been known to function by 
acting at the cell surface and then activating a cascade of intracellular second 
messengers.  Recent evidence shows that the mode of action may be more 
complicated and that internalisation in endosomal vesicles may contribute to 
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ensuring they persist intracellularly in order to fulfil their biological role.  
Examples include fibroblast growth factors (FGF), EGF and PRL, with PRL 
requiring CypB to enhance its effects (Rycyzyn et al., 2000; Tran et al., 2003; 
Planque, 2006).  Studying more patients and more time points correlated with 
clinical severity would be important to establish the effect of CsA on CypB in 
keratinocytes in vivo. 
 
An interesting finding was that FLG gene expression changed in eczematous 
skin during CsA treatment.  Since the discovery that mutations in the FLG gene 
contribute to atopic eczema (Palmer et al., 2006), the concept that an epidermal 
barrier defect plays a primary role in the development of inflammatory skin 
disease has strengthened.  The intragenic copy number of FLG repeats is also 
known to be important: the greater the FLG copy number the less likely an 
individual is at risk of developing atopic eczema (S. J. Brown et al., 2012).  FLG 
expression has been shown to be downregulated in all cases of moderate-
severe atopic eczema even in the absence of a FLG mutation (Kezic et al., 
2011), probably as a result of inflammatory cytokines (Howell, Kim et al. 2007).    
Atopic eczema is characterised by the overexpression of TH2 cytokines – IL-4 
and IL-13, which are known to induce atopic disease and downregulate genes 
involved in the innate immune response (Howell et al., 2007).  Howell et al 
showed that patients with atopic eczema acquire the FLG deficiency and 
subsequent barrier disruption as the result of the local inflammatory immune 
response which contributes to decreased FLG expression in patients with wild-
type as well as null mutations in the FLG gene (Howell et al., 2007).  They also 
showed that FLG staining in lesional and uninvolved skin from patients with 
atopic eczema was less intense than in skin from normal healthy subjects.  FLG 
staining was also greater in uninvolved atopic eczema skin compared with 
lesional atopic eczema skin from the same subjects, suggesting that FLG 
mutations do not account for the decrease in filaggrin expression.   
 
Approximately 8.8% of the general population carry one or more FLG null 
alleles, whereas 42% of patients with severe atopic eczema attending 
dermatology departments carry one or more of these FLG alleles (Barker et al., 
2007).  It would be important to establish the FLG mutation status of our 
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patients in order to further understand the changes in FLG expression seen in  
eczematous skin of our patients as our results revealed that eleven out of 
twelve patients with atopic eczema showed a decrease in FLG expression in 
eczematous skin compared to the normal skin control prior to treatment with 
CsA.  Following CsA treatment, ten of the patients with a reduction in FLG 
expression in eczematous skin showed an increase in FLG expression and of 
these, seven patients showed an increase in FLG expression to above the 
intensity seen in the normal control.  These changes occurred early on during 
treatment, and in all patients an improvement in their eczema was seen as 
shown by their SASSAD score.  Furthermore, we observed a positive 
correlation between disease activity and FLG expression where improvement in 
eczema severity correlated to an increase in FLG expression.  Brown et al have 
shown that the copy number variation (CNV) within FLG significantly affects 
atopic eczema risk and this is independent of FLG null mutation although the 
overall effect size is smaller.  The risk of atopic eczema decreases as the 
number of FLG repeats increases and a 5-10% increase in FLG ‘dose’ resulted 
in a significant reduction in the incidence of atopic eczema (S. J. Brown et al., 
2012).  If CNV within FLG significantly affects atopic eczema, Brown et al 
suggest that treatments increasing FLG expression may have a therapeutic 
effect on prevention and/or treatment of atopic eczema (S. J. Brown et al., 
2012).   
 
Our findings suggest that CsA does exert a direct effect on the epidermis, 
influencing FLG expression and thus potentially contributing to epidermal barrier 
repair.  However, whether this effect is mediated through direct interaction with 
CypB, keratinocytes or through downregulation of inflammatory cytokines 
remains to be determined.   Human DNA microarrays used to identify gene 
expression profiles in skin biopsies taken from lesional atopic eczema skin 
revealed up-regulation of immune and inflammatory response genes, including 
cytokines, chemokines and cell surface antigens along with T-cells, dendritic 
cells and the complement pathway. Down-regulation of gene encoding enzymes 
involved in lipid homeostasis was also seen.  In addition, transglutaminases 
were enhanced in atopic eczema skin (Saaf et al., 2008).  Changes in gene 
expression in lesional atopic eczema skin have also been shown following 
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treatment.  Jensen et al studied gene expression profiles in skin biopsies of 
patients with atopic eczema subjected to a within patient trial comparing topical 
1% pimecrolimus cream on one upper limb and 0.1% betamethasone valerate 
on the other twice daily for 3 weeks.  Both treatment regimens showed down 
regulation of genes involved in inflammation and the immune response which 
was more pronounced after treatment with betamethasone valerate than with 
pimecrolimus.   Pimecrolimus specific effects were seen to be involved in cell 
proliferation and cell homeostasis.  Both treatment modalities normalised the 
expression of FLG and loricrin (Jensen et al., 2012).  Vahavihu et al showed 
that following narrowband UVB treatment a reduction in the initially increased 
expression of antimicrobial peptide human β-defensin, which acts as a 
proinflammatory mediator or alarmin in the skin, linking the adaptive and innate 
immune response, was seen in healing AD lesions (Vahavihu et al., 2010).  
Jensen et al have also shown that immunohistological staining  of FLG in 
lesional skin of AE shows gaps that normalise during treatment with both 
pimecrolimus and betamethasone (Jensen et al., 2009).  Our data also revealed 
patchy staining of FLG in lesional atopic eczema skin, which improved during 
treatment. 
 
There is some overlap between the list of inflammatory conditions where there 
is an increase in cyclophilins and those conditions in which there is upregulation 
of CD147.  These include lupus and rheumatoid arthritis (Yurchenko, Constant 
et al. 2010).  Interestingly, in our experiments, changes in CypB expression and 
in CD147 expression were detected in the skin biopsies of patients with atopic 
eczema.  Interestingly, the distribution of CD147 was seen to change following 
CsA treatment in eczematous skin.  The changes were not consistent, as in one 
patient a reduction of CD147 was seen throughout the epidermis of atopic 
eczema in both pre and post CsA sections.   In another two patients, the 
distribution of CD147 changed from increased expression in the basal layer, pre 
CsA treatment, to a greater expression in the differentiating layers during 
treatment.  In another, the intensity of CD147 increases throughout the 
epidermis after two weeks of treatment and in a further patient  the intensity of 
CD147 expression increases in the basal layer of the epidermis, during 
treatment.  This may suggest that changes in expression of CD147 occur 
125 
 
depending on the extent of inflammation or in response to CsA therapy or 
represent the dynamic changes that may be occurring with regards to CypB 
secretion and uptake between proliferating and differentiating keratinoctyes.  
Further work in more patients would be required to further clarify these 
observations but the changes in CypB expression in eczematous skin following 
CsA treatment further suggests that CsA exerts a direct effect in the epidermis. 
 
Two other areas of interest of CypB expression and function are in psoriasis 
and also in skin cancers.  CypB positively influences keratinocyte growth and 
overproliferation of keratinocytes is a hallmark of psoriasis.  Syndecan-1 is 
expressed throughout the basal and suprabasal layers of the epidermis in 
psoriasis which was felt to be associated with development of psoriasis (Tomas 
et al., 2008).   Interestingly, a high expression of CD147 is seen in squamous 
cell carcinomas.   A trend was observed in advanced SCCs expressing CD147 
and reduced survival (Sweeny et al., 2012).  This is highly interesting, not only 
because patients on CsA are at increased risk of SCC but also HPV infection, 
which in itself may be associated with non-melanoma skin cancer (Lajer and 
von Buchwald 2010).  Certainly immunosuppressed patients with SCC are more 
likely to have HPV associated SCC than in immunocompetent groups (Harwood 
et al., 2000).  With CypB playing a role in HCV and HIV viral replication, the role 
of CypB in HPV may be relevant.  Recently, CypB has been shown to have an 
essential function in protecting hepatoma cells against ROS mediated apoptosis 
through binding to CD147 and regulating the ERK pathway.  This protective 
effect is dependent on its PPIase activity (K. Kim et al., 2012). 
 
For a small protein, CypB has numerous functions and has been shown to be 
involved in a number of important intracellular and extracellular activities in a 
number of different cell types.  In summary, these studies indicate that CypB 
stimulates keratinocyte differentiation consistent with its expression pattern but 
also significantly promotes proliferation through autocrine and/or paracrine 
effects and may be important in regulating epidermal homeostasis.   
Furthermore, we found that in eczematous skin treated with CsA, changes in 
expression of CypB and CD147 occur which need to be further explored.  
Moreover, the early changes in expression in FLG in eczematous skin during 
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treatment suggest that CsA acts by positively repairing impaired barrier function 
and further work is required to investigate this hypothesis. 
 
These data suggest that CypB may have an autocrine or paracrine role in 
keratinocytes and that CsA may exert effects in inflammatory skin disease, at 
least in part, by regulating CypB.  In addition to exploring if CypB works 
synergistically with other cytokines, growth factors or hormones in keratinocyte 
growth, proliferation and differentiation, further work investigating receptor 
binding/interactions with CypB and its signalling pathways and the role of 
PPIase activity in keratinocytes would also be important to shed further light on 
our findings.  CypB could be a potential therapeutic target and further 
investigation into its functions in the skin is essential. 
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FINAL REFLECTION 
 
The valued review of this data by the examiners has further helped to clarify 
some of the observations described above.   
 
Review of the data regarding CypB secretion from keratinocytes transduced 
with wild type and mutant CypB compared to empty vector control, highlighted 
that more work in this area could help to validate our observations. Identification 
of CypB secretion from these cells was performed using western blot.  
Quantification of the amount of protein present can also be performed using 
western blot however, as there are no established secreted control proteins, this 
is difficult to perform.  As CypB may be acting as a cytokine and/or 
synergistically with other proteins that are not yet identified, techniques to 
identify bound CypB would be important.  As stated earlier, techniques such as 
ELISA would allow quantification of the amount of CypB present in the samples.  
Furthermore, using FACS to count the number of cells in a sample would be 
helpful to accurately identify how much protein is being produced by a known 
number of cells.   
 
It is important to document information on the patient groups investigated.  
Providing details of the demographics of the patient groups from whom skin 
biopsies were taken for CypB, FLG and CD147 protein expression before and 
after CsA treatment, and also of the keratinocyte donors adds further 
information to the work, as does information regarding the site of biopsy and 
any co-morbidities.  This allows clinicians to know whether study results are 
relevant to the patient populations they manage.  The majority of our patients 
were between the ages of 25 – 45 and some had other atopic disease 
associated.  Patients who have been referred as adults with atopic eczema to 
secondary and tertiary care often have a more severe, chronic eczema 
persisting from childhood into adult life.  However there continues to be limited 
treatment and support available to patients (Skin, 2013).    Further work to 
establish each patient’s FLG status (whether patients have an inherited FLG 
mutation, the number of FLG repeats they may have or whether they have 
acquired a FLG deficiency) would also be an important observation to establish 
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due to the association between reduced FLG protein and increased risk of 
atopic eczema and other atopic and allergic disease and to understand further 
the impact of treatment on FLG protein expression. 
 
Re-examination and re-analysis of data is an important part of reassessing 
observations that have been found.  Therefore, re-evaluation of the 
immunohistochemistry data and normalising FLG expression pre and post CsA 
to the Toto nuclear stain control was important to confirm the findings shown.  
The main reason to undertake this review was to reduce any errors introduced 
by pipetting technique and the observation that some of the images with the 
brightest protein expression also had the brightest toto-3 expression.  In the 
skin biopsies identifying CypB localisation via immunohistochemistry, this was 
seen in one patient pre CsA treatment (patient 5) and one patient post CsA 
(patient 7).  In the skin biopsies identifying FLG localisation this was seen in 
three patients (patients 5,7 and 9)  post CsA treatment.  In the skin biopsy 
identifying CD147 localisation, this was seen in one patient (patient 7) post CsA.  
Due to time restrictions, re-analysis was performed on the FLG samples only. 
 
In the original analysis, the parameters set for detecting the signal were 
established using the normal control and the images subsequently captured for 
each sample pre and post CsA treatment were therefore controlled to the 
normal sample.  Thus any brightness in signal was detected using the original 
parameters for detecting the signals on the normal control.  Re-analysis was 
performed using Toto-3 nuclear stain as an internal control.   Re-analysis 
showed similar results to the original, in that the majority of patients treated with 
CsA (11 out of 12) demonstrated an increase in FLG levels in the stratum 
granulosum following 2 weeks of CsA therapy.  Patient 6 showed an increase in 
FLG expression following the re-analysis, whereas a decrease following CsA 
treatment was seen in the original analysis.  
 
Using the normal skin control for comparison of the intensity of protein is an 
appropriate way of assessing changes in the protein levels seen in the skin.  
The sample of patients is small and further work looking at expression of FLG 
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before and after CsA treatment in more patients would help to consolidate our 
findings.   
 
Whilst undertaking this research, there has been an expanse of knowledge 
regarding both CypB and FLG that has come to attention in the literature.  Both 
have been shown to have important functions.  Having investigated these 
proteins during this time has been both enjoyable and exciting.  Further work to 
publish the data in this thesis will add to this knowledge. 
 
I wish to extend my thanks to my examiners for their time and review of this 
work.  
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